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The NOW Trial: A Pragmatic Randomized Controlled Trial of 
Personalized, Genetic-Based Lifestyle Advice 
 
Abstract 
 
Background: The impact of nutrigenomics and lifestyle genomics interventions on health 
outcomes and behaviours remains controversial and under-explored.  
Objectives: To determine the short-term (3-month), moderate-term (6-month) and long-term 
(12-month) impact of providing personalized, genetic-based lifestyle information and advice on 
anthropometric measures, as well as dietary intake and adherence. 
Methods: The nutrigenomics, overweight/obesity and weight management trial (NOW Trial) is a 
pragmatic randomized controlled trial that was incorporated into the Group Lifestyle Balance™ 
(GLB) program (N=140). Inclusion criteria: overweight or obesity (BMI ≥ 25 kg/m2), ≥ 18 years 
of age, English-speaking, having access to internet at least one day per week, willing to undergo 
genetic testing, and not seeing another healthcare provider outside of the study for weight-loss 
advice. Exclusion criteria: Pregnancy and lactation. Twelve-month GLB weight management 
program groups were randomized 1:1 to receive either the standard GLB program or a modified 
nutrigenomics-based GLB program (GLB+NGx). Data collection occurred at baseline, 3-, 6- and 
12-month follow-up. The predetermined primary outcome was change in body fat percentage 
(BFP). Dietary intake and adherence were secondary outcome measures.  
Statistical Analysis: Statistical tests conducted using SPSS (version 26.0) included: repeated 
measures analyses of variance (ANOVAs), split-plot ANOVAs, two-way ANOVAs, chi-square 
ii 
 
and Fisher’s exact tests and logistic regression. Key components of the Theory of Planned 
Behaviour were considered in the dietary intake analyses.  
Results: After 3- and 6-month follow-up, the GLB+NGx group improved (reduced) their BFP to 
a significantly greater extent (p<0.05) than the standard GLB group. There were no statistically 
significant differences in BFP between groups after 12 months. Furthermore, the GLB+NGx 
group significantly reduced their total fat intake after 12 months; the standard GLB group did 
not. Dietary adherence to saturated fat and total fat recommendations were significantly (p<0.05) 
greater in the GLB+NGx group compared to the standard GLB group at 12 months.  
Conclusion: Genetically-tailored lifestyle advice can lead to improvements in body composition 
over the short-term and moderate-term, and motivate long-term dietary changes and adherence to 
nutrition recommendations. Biological mechanisms may challenge long-term weight loss, even 
with genetically-tailored advice that motivates long-term dietary changes.  
 
Keywords: nutrigenomics, nutritional genomics, nutrigenetics, lifestyle genomics, genetics, 
nutrition, overweight, obesity, Theory of Planned Behaviour, Theory of Planned Behavior 
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Summary for Lay Audience  
 
Nutrigenomics is a science that explores how our genes impact the way our bodies respond to the 
foods, beverages and nutrients we consume. For example, one person may lose more weight by 
following a lower saturated fat nutrition plan compared to someone else. Nutrigenomics can be 
used to provide more personalized nutrition advice. Some studies have shown that giving 
personalized, genetic-based information and advice can help motivate individuals to make 
dietary changes. Very few studies have assessed the effectiveness of nutrigenomics-based weight 
loss interventions. Therefore, the studies included in this dissertation aimed to build upon past 
research and provide new insights into whether providing people with genetic-based lifestyle 
advice results in improvements in dietary intake, weight and body fat. To study this, we 
randomly assigned people to receive either standard advice for weight management or genetic-
based advice for weight management and then followed up with them after 3, 6 and 12 months. 
The study participants also participated in a 12-month intervention. Overall, people who received 
the genetic-based advice experienced a decrease in body fat, more so than the people who 
received the standard advice after 3 and 6 months. After 12 months, there was no major 
difference in body fat between these two groups. When we looked at changes to their nutritional 
intake, people who received the genetic-based advice significantly reduced their overall intake of 
dietary fat after 12 months, whereas those who received the standard advice did not. 
Additionally, after 12 months, people who received the genetic-based advice better adhered to 
the recommendations for total fat and saturated fat compared to those who received the standard 
intervention. Overall, we found that nutrigenomics interventions can motivate long-term (12-
month) dietary changes and can lead to improvements in body fat over the short-term (3-month) 
and moderate-term (6-month) to a greater extent than standard advice. Previous research shows 
that over time, the body tries to compensate for weight loss with physiological mechanisms 
promoting weight regain. This may help to explain why we found that after 12 months, the group 
receiving the standard advice had lost a similar amount of body fat as the group receiving 
genetic-based advice, despite the genetic intervention group improving their diet to a greater 
extent.    
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CHAPTER 1: INTRODUCTION 
 
 
 
 
 
  
2 
 
1.1 Introduction  
 
Nutrigenomics is a science that seeks to explore interactions between genetic variation, 
nutritional intake, and subsequent health outcomes (Gibney and Walsh 2013). The terms 
nutrigenomics and nutritional genomics are often used interchangeably.  Recently, the more 
broad definition lifestyle genomics has been coined, which is used to describe the study of 
interactions between genetic variation, lifestyle habits (such as nutrition, physical activity, 
smoking, etc.) and subsequent health and disease outcomes (Karger 2019). Table 1.1 provides an 
overview of key terms and definitions which appear throughout this dissertation and are related 
to the field of genetics.  
Table 1.1: Key terms and definitions 
 
Term Definition 
Gene A section of DNA, which forms part of the chromosome. It is the 
functional unit of heredity. Everyone has the same genes, but 
individuals differ in their genetic variants (see definition below).  
Variant (Genotype) A set of two alleles, typically making a single nucleotide 
polymorphism (SNP) (e.g. a “TT” variant/genotype). 
Variants/genotypes can also exist in the form of copy number variants.  
SNP When one allele is replaced by a different allele (e.g. a “T” replacing 
an “A”). This is the most common type of variation within the genetic 
code.  
Allele One of two variant forms of a genotype (e.g. a “T” allele). 
rs# A number used to identify a specific location on a gene. The letters 
“rs” stand for Reference SNP.  
Linkage 
Disequilibrium  
The association between alleles in different locations on the genome, 
whereby having a specific genetic variant at one location, predicts a 
strong likelihood of having a certain genetic variant at another, nearby 
genetic location.  
Nutrigenomics 
(Nutritional 
Genomics, 
Nutrigenetics) 
Terms used to describe the study of the interaction between genetic 
variation, nutritional intake, and subsequent health outcomes.  
Lifestyle Genomics The study of the interaction between genetic variation, lifestyle habits 
(e.g. physical activity, sleep, smoking, nutrition, etc.), and subsequent 
health outcomes.  
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From a weight management perspective, lifestyle genomics and nutrigenomics help to 
explain why some individuals lose more weight or improve their body composition to a greater 
extent than others, even when they are following the same nutrition and physical activity plan.  
1.2 Research Purpose, Objectives and Hypotheses 
 
The overarching aim of this dissertation is to provide new insights into whether providing 
people with genetic-based nutrition advice can improve nutrition- and health-related outcomes. 
Overall, it is hypothesized that when patients enrolled in a genetically-tailored weight 
management program receive genetic-based lifestyle information and advice, this will reduce 
weight and positively impact body composition, dietary intake, and dietary adherence to a 
greater extent than population-based lifestyle information and advice over the short-term (3 
months), moderate-term (6 months) and long-term (12 months). 
Objectives: 
• To review and summarize the literature on the impact of providing genetic-based lifestyle 
information and advice on weight-related outcomes and lifestyle changes 
• To determine if the provision of genetic-based lifestyle information and advice is more 
effective than population-based lifestyle advice for improving: 1) anthropometric 
measures [body fat percentage (BFP) as the predetermined primary outcome; weight and 
BMI as predetermined secondary outcomes], 2) dietary intake, and 3) dietary adherence. 
• To compare the short-term (3 month), moderate-term (6 month) and long-term (12 
month) impact of providing personalized lifestyle advice on: 1) anthropometric measures, 
2) dietary intake, and 3) dietary adherence. 
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1.3 The Science of Nutrigenomics and Lifestyle Genomics  
 
1.3.1 Background Information 
 
There are numerous examples of gene-diet-health outcome interactions reported in the 
literature (Zhang et al. 2012; Grau et al. 2010; Corella et al. 2009; Cornelis et al. 2006).  At the 
same time, consumer interest in nutrigenetic testing continues to grow. In response, genetic 
testing companies now offer several different nutrigenetic and lifestyle genomics tests to 
consumers. While systematically reviewing the quality of the evidence to support the 
information included in commercially available consumer nutrigenetic tests is beyond the scope 
of this dissertation, a brief summary of nutrigenomics and lifestyle genomics interactions 
relevant to the present dissertation is provided below. Details on how this science can be 
translated and incorporated into clinical practice is further outlined in Chapter 5 (section 5.4.12 
and Supplementary Table 5.4).  
1.3.2 Nutrigenomics and Lifestyle Genomics Examples  
 
Genetic-based information and/or recommendations which are related to weight 
management can be provided to patients for: calories, protein, total fat, monounsaturated fat, 
polyunsaturated fat, saturated fat, appetite, and physical activity. The goal of providing these 
personalized lifestyle recommendations and information is to motivate health behaviour change 
and/or optimize health outcomes by providing advice that is tailored towards the individual. As 
such, several consumer genetic testing services offer information related to one or more of these 
gene-nutrient interactions (Nutrigenomix 2019; Athletigen 2018; MyDNA 2019). Genes 
included in these consumer tests include, but are not limited to: UCP1, FTO, TCF7L2, APOA2, 
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PPARγ2, MC4R, ADRB3, NRF2, GSTP1, NFIA-AS2 and ACTN3. Each of these will be further 
discussed below. 
UCP1 and Calories 
The uncoupling protein 1 (UCP1) gene plays a role in separating oxidative 
phosphorylation from ATP synthesis, while producing heat as a result of this metabolic process 
(Gene Cards n.d.). This particular gene is expressed almost exclusively in brown adipose tissue, 
which is more metabolically active than white adipose tissue (Jorge et al. 2017).  Research has 
demonstrated that individuals with GG or GA genotype at UCP1 rs1800592 have lower 
metabolic rates than those with the AA genotype (Nagai et al. 2011) and therefore calorie intake 
can be targeted based on individual genetic variation. In addition, the presence of at least one G 
allele has also been associated with obesity (Hayakawa et al. 1999; Heilbronn et al. 2000; Ramis 
et al. 2004).  
FTO and Protein 
Common variants within the fat-mass and obesity-associated (FTO) gene have been 
consistently linked to overweight and obesity whereby A allele carriers are at an increased risk of 
obesity and obesity-related conditions (Yang et al. 2017). FTO genetic variation is associated 
with differences in hunger/satiety and food intake, likely caused by FTO genetic variation 
affecting leptin and ghrelin levels. There does not appear to be a link between resting energy 
expenditure and FTO variation (Speakman 2015). In terms of weight loss, results from a 2-year 
randomized controlled trial (RCT) demonstrated that individuals with the risk allele of FTO 
rs1558902 (in strong linkage disequilibrium with rs9939609) had greater improvements in body 
composition and greater weight loss when following a higher protein diet (25% of calories from 
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protein) (Zhang et al. 2012). This protective effect of protein intake on obesity in high-risk FTO 
genotypes was recently replicated in a cross-sectional study (Merritt et al. 2018).  
TCF7L2 and Total Fat 
Transcription factor 7 like 2 (TCF7L2) plays an important role in the synthesis of 
glucagon-like peptide 1, which contributes to body weight via appetite, adipose tissue 
metabolism and insulin signalling (Flint et al. 1998; Verdich et al. 2001; Azuma et al. 2008; 
Boschmann et al. 2009; Gao et al. 2007). The release of glucagon-like peptide 1 is stimulated 
differently by fat and carbohydrate whereby there is a greater release after ingesting dietary fat, 
therefore altering intakes in these dietary components could impact weight-loss response (Eller et 
al. 2008; Paniagua et al. 2007). Results from a 2-year RCT found that consuming a diet lower in 
total fat (20% of calories) can reduce body adiposity in those with high-risk genetic variants in 
TCF7L2 rs12255372 (Mattei et al. 2012) [in strong LD with rs7903146 in some ethnicities 
(Humphries et al. 2006)]. Another RCT demonstrated the effectiveness of following a dietary 
pattern low in total fat (20-25% of calories) for weight loss in individuals with the TT genotype 
of TCF7L2 rs7903146 (Grau et al. 2010). 
APOA2 and Saturated Fat 
Apolipoprotein A-II (APOA2) is a major component of high-density lipoprotein particles 
and regulates both triglyceride and postprandial metabolism (Delgado-Lista et al. 2018; Julve et 
al. 2010). There is an association between APOA2 genetic variation, saturated fat intake, and 
obesity. Individuals who carry the CC variant of the APOA2 gene (rs5082) are at an increased 
risk of obesity when their intake of saturated fat is high. Consuming a diet low in saturated fat 
(<22 g per day) is associated with a lower body mass index (BMI) in individuals with the risk 
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variant (Corella et al. 2010; Corella et al. 2011). While the mechanism for this nutrigenomics 
interaction is not well-understood, individuals with the CC variant of APOA2 (rs5082) have 
demonstrated low ghrelin levels when consuming a low saturated fat diet, thus demonstrating a 
proposed mechanism for the association between saturated fat intake, obesity, and APOA2 
genetic variation via regulation of a hormone involved in hunger signalling (Smith et al. 2012).   
FTO, Saturated and Unsaturated Fat 
As indicated above, FTO genetic variation is linked to risk of obesity and obesity-related 
conditions (Yang et al. 2017), likely due to the effects on leptin and ghrelin levels leading to 
differences in hunger/satiety and food intake (Speakman 2015). FTO genetic variation at 
rs9939609 impacts individual responses to dietary unsaturated fat intake whereby a diet high in 
saturated fat (≥15.5% of calories) and low in polyunsaturated fat (polyunsaturated fat: saturated 
fat ratio <0.38) accentuates the risk of obesity (Phillips et al. 2012). Another study found that A 
allele carriers following a hypocaloric diet high in polyunsaturated fat (6% of calories; 7 grams 
omega-6; 2 grams omega-3 per day) had a lower BMI, weight and fat mass compared to 
individuals with TT genotypes following the same dietary pattern (De Luis et al. 2015).   
PPARγ2 and Monounsaturated Fat 
The peroxisome proliferator-activated receptor gamma 2 (PPARγ2) plays an important 
role in regulating adipogenesis – a process in which pre-adipocytes become adipocytes (fat cells, 
which make up adipose tissue) (Memisoglu et al. 2003). Memisoglu et al. (2003) were the first to 
discover an interaction between PPARγ2 genetic variation, monounsaturated fat intake, and body 
mass index BMI (Memisoglu et al. 2003). Later research discovered that a higher intake of 
monounsaturated fat (comprising approximately 50% of total fat) was associated with 
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significantly lower body fat and BMI in individuals with high risk genotypes of PPARγ2 
(Garaulet et al. 2011).  
ACE and Sodium  
The angiotensin-converting enzyme (ACE) is part of the renin-angiotensin-aldosterone 
system (RAAS), which plays a role in blood pressure regulation. Within the RAAS system, ACE 
is responsible for cleaving angiotensin I to form angiotensin II (Lifton 1996). It is postulated that 
salt-sensitive individuals experience a blunted RAAS response to high dietary sodium, thus 
increasing the risk of salt-sensitive hypertension (Poch et al. 2007).  Salt-sensitive hypertension 
can be measured by monitoring ambulatory blood pressure following high sodium intake. 
Research demonstrates that individuals with high-risk genetic variants in the ACE gene are more 
prone to high blood pressure when consuming a high intake of sodium (approximately 2300 mg 
daily). Those with low-risk genetic variants are less likely to present with high blood pressure in 
response to a high sodium intake (Poch et al. 2007; Giner et al. 2012).  
MC4R and Snacking (Appetite) 
Individual genetic variation can also have an impact on eating behaviours. The 
melanocortin 4 receptor (MC4R) gene codes for a receptor found in the hypothalamus region of 
the brain where hunger and appetite are controlled (Adan et al. 2006). Studies have demonstrated 
that individuals with the CC or CT variant (C allele carriers) of MC4R (rs17782313) are more 
likely to eat more frequently during the day and have an intensified appetite (Stutzmann et al. 
2009). On the contrary, those with the TT variant are less likely to eat frequently through the day 
(Stutzmann et al. 2009). Research further demonstrates that individuals with the CC or CT 
variant at rs17782313 of the MC4R gene are more likely to be overweight/obese (Srivastava et 
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al. 2014; Loos et al. 2008; Zobel et al. 2009). MC4R variants have also been linked to higher 
intakes of calories and fat, binge eating, excessive hunger, hyperphagia, and food-seeking 
behaviours (Adan et al. 2006; Qi et al. 2008; Branson et al. 2003). 
FTO and Physical Activity  
While dietary strategies exist to mitigate obesity-risk associated with FTO genetic 
variation, it has also been well-established that physical activity can attenuate the obesity-
associated effects in high risk FTO genotypes. Numerous studies have demonstrated this 
association and results from the current body of literature have been highly consistent (Sonestedt 
et al. 2011; Q. Yang et al. 2017; Celis-Morales et al. 2016; Andreasen et al. 2008; Zou et al. 
2015; Speakman 2015; Corella et al. 2012; Lee et al. 2010; Kilpeläinen et al. 2011; Sonestedt et 
al. 2009; Ahmad et al. 2010; Rampersaud et al. 2008; Vimaleswaran et al. 2009; Scott et al. 
2010; Xi et al. 2011; Zhu et al. 2014). The attenuating effects of physical activity on FTO-related 
overweight and obesity provide an example of a lifestyle genomics interaction.  
ADRB3, NRF2, GSTP1, NFIA-AS2 and Endurance  
Several genes have been demonstrated to impact genetic predisposition to excel at 
endurance/aerobic-based activities. Studies have assessed associations between certain genetic 
variants and elite endurance performance, running economy, maximal oxygen uptake, and 
maximum ventilation. The following genes appear to play a significant role in this endurance 
athletic predisposition: adrenergic receptor beta 3 (ADRB3), nuclear factor erythroid 2-related 
factor 2 (NRF2), glutathione S-transferase pi 1 (GSTP1), and nuclear factor I A antisense RNA 2 
(NFIA-AS2) (Santiago et al. 2011; He et al. 2007; Zarebska et al. 2014; Ahmetov et al. 2015). 
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ACTN3 and Strength  
The alpha-actinin-3 (ACTN3) gene encodes for a protein that is expressed almost 
exclusively in type 2 (fast twitch) muscle fibres (North et al. 1999). The CC and TC genotypes in 
the ACTN3 gene (rs1815739) have been significantly associated with speed and power 
phenotypes across numerous studies (Ahmetov et al. 2011; Kikuchi et al. 2016; N. Yang et al. 
2003; Ma et al. 2013; Eynon et al. 2009). As such, ACTN3 has been referred to as “a gene for 
speed” (Pickering and Kiely 2017).  
In summary, there are several lifestyle genomics interactions relevant to weight 
management and available through consumer genetic testing services. It is plausible that 
personalizing weight management strategies through genetically-guided nutrition and physical 
activity advice could result in improved health-related outcomes. 
  
1.4 Consumer Nutrigenetic and Lifestyle Genomics Testing 
 
1.4.1 The Current State of the Canadian Industry 
 
Canadians have expressed great interest in nutrigenetic testing (Nielsen et al. 2014; 
Vallée Marcotte et al. 2019). With increasing scientific knowledge, coupled with significant 
consumer interest in genetic testing for personalized nutrition, there are several companies 
offering nutrigenetic testing services to consumers. Many of these companies offer information 
and advice related to both physical activity and nutrition, based on the results of their genetic 
test. Questions have been raised about the scientific validity and clinical utility of such tests, 
given the lack of regulatory industry oversight (San-Cristobal et al. 2013; Grimaldi et al. 2017). 
Indeed, there is variable scientific validity and clinical utility among currently available 
consumer genetic tests, and this has led researchers to develop proposed guidelines to assess the 
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scientific validity of such tests (Grimaldi et al. 2017). Overall, the current Canadian industry 
allows for the widespread consumer availability of nutrigenetic and lifestyle genomics testing to 
those willing and/or able to pay between approximately $90 - $450 CDN (23andMe n.d.; 
MyDNA 2019; Pathway Genomics n.d.; Nutrigenomix Inc n.d.). Consumers can purchase such 
tests via direct-to-consumer (DTC) services, or through a healthcare provider.  
 
1.4.2 The Nutrigenetic and Lifestyle Genomics Testing Process  
 
The complete nutrigenetic testing process moves from science through to consumers 
(Horne et al. 2020). Scientific knowledge provides the basis for developing consumer genetic 
tests and reports. Industry’s responsibilities include reviewing and interpreting science and 
collaborating with genetic testing laboratories for the genetic analyses. Consumers provide a 
saliva sample or buccal swab to the company [or to the healthcare provider (HCP) offering the 
services], which is sent to the laboratory for analysis. In DTC genetic testing, the company sends 
the genetic report directly to the consumer. When such testing is offered through a HCP, the 
genetic testing company sends the genetic report to the HCP, who then sets up a meeting with the 
patient to review their report. Notably, the vast majority of companies offer their genetic testing 
services to consumers via DTC pathways; it is less common for a company to offer their services 
exclusively through HCPs (Horne et al. 2020). It has been suggested that many ethical concerns 
exist with DTC genetic testing (Trent 2013) and as such, offering genetic testing exclusively 
through a HCP could be superior to DTC genetic testing. Because of widespread ethical 
concerns, several American states have banned DTC genetic testing altogether (Hogarth et al. 
2008). The process for genetic testing via DTC services and via a HCP are outlined in Figures 
1.1 and 1.2, respectively.  
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Figure 1.1: The DTC process for genetic testing 
 
 
 
 
 
Figure 1.2: The process for genetic testing through a HCP  
 
 
 
1.5 The Missing Link Between Science and Consumer Services 
 
There is scientific evidence to support several gene-lifestyle-health outcome interactions 
(Zhang et al. 2012; Stutzmann et al. 2009; Phillips et al. 2012; Yang et al. 2017; Corella et al. 
2010; Grau et al. 2010; Ma et al. 2013). With advancing scientific knowledge, consumer genetic 
testing companies are offering personalized nutrition and physical activity recommendations to 
consumers. Given that consumers express great interest in DNA-based personalized nutrition 
(Nielsen et al. 2014; Vallée Marcotte et al. 2019), and some studies demonstrate that patients are 
more motivated to change health behaviours when they receive personalized, DNA-based dietary 
advice (Vernarelli et al. 2010; Egglestone et al. 2013; Nielsen and El-Sohemy 2014; Hietaranta-
Luoma et al. 2014; Kaufman et al. 2012), nutrigenomics and lifestyle genomics certainly warrant 
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further investigation. To date, minimal research has assessed the impact of the pragmatic 
incorporation of personalized, genetic-based weight management interventions in clinical 
practice, yet such interventions are used by numerous HCPs globally. Furthermore, significant 
methodological flaws limit the small body of knowledge that exists in this area; this is further 
discussed in Chapter 4. More broadly, research on the effectiveness of the variety of consumer 
lifestyle genomics tests available on the market is lacking. With respect to lifestyle changes 
resulting from genetic testing, several studies have been conducted, but there has been minimal 
consideration of established behaviour change theories within the existing body of literature 
(Horne et al. 2018); Chapter 3 provides more detail on this. Thus, there are several important 
research gaps to be filled in this niche area of personalized nutritional sciences and human 
behaviour.  
 
1.6 Outline of Dissertation 
 
This dissertation is organized into an integrated manuscript format. As such, there may be 
some repetition among the chapters. Additionally, abstract formatting varies throughout this 
dissertation as each abstract style is specific to the journal that the manuscript was published in, 
or that the manuscript was submitted to. 
 
The purpose of this introductory chapter was to provide a brief overview of the science of 
nutrigenomics and lifestyle genomics, including a review of genetic variants that were used on 
the Nutrigenomics, Overweight/Obesity and Weight Management (NOW) trial intervention. An 
overview of consumer nutrigenetic and lifestyle genomics testing was also presented. Moreover, 
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this chapter introduced the overarching objectives and hypotheses of the present dissertation, 
which are further detailed in later chapters.  
 
Chapter 2 presents a call to action for personalized healthcare behaviour change 
researchers to incorporate the Theory of Planned Behaviour (TPB) into their work. This chapter 
additionally provides a thorough overview of the TPB and proposes a possible theoretical 
expansion to include personalization in the model. This manuscript has been published in the 
journal Personalized Medicine.  
 
In Chapter 3, we systematically reviewed and summarized the current body of literature 
on the impact of genetic testing on lifestyle behaviour change. This chapter further assesses the 
quality of the genetic interventions provided to participants and whether researchers have 
considered established theories of human behaviour in their work. This manuscript has been 
published in the journal Lifestyle Genomics. 
 
Chapter 4 critically reviews and summarizes the literature on the effectiveness of 
pragmatic lifestyle genomics interventions on weight management. This manuscript has been 
submitted for publication. 
 
Following the literature review chapters, Chapter 5 provides a detailed overview of the 
study design for the NOW trial, which builds on past research. This chapter has been published 
in the journal BMC Public Health.  
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The results chapters start with Chapter 6, which gives an overview of dietary change and 
adherence in the NOW trial, and then moves to Chapter 7, which details the resulting weight and 
body composition outcomes. Chapter 6 provides an analysis and summary of the dietary intake 
and adherence results from the NOW trial, and is followed by Chapter 7, which provides an 
analysis and summary of weight-related outcomes of the NOW trial. These chapters have been 
submitted for publication.  
 
Finally, Chapters 8 and 9 wrap up the dissertation with an integrated discussion and 
conclusion on the key findings of the NOW trial. These chapters discuss how the NOW trial 
findings relate to past work and how the results can be used to inform future research 
endeavours. 
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CHAPTER 2: THE THEORY OF PLANNED BEHAVIOUR AND 
PERSONALIZED HEALTHCARE BEHAVIOUR CHANGE 
RESEARCH 
 
As published* in Personalized Medicine: 
 
Horne J, Madill J, Gilliland J. 2017 “Incorporating the ‘Theory of Planned Behavior’ into 
personalized healthcare behavior change research: A call to action.” Personalized Medicine 
14(6): 521-29. 
 
*Reference formatting, table numbers, spelling (Canadian) and figure numbers have been revised for consistency with the present 
dissertation. 
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2.1 Title: Incorporating the ‘Theory of Planned Behaviour’ into personalized 
healthcare behaviour change research: A call to action  
 
2.1.1 Abstract 
The ‘Theory of Planned Behaviour’ (TPB) has been tested and validated in the scientific 
literature across multiple disciplines and is arguably the most widely accepted theory among 
behaviour change academics. Despite this widespread acceptability, the TPB has yet to be 
incorporated into personalized healthcare behaviour change (PHBC) research. Several prominent 
personalized healthcare researchers suggest that personalizing healthcare recommendations have 
a positive impact on changes in lifestyle habits. However, research in this area has demonstrated 
conflicting findings. We provide a scientific and theoretical basis to support a proposed 
expansion of the TPB to include personalization and call to action personalized healthcare 
behaviour change researchers to test this expansion. Specific recommendations for study designs 
are included.  
 
2.1.2 Background 
The ‘Theory of Reasoned Action’, developed in the late 1960s, focused on attitudes and 
subjective norms as key predictors of human behaviour. In 1991, Ajzen published a seminal text 
in Organizational Behavior and Human Decision Processes where he proposed an important 
expansion of Ajzen and Fishbein’s ‘Theory of Reasoned Action’ (Ajzen 1991). He coined this 
new expanded theory, the ’Theory of Planned Behaviour’ (TPB; see Figure 2.2) (Ajzen 1991).  
 
The TPB posits that there are three main factors contributing to one’s intention to 
perform a behaviour, as well as the resulting actual behaviour. These three independent factors 
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include: attitudes, subjective norms and perceived behavioural control (Figure 2.2). The reasoned 
action approach (RAA) (Fishbein and Ajzen 2010) further breaks down these main categories 
into more descriptive subcategories. Attitudes can be classified as either experiential attitudes or 
instrumental attitudes. The former refers to affective attitudes such as pleasant–unpleasant, 
whereas the latter refers to cognitive attitudes such as health–unhealthy (Mceachan et al. 2016). 
Subjective norms refer to perceived social pressures to perform a behaviour, as well as the 
individual’s weighting on the importance of the opinions of others, which leads to behavioural 
intention through social reward/punishment. This is referred to as the subcategory of injunctive 
norms. Descriptive norms is the second subcategory for this key construct, and simply refers to 
the perceived behaviours of others (Mceachan et al. 2016). Perceived behavioural control refers 
to the perceived extent to which an individual has access to the appropriate resources and 
opportunities to perform a given behaviour and comprises the subcategories of capacity and 
autonomy. Capacity refers to the perceived ease/difficulty of a given behaviour, whereas 
autonomy refers to one’s perception of control over a given behaviour (Mceachan et al. 2016). 
An individual’s intention (motivation) to perform a behaviour is central to the TPB and can be 
influenced by these three independent factors and six related subcategories (Ajzen 1991; 
Fishbein and Ajzen 2010; Mceachan et al. 2016). Overall, the TPB/RAA identifies key proximal 
determinants of behaviour change, which should be considered in intervention studies aimed 
toward assessing behaviour change. 
 
Ajzen’s work has been distinguished as having the highest scientific impact score of all 
Canadian and American social psychology research (Ajzen 2011). Meta-analyses have found that 
the TPB can be used to predict behaviours from behavioural intention or perceived behavioural 
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control with mean correlations ranging from 0.4 to 0.53 (Rivis and Sheeran 2003; Armitage and 
Conner 2001). Meta-analyses have further found that attitudes, subjective norms and/or 
perceived behavioural control can be used to predict intentions with mean multiple correlations 
ranging from 0.59 to 0.66 (Rivis and Sheeran 2003; Armitage and Conner 2001; Cheung and 
Chan 2000; McEachan et al. 2011;  Notani 1998; Schulze and Wittmann 2003). Moreover, with 
the exception of autonomy, all subcategories of the RAA (outlined above) were found to be 
significant predictors of behavioural intention in recently completed regression analyses 
(Mceachan et al. 2016). Meta-analyses of the TPB in relation to specific health-related 
behaviours including alcohol consumption, diet, sexual health behaviours and treatment 
adherence in chronic illness have also been recently conducted (Cooke et al. 2016; Andrew et al. 
2016; Rich et al. 2015; Mcdermott et al. 2015). Notably, the vast majority of these meta-analyses 
consistently demonstrated medium to large associations between the key constructs of the TPB 
and behavioural intention as well as actual behaviour engagement, with the exception of 
treatment adherence in chronic illness whereby intention-behaviour effect sizes were small 
(Cooke et al. 2016; Andrew et al. 2016; Rich et al. 2015; Mcdermott et al. 2015). While the TPB 
has proven to be a strong predictor of behaviour change, and is widely used by behaviour change 
researchers, it is clear that there are other factors contributing to behaviour change that have not 
yet been identified and validated within the context of this theory.  
 
With recent advances in personalized healthcare technology, there has been a 
considerable increase in research pertaining to personalization of healthcare information and 
recommendations. Personalized healthcare, for the purposes of this paper, refers to healthcare 
information and recommendations, based on an individual’s blood work results and/or individual 
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genetic profile. Several prominent researchers in the field of personalized healthcare suggest that 
individualizing lifestyle recommendations based on genetics or blood work could have a 
favorable impact on motivation (behavioural intention) and behaviour change (Nielsen, Shih, and 
El-Sohemy 2014; Nielsen and El-Sohemy 2014; Celis-Morales et al. 2015). To date, changes in 
several behaviours have been studied in personalized healthcare research including alcohol, 
nutrition, physical activity, smoking and health-screening behaviours (Nielsen and El-Sohemy 
2014; Hendershot et al. 2010; Marsaux et al. 2016; Hishida et al. 2010; Bloss, Schork, and Topol 
2011; Roke et al. 2017). Despite the widespread validation and acceptance of the TPB among 
academics, the use of this theory in personalized healthcare research is lacking. Notably, a 
PubMed search of ([‘Theory of Planned Behavior’ AND ‘personaliz*’ AND ‘health’] OR 
[‘Theory of Planned Behavior’ AND ‘personalis*’ AND ‘health’] OR [‘Theory of Planned 
Behaviour’ AND ’personaliz*’ AND ’health’] OR [‘Theory of Planned Behaviour’ AND 
’personalis*’ AND ’health’]), conducted in April 2017 yielded only two results, neither of which 
would be considered personalized healthcare research (Middlemass et al. 2012; Denison et al. 
2015).  
 
Based on the current state of knowledge pertaining to behaviour change and personalized 
healthcare, this paper calls to action PHBC researchers for the incorporation of the TPB into 
scientific research methods. Furthermore, this paper is the first of its kind to propose a potential 
expansion of the TPB, based on personalization. It is recommended that this expansion be tested 
in robust personalized healthcare research to determine if the TPB should be revised to 
incorporate personalization as a significant predictor of behavioural intention and actual 
behaviour, alongside attitudes, subjective norms and perceived behavioural control. In particular, 
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within the TPB, it is hypothesized that personalization will have a significant impact on attitudes 
and subjective norms (Figure 2.2). 
 
2.1.3 Attitudes Towards Personalized Healthcare 
Prior to delving further into PHBC research conducted to date, it is important to 
understand the attitudes of healthcare professionals, students in post-secondary health programs 
and consumers toward personalized healthcare, as these individuals will largely affect the uptake 
and acceptability of personalized healthcare in society. Most studies assessing attitudes toward 
personalized healthcare have focused on personalization based on genotyping. 
 
A recent randomized clinical trial found that consumers had favorable attitudes toward 
participating in genetic testing for personalized healthcare, and those who underwent genetic 
testing were more likely to recommend it to friends and family (Kattel et al. 2017). Another 
recent study found that ‘perceived personalization benefit’ played a larger role in consumers’ 
intention to utilize personalized nutrition services than ‘perceived personalization risk’ 
suggesting that attitudes toward personalized healthcare based on genetics were overall positive 
(Berezowska et al. 2014). Additionally, a review article concluded that extensive research has 
demonstrated consumers’ keen interest to undergo genetic testing for personalized healthcare 
(Gibney and Walsh 2013). Given these findings, it is not surprising that significant economic 
growth of genetic testing has been predicted (Vickery and Cotugna 2005). 
 
For healthcare professionals and students in health programs (many of whom will 
become healthcare professionals), attitudes have been variable with some expressing skepticism 
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and others expressing more positive attitudes toward genetic testing (Bouwman, Molder, and 
Hiddink 2009; Collins et al. 2013; Cormier et al. 2014; Horne, Madill, and O’Connor 2016). 
Overall, the availability of genetic testing in clinical practice is growing rapidly (Downie, 
Donoghue, and Stutterd 2017). With increasing uptake in clinical practice, the question of 
whether or not personalized healthcare impacts behaviour change is an important one to consider 
and is proving to be a priority area of research, with at least four review articles published on this 
topic over the past year alone (O’Donovan et al. 2017; Li et al. 2016; Hollands et al. 2016; 
French et al. 2017). 
 
2.1.4 Current State of PHBC Research 
Over the past decade, there has been a considerable amount of research conducted 
examining the impact of providing personalized healthcare recommendations on motivation and 
behaviour change. One of the largest projects currently underway is the ‘Food4Me’ project, 
which commenced its research activities in 2011. ‘Food4Me’ is a EU funded, large-scale 
research initiative, which aims to improve scientific knowledge pertaining to personalized 
healthcare, including motivation and behaviour change resulting from the provision of 
personalized nutrition and physical activity recommendations (Food4Me 2011). We reviewed the 
29 peer-reviewed publications posted on the ‘Food4Me’ website (Food4Me n.d.) and found eight 
unique articles pertaining to the impact of personalized nutrition and physical activity 
recommendations on one or more of the following components of the TPB: attitudes and 
behaviour (Berezowska et al. 2014; Marsaux et al. 2016; Fallaize et al. 2013; Marsaux et al. 
2015; Poinhos et al. 2014; Stewart-Knox et al. 2013; Stewart-Knox et al. 2009). However, none 
of the eight manuscripts specifically referred to the TPB, therefore, it is possible that one or more 
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components of the TPB were included unintentionally. No study from the ‘Food4Me’ project 
was designed based upon the TPB specifically. 
 
Despite the lack of consideration of the TPB in the ‘Food4Me’ project and other 
personalized healthcare research projects assessing behaviour change, several components of the 
TPB can be found within PHBC research methods. Of the 29 articles published on the 
‘Food4Me’ website, five studies assessed attitudes related to genetic testing and personalized 
healthcare, which tended to be positive (Berezowska et al. 2014; Fallaize et al. 2013; Poinhos et 
al. 2014; B. Stewart-Knox et al. 2013; Stewart-Knox et al. 2009). Two ‘Food4Me’ studies 
analyzed behaviour change, and each article found no significant impact on behaviour change 
with the provision of personalized healthcare reports and/or recommendations (Marsaux et al. 
2016, 2015).While these studies did not find an impact on behaviour change, a recent 
randomized controlled trial (RCT) found significantly greater reductions in sodium intake when 
individuals were provided with personalized nutrition advice based on genetics, in comparison to 
those who were provided with population-based health recommendations (Nielsen and El-
Sohemy 2014). Similarly, a study assessing changes in lifestyle following a genetic-based 
hypertension intervention also found significant changes in sodium intake among participants 
provided with DNA-based advice (Taylor and Wu 2010). Furthermore, an RCT found that the 
provision of personalized nutrition advice enhances motivation (behavioural intention) to change 
lifestyle behaviours (Nielsen and El-Sohemy 2014). 
 
The inconsistent findings of PHBC research suggest that there are confounding factors 
influencing behaviour change, which are not being considered in the scientific methods. This is 
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likely due to the minimal use of validated theoretical underpinnings to inform study design. 
While the current body of knowledge appears to have unintentionally addressed one or more 
components of the TPB, a more comprehensive and intentional approach to the incorporation of 
the TPB in study design and methodology is required. This would allow for an improved 
understanding of the extent to which personalized healthcare recommendations, based on 
genetics and/or blood work, may affect behavioural intention and actual behaviour performance. 
Studies assessing motivation and behaviour change should include an analysis of attitudes, 
subjective norms, perceived behavioural control and actual behavioural control to determine how 
these factors may alter study outcomes. 
 
2.1.5 A Call to Action for PHBC Research 
It is well known that nutrition, physical activity and wellness strategies can be used to 
improve health and well-being and decrease the risk for chronic disease, but despite this 
knowledge, rates of obesity and chronic disease continue to climb (Arena et al. 2017). Behaviour 
change (or lack thereof) is a key contributor to the increasing rates of obesity and chronic disease 
despite our increased knowledge of methods to improve health through lifestyle modification 
(Arena et al. 2017). As such, innovative strategies are needed to enhance both intention to 
change lifestyle habits as well as actual change in lifestyle habits, and personalized healthcare is 
garnering considerable attention as an innovative healthcare strategy to help combat current 
global health crises. This paper calls to action PHBC researchers to test the potential expansion 
of the TPB to include ‘personalization’ as a possible novel component of the TPB (Figure 2.2). 
We propose that personalization may have a significant impact on attitudes and normative beliefs 
and therefore has the potential to significantly influence behaviours. 
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In order to incorporate the TPB into personalized healthcare research, it is first important 
to understand the different components of the theory, including attention to key constructs such 
as behavioural beliefs, attitude toward the behaviour, normative beliefs, subjective norms, 
control beliefs, perceived behavioural control, actual behavioural control, intention and 
behaviour (Figure 2.1). In brief, in the TPB, behavioural beliefs are seen to influence attitudes, 
normative beliefs to influence subjective norms and control beliefs to influence perceived 
behavioural control. Attitudes, subjective norms and perceived behavioural control all have a 
significant impact on one’s behavioural intention and actual behaviour. However, it is also 
important to note that factors influencing actual behavioural control, such as the social 
determinants of health (Public Health Agency of Canada, 2016), strongly predict behaviours 
regardless of attitudes and subjective norms. Describing each component of the TBP in detail is 
beyond the scope of this paper and has been accomplished elsewhere (Ajzen 1991, 2006; 
Fishbein and Ajzen 2010). Several key resources and seminal texts provide a solid background 
for deepening understanding of the TPB (Ajzen 1991, 2006; Fishbein and Ajzen 2010). 
 
We contend that this theoretical background could be translated into a more practical 
application to inform the development of assessment tools with theoretical and practical utility 
for research in the field. Instructions on completing a TPB questionnaire are available on the 
University of Massachusetts website (Ajzen 2006). This resource provides a step-by-step 
guideline to develop a TPB questionnaire, which includes defining the behaviour, specifying the 
research population, formulating items for direct measures and administering a pilot 
questionnaire. Sample TPB questionnaires are also available on the website and can be used for 
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guidance in the development of assessment tools to be used in the field (Ajzen 2006). Ajzen 
suggests that multiple regression or structural equation modeling analyses can be used to 
establish the extent to which attitudes, subjective norms and perceived behavioural control may 
have contributed to intentions. These methods of statistical analyses can also be used to 
determine the extent to which intentions and perceived behavioural control may have predicted 
actual behaviour(s) (Ajzen 2006). 
 
To test the proposed addition of personalization within the TPB, we further advise that an 
assessment of attitudes toward genetic testing and/or blood work (depending on the method of 
personalization within the study) be included within the TPB questionnaire. Attitudes toward 
personalization can be measured on a Likert scale, similar to other questions on Ajzen’s sample 
TPB questionnaire (Ajzen 2006). Ideally, a randomized clinical intervention trial study design 
could be used for this research, whereby participants are randomly selected to either receive 
personalized healthcare advice or general population-based healthcare advice. While blinding 
typically enhances the quality of an RCT, for PHBC research blinding may actually diminish the 
quality of the results; knowing that one’s recommendations are based on their genetics or blood 
work could influence several aspects of the TPB including behavioural beliefs, attitudes, 
normative beliefs and subjective norms, thus impacting behavioural intention and behaviours. 
Therefore, we do not recommend the blinding of participants. Through the use of repeated 
measures analysis of variance and multiple regression, comparisons can then be made within and 
between groups to determine the extent to which personalized healthcare advice may have 
impacted attitudes and subjective norms, and thus behavioural intention as well as actual 
behaviour. To further enhance study design, consideration of the social determinants of health 
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(Public Health Agency of Canada, 2016) could additionally be incorporated within the study 
questionnaire to determine if factors such as income, education level, housing and employment, 
for example, influenced perceived behavioural control and thus behavioural intention and actual 
behaviour.  
 
In addition to testing the proposed expansion of the TPB, several hypotheses could be 
tested in PHBC research, which incorporate the key constructs of the TPB. Perhaps receiving 
genetic testing or blood work results could lead to more positive attitudes toward a behaviour 
such as exercising. This may translate into greater intentions to participate in physical activity 
and actual engagement in physical activity. Or rather, perhaps personalized healthcare only has a 
significant impact on behaviour change in those with a baseline negative attitude toward the 
behaviour of interest; personalized healthcare may significantly alter attitudes and thus lead to 
greater behaviour change but only in those with baseline negative attitudes. These hypotheses 
have yet to be tested in PHBC research, and should be tested in future studies to advance our 
understanding of determinants of behaviour change in relation to personalized healthcare.  
 
Furthermore, it would be beneficial to conduct a systematic review of PHBC research 
with a focus on assessing how the (likely unintentional) incorporation of components of the TPB 
may have impacted the findings of studies conducted to date. While several reviews have been 
published on the topic of behaviour change resulting from personalized healthcare, no review has 
evaluated studies within the context of the TPB (O’Donovan et al. 2017; Li et al. 2016; Hollands 
et al. 2016; French et al. 2017). Based on the information presented in this paper, it is evident 
that there is a need for researchers in the field of personalized healthcare and behaviour change 
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to incorporate the TPB into their work as a key theoretical underpinning of study design. Past 
research in other disciplines can be used to guide research methods (McEachan et al. 2011; 
Cooke et al. 2016; Andrew et al. 2016; Rich et al. 2015; Mcdermott et al. 2015). 
 
2.1.6 Conclusion  
The lack of consideration of validated theory in the design of studies assessing PHBC can 
have a significant impact on the results, as these studies fail to consider key factors that have 
been shown to affect behaviour change. This paper calls to action PHBC researchers to 
incorporate the TPB in their methods in order to provide a more accurate and thorough 
assessment of whether personalized healthcare advice, based on genetics and/or blood work, has 
a significant impact on behaviour change. This paper suggests that the next expansion of Ajzen’s 
TPB may be the addition of personalization (Figure 2.2). Future research should seek to test the 
addition of personalization within the TPB through robust research methods such as RCTs. This 
call to action is timely in light of the increased focus on innovative healthcare strategies to 
address the myriad of health concerns arising globally, whereby interventions facilitating 
behaviour change could have a significant impact on global health. 
 
2.1.7 Future Perspective  
Based on the current body of knowledge, in addition to the authors’ clinical and academic 
experience, we predict that testing the proposed expansion of the TPB will yield positive 
findings toward personalization of healthcare recommendations significantly impacting 
behaviour change within some limits. While we predict that personalization will significantly 
influence behaviour change, the ability to change one’s behaviour must still remain within the 
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individual’s actual and perceived behavioural control. In addition, we predict that the method of 
communicating genetic information will play into one’s likelihood of changing, whereby the use 
of gain-framed messages and actionable advice may have a more favorable impact on one’s 
likelihood of altering their lifestyle habits. Comprehension of the results of personalized 
healthcare testing and recommendations will also play into likelihood of behaviour change. As 
an example, the results of a nutrigenomics test may inform an individual that they have an 
increased risk for cardiovascular disease, but by limiting caffeine intake this elevated risk could 
be reduced. This personalized genetic result and consequent gain-framed, actionable 
recommendation will likely alter one’s attitudes toward changing the behaviour. If the individual 
was to inform their family and/or friends about the results of the genetic test, it is likely that they 
would feel pressure from their social circle to abide by the recommendation. While 
personalization of healthcare will likely impact attitudes and subjective norms, it is unlikely that 
it will be a strong enough force to impact perceived and actual behavioural control. If the 
pressures of work and home life do not allow for adequate sleep and lead to increased stress, one 
may continue to consume a high quantity of caffeine, regardless of their genetic test. Thus, 
perceived and actual behavioural controls remain unchanged. It is for this reason that Figure 2.2 
depicts an influence of personalization on attitudes and subjective norms, but not perceived 
behavioural control. Considering the above-mentioned points, if the individual was sleeping 
adequately and consumed caffeine for the simple enjoyment of the taste of the caffeinated 
beverages, the results of the genetic test would likely motivate them to stop drinking caffeinated 
beverages.  
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It is further predicted based on clinical experience and our review of the literature that 
specific aspects of personalized healthcare interventions facilitate behaviour change to a greater 
extent than others. For example, providing genetic testing through a trained healthcare 
professional rather than using direct-to-consumer methods will likely facilitate behaviour change 
to a greater extent. Moreover, providing actionable recommendations rather than disease risk 
estimates is likely to result in greater behaviour change. We posit that future research will be 
able to identify similar factors in PHBC research that have been shown to facilitate behaviour 
change and will use this knowledge to design an algorithm for effective personalized healthcare 
results and recommendations. To our knowledge, this hypothesis has yet to be tested in scientific 
research. 
 
Overall, we predict that personalization of healthcare will be added to the TPB as a key 
factor influencing attitudes and subjective norms and thus intention and behaviour. Achieving 
behaviour change when it comes to lifestyle habits is arguably one of the most challenging 
aspects of clinical practice. We further predict that the field of genetic testing will continue to 
grow as more robust PHBC research is conducted and published. These predictions stem from 
clinical and academic experience, our review of the literature and theoretical perspectives. 
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2.1.8 Figures and Executive Summary  
Figure 2.1: The ‘Theory of Planned Behaviour’ 
 
 
 
 
 
 
 
Figure 2.2: Personalization: A proposed expansion of the ‘Theory of Planned Behaviour’  
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Figure 2.3: Executive summary 
Executive summary 
The ‘Theory of Planned Behaviour’ (TPB) 
• The TPB is a widely accepted and validated behaviour change theory, which suggests that 
there are three main factors contributing to behaviour change: attitudes, subjective norms 
and behavioural control (perceived and actual). 
Consideration of theory in personalized healthcare behaviour change research 
• To date, consideration of theory (especially the TPB) is limited in personalized healthcare 
behaviour change (PHBC) research. 
• This lack of consideration of theory helps to explain the heterogeneity of current PHBC 
research findings. 
Predictions for the future 
• We predict that robust research will demonstrate that personalization will significantly 
influence behaviour change and thus personalization will be added to the TPB. 
• The impact of personalization on behaviour change will be limited to a significant influence 
on attitudes and subjective norms. 
Call to action 
• This paper calls to action PHBC researchers to test the proposed expansion of the TPB to 
include personalization.  
Conclusion 
• Present research demonstrates a lack of consideration of theoretical underpinnings to 
inform study design, yet the results of several articles demonstrate that personalization is 
likely a key component to be added to behaviour change theory. 
• Future research should seek to inform study design using the TPB and determine the extent 
to which personalization influences key components of the TPB. 
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CHAPTER 3: A SYSTEMATIC REVIEW OF GENETIC TESTING 
AND LIFESTYLE BEHAVIOUR CHANGE 
 
As published* in Lifestyle Genomics:  
  
Horne J, Madill J, O ’Connor C, Shelley J, Gilliland J. 2018 “A systematic review of genetic 
testing and lifestyle behaviour change: Are we using high-quality genetic interventions and 
considering behaviour change theory?” Lifestyle Genomics 11(1): 49-63. 
 
*Reference formatting, table numbers and figure numbers have been revised for consistency with the present dissertation. 
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3.1 Title: A systematic review of genetic testing and lifestyle behaviour change: 
Are we using high-quality genetic interventions and considering behaviour 
change theory? 
 
3.1.1 Abstract 
 
Background: Studying the impact of genetic testing interventions on lifestyle behaviour change 
has been a priority area of research in recent years. Substantial heterogeneity exists in the results 
and conclusions of this literature, which has yet to be explained using validated behaviour 
change theory and an assessment of the quality of genetic interventions. The theory of planned 
behaviour (TPB) helps to explain key contributors to behaviour change. It has been hypothesized 
that personalization could be added to this theory to help predict changes in health behaviours.  
Purpose: This systematic review provides a detailed, comprehensive identification, assessment, 
and summary of primary research articles pertaining to lifestyle behaviour change (nutrition, 
physical activity, sleep, and smoking) resulting from genetic testing interventions. The present 
review further aims to provide in-depth analyses of studies conducted to date within the context 
of the TPB and the quality of genetic interventions provided to participants while aiming to 
determine whether or not genetic testing facilitates changes in lifestyle habits. This review is 
timely in light of a recently published “call-to-action” paper, highlighting the need to incorporate 
the TPB into personalized healthcare behaviour change research.  
Methods: Three bibliographic databases, one key website, and article reference lists were 
searched for relevant primary research articles. The PRISMA Flow Diagram and PRISMA 
Checklist were used to guide the search strategy and manuscript preparation. Out of 32,783 titles 
retrieved, 26 studies met the inclusion criteria. Three quality assessments were conducted and 
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included: (1) risk of bias, (2) quality of genetic interventions, and (3) consideration of theoretical 
underpinnings – primarily the TPB.  
Results: Risk of bias in studies was overall rated to be “fair.” Consideration of the TPB was 
“poor,” with no study making reference to this validated theory. While some studies (n = 11; 
42%) made reference to other behaviour change theories, these theories were generally 
mentioned briefly, and were not thoroughly incorporated into the study design or analyses. The 
genetic interventions provided to participants were overall of “poor” quality. However, a 
separate analysis of studies using controlled intervention research methods demonstrated the use 
of higher-quality genetic interventions (overall rated to be “fair”). The provision of actionable 
recommendations informed by genetic testing was more likely to facilitate behaviour change 
than the provision of genetic information without actionable lifestyle recommendations. Several 
studies of good quality demonstrated changes in lifestyle habits arising from the provision of 
genetic interventions. The most promising lifestyle changes were changes in nutrition.  
Conclusions: It is possible to facilitate behaviour change using genetic testing as the catalyst. 
Future research should ensure that high-quality genetic interventions are provided to participants, 
and should consider validated theories such as the TPB in their study design and analyses. 
Further recommendations for future research are provided. 
 
3.1.2 Background 
 
Since decoding the entire human genome in 2003 (National Institutes of Health 2015), 
there have been considerable advances in genetic research and the clinical utility of genetic 
testing. The terms nutrigenomics or nutritional genomics describe the study of how genes 
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interact with the foods, beverages, and supplements consumed to influence health outcomes 
(Gibney and Walsh 2013). Currently, there are no generally accepted or standardized terms 
describing the study of how genes interact with physical activity, sleep, or smoking to influence 
subsequent health outcomes. These gene-lifestyle interactions can be referred to using the broad 
term lifestyle genomics. Despite the lack of a standardized terminology, research pertaining to 
nutrigenomics and other emerging genomic sciences continues to advance. Specifically, 
behaviour change guided by genetic testing results or other personalized healthcare information 
is emerging as a priority area of research, with several reviews on this topic published in recent 
years (Hollands et al. 2016; French et al. 2017; O’Donovan et al. 2017). 
 
Genetic testing is increasingly used in clinical practice to provide personalized 
information and recommendations about health risks and lifestyle habits at a relatively low cost 
(Caulfield and McGuire 2012). However, studies assessing whether or not genetic testing 
promotes changes in lifestyle habits have conflicting findings (Egglestone, Morris, and O’Brien 
2013; Hietaranta-Luoma et al. 2014; Nielsen and El-Sohemy 2014; Marsaux et al. 2016). Given 
that chronic diseases can often be managed through lifestyle interventions alone, or a 
combination of lifestyle interventions and medication (Knowler et al. 2002; Roth et al. 2017; 
CDC 2016), genetic tests providing personalized lifestyle recommendations hold considerable 
promise. 
 
Behaviour change is a multifactorial, complex area of research and clinical practice. The 
theory of planned behaviour (TPB) is arguably the most widely accepted behaviour change 
theory in academia (Ajzen 2011). This theory posits that attitudes, subjective norms, and 
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perceived behavioural control are key constructs that can be used to predict behaviours. Actual 
behavioural control, which typically refers to factors such as income, educational level, and other 
social determinants of health for the purposes of healthcare research, further contributes to one’s 
likelihood of performing a behaviour (Ajzen 2011, 1991). It is important for genetic testing 
behaviour change research to consider validated theories in order to control for a number of 
confounding factors that could significantly influence the results of a study. 
 
Despite the complexity of behaviour change, genetic testing behaviour change studies do 
not often use any theoretical underpinnings to inform their study design, or for the analysis and 
interpretation of their data. This is concerning, as it implies that these studies did not report 
whether they considered the many confounding factors impacting behaviour change, including 
but not limited to attitudes, subjective norms, and perceived and actual behavioural control 
(Ajzen 2006). Consideration of such factors could help explain why some studies conclude that 
genetic testing facilitates health behaviour change, while others conclude that it does not. For 
example, a study may find that genetic testing has a positive influence on attitudes and subjective 
norms, but it is only when behavioural control is high (for example, with a higher income or 
education level) that genetic testing facilitates health behaviour change. The importance of such 
considerations has been highlighted in a recent call to action for personalized healthcare 
behaviour change research, which recommended the completion of a systematic review with 
perspective from the TPB as an important next step in advancing knowledge in personalized 
healthcare behaviour change literature (Horne, Madill, and Gilliland 2017). 
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Systematic reviews and meta-analyses are typically considered the highest quality of 
scientific evidence and, notably, often guide clinical practice (West et al. 2002). When it comes 
to systematic reviews assessing behaviour change as a result of genetic testing interventions, a 
simple risk-of-bias assessment is not sufficient to develop the most meaningful conclusions; yet 
it is often the only quality assessment conducted in this type of work (Hollands et al. 2016; 
French et al. 2017; Li et al. 2016). It is further important to consider the delivery of a 
health/genetic intervention (such as considering the provision of disease risk estimates vs. 
actionable behaviour change recommendations) and to consider behaviour change theories 
(Horne, Madill, and Gilliland 2017). Therefore, the development of more comprehensive 
methods for reviewing and compiling the primary research articles conducted to date related to 
genetic testing behaviour change is needed. 
 
The present review provides an in-depth analysis and summary of the current body of 
knowledge, thus presenting the most robust and comprehensive review of genetic testing 
behaviour change research conducted to date. Overall, the purpose of this comprehensive 
systematic review is to use these novel perspectives to answer the following research questions: 
Are we considering validated behaviour change theory (particularly the TPB) in genetic testing 
behaviour change research? Are we using high-quality genetic interventions in genetic testing 
behaviour change research? What is the impact of genetic testing on behaviour change pertaining 
to four lifestyle factors: nutrition, physical activity, smoking, and/or sleep? These four lifestyle 
factors were chosen as they have all been shown to have a significant impact on chronic disease 
management (Audrain et al. 1997; Dean and Söderlund 2015; Walker et al. 2010; Zhu et al. 
2017; Wu, Zhai, and Zhang 2014). Behaviour change is challenging, and it is important to find 
39 
 
strategies that effectively facilitate beneficial lifestyle changes related to nutrition, physical 
activity, smoking, and/or sleep. Genetic tests may provide information on disease risk, which can 
be mitigated through specific alterations in lifestyle habits such as improving nutrition, 
optimizing physical activity habits, quitting smoking or smoking less, and engaging in healthful 
sleep-related behaviours. 
 
3.1.3 Methods 
 
Search Strategy 
The systematic review protocol that was used to guide this review is detailed elsewhere 
(Petticrew and Roberts 2006). In brief, the search strategy was guided by the PRISMA Flow 
Diagram (Moher et al. 2009). From February to April 2017, the following databases were 
searched for relevant articles: PubMed, Scopus, and Nursing and Allied Health. Publications 
posted on the Food4Me website (Food4Me n.d.), as well as the reference lists of 4 recent review 
articles published on topics similar to those of the present review (Hollands et al. 2016; 
O’Donovan et al. 2017; French et al. 2017; Li et al. 2016), were also screened for articles 
relevant to the research questions. After the number of records had been condensed through title 
and abstract screening, the full-text articles were reviewed to assess each one for eligibility 
according to predetermined inclusion and exclusion criteria. The complete search terms and 
search strategy were developed and approved by all authors, and they are detailed in Figure 3.1 
and Figure 3.2, respectively.  
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Selection Criteria 
 To capture a comprehensive summary of the research conducted to date, the present 
review was not limited to a single, specific study design. We included primary research articles 
published in English in peer-reviewed journals from all years which assessed the impact of 
genetic testing on one or more of the four lifestyle habits of interest (nutrition, physical activity, 
smoking, and/or sleep). Both qualitative and quantitative studies were included. Studies were 
excluded if there was not at least one group of participants who underwent genetic testing and/or 
if the study did not provide follow-up data related to one or more of the lifestyle habits of interest 
after the participants had received the results of a genetic test. One author (JH) completed data 
extraction using piloted forms (The Cochrane Collaboration 2011), which were tested on 4 
studies, reviewed by another author (JG), and modified during the piloting process by two 
authors (JH and JG).  
Analysis 
 The National Institutes of Health (NIH) Study Quality Assessment Tools were used to 
conduct a risk-of-bias assessment in quantitative research (National Institutes of Health n.d.). 
The Critical Appraisal Skills Programme Qualitative Research Checklist (Critical Appraisal 
Skills Programme 2017) was used to assess risk of bias in qualitative research. The quality of the 
genetic intervention was also assessed. To our knowledge, there currently is no tool available for 
assessing the quality of a genetic intervention. As such, we developed the first assessment tool 
for evaluating the quality of a genetic intervention provided to subjects (Supplementary Table 
3.4). The quality rating and general outline for this new tool was based on the format of the NIH 
Study Quality Assessment Tools (National Institutes of Health n.d.). The questions included 
were developed from a review of previously identified critiques and concerns related to genetic 
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testing and health risk messages (Nielsen and El-Sohemy 2014; Fenech 2008; Katsanis and 
Katsanis 2016; Witte, Meyer, and Martell 2001; Hall, Weinman, and Marteau 2004; Legenthal et 
al. 1997; Bloss, Schork, and Topol 2011; Bloss et al. 2013; Ferguson and Barnett 2012).  
 Consideration of the main components of the TPB (attitudes towards a behaviour, 
subjective norms, behavioural control, and intention) (Ajzen 2006), as well as consideration of 
theory more generally, was assessing using deductive content analysis of the manuscripts (Elo 
and Kyngäs 2008). The deductive content analyses of consideration of the TPB and its key 
components in each study was then translated into a rating, based on the rating system generated 
in the NIH Study Quality Assessment Tools, whereby “good” indicates a robust consideration of 
the main components of the TPB, “fair” indicates intermediate consideration of the main TPB 
components, and “poor” represents little to no consideration of the main TPB components. An 
overall quality score was assigned to each article based on a point system, where “good” ratings 
were awarded 3 points, “fair” ratings were awarded 2 points, and “poor” ratings were awarded 1 
point. The maximum possible overall quality rating was 9/9, upon consideration of all three 
assessments.  
 
3.1.4 Results 
 
The comprehensive electronic literature search returned a total of 32,783 results, with 26 
studies meeting the predetermined inclusion criteria. In these 26 studies, the following outcomes 
were assessed: nutrition (n = 18), physical activity (n = 16), and smoking (n = 12) (Figure 3.2), 
with 14 articles assessing more than one lifestyle habit of interest to this review. The vast 
majority of the literature has been published over the past decade, with a large spike in 
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publications recently in 2015 (Supplementary Figure 3.3). Consistent with recommendations for 
systematic reviews (Petticrew and Roberts 2006), our review was analytic and descriptive in 
nature and included: (a) a tabulation of the study characteristics and findings (Table 3.1); (b) a 
thorough and robust quality assessment (Table 3.2); and (c) a narrative synthesis. Research 
conducted thus far has focused on a variety of genes, as outlined in (Table 3.3). It is concerning 
to note that 12 studies (46%) did not report whether or not the authors had a conflict of interest 
(COI). The vast majority of the literature has focused on genetic testing for determining the risk 
of developing certain diseases or conditions (88%; n = 23), while only a small number of studies 
have focused on nutrient metabolism (12%; n = 3), which indirectly affects the risk of 
developing diseases or conditions (Siscovick et al. 2017; Cornelis et al. 2006; Hietaranta-Luoma 
et al. 2014). The three separate quality assessments completed on each study are summarized in 
Table 3.2. Risk of bias was overall rated as “fair.” 
Are We Using High-Quality Genetic Interventions? 
Although some risk of bias is apparent, the ratings for the quality of the genetic 
interventions were more concerning, since overall the ratings were “poor” and only 6 of the 26 
studies (23%) received a “good” rating. Thus, it is clear that the studies did not provide high-
quality interventions to their participants, which helps to explain why the majority of studies did 
not report that genetic interventions facilitated lifestyle behaviour change. 
Are We Considering Validated Behaviour Change Theory? 
Consideration of the TPB and/or one or more of the theory’s three key components had 
mode overall ratings of “poor.” The deductive content analyses of the theoretical underpinnings 
mentioned in the studies are summarized in Supplementary Table 3.5. Fifteen studies (58%) did 
not make reference to any specific behaviour change theory or model within the text. When a 
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theory was included, it was generally only briefly mentioned and was not thoroughly 
incorporated into the study design, or expanded upon in the discussion. No study specifically 
referred to the TPB, suggesting that researchers have yet to consider this important theory in 
their study design or interpretation of findings. Several studies incidentally considered certain 
aspects of the TPB in the development of their scientific methods or within the text, such as the 
consideration of behavioural control by assessing one or more social determinants of health, 
such as income (Public Health Agency of Canada 2016). Overall, behaviour change theory is not 
being thoroughly incorporated into genetic testing behaviour change research. 
Does Genetic Testing Impact Changes in Nutrition, Physical Activity, and/or Smoking 
Behaviour? 
Overall. Given the heterogeneity of the literature and complexity of genetics-based 
behaviour change research, a cause-and-effect relationship between genetic testing and health 
behaviour change cannot be identified. Notably, it appears that it is unlikely that genetic testing 
has a “fatalistic” or negative impact on health behaviour change related to nutrition, physical 
activity, and smoking, since no study found that genetic testing negatively impacted the health 
behaviours of interest to the present review. Interestingly, 78% of the studies with health-
promoting lifestyle behaviour change findings provided their participants with a genetics-based 
intervention that included actionable health behaviour recommendations. Examples of actionable 
recommendations provided to participants for each lifestyle factor included recommendations to 
reduce sodium intake (nutrition) (Nielsen and El-Sohemy 2014), incorporate exercise into one’s 
daily routine (physical activity) (Meisel et al. 2015), and quit smoking (smoking) (Audrain et al. 
1997). Conversely, only 50% of the studies with null findings provided their participants with 
actionable health behaviour recommendations. Since an overarching cause-and-effect statement 
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about the impact of genetic testing on behaviour change cannot be made, a best evidence 
synthesis is provided below. 
 
Nutrition. Of the 18 articles that assessed a nutrition-related outcome, 6 (33%) showed a 
positive, health-promoting effect of genetic testing on behaviour change at one or more time 
points (both short term and long term, as further outlined in Tables 3.1 and 3.2). While this does 
not indicate that the majority of studies positively influenced nutrition, multiple studies of good 
quality (n = 6) have demonstrated that it is possible to facilitate healthier nutritional behaviours 
through the provision of genetic testing (Egglestone, Morris, and O’Brien 2013; Hietaranta-
Luoma et al. 2014; Nielsen and El-Sohemy 2014; Voils et al. 2015; Kaufman et al. 2012; 
Vernarelli et al. 2010). 
 
Physical Activity. The provision of genetic testing to facilitate physical activity behaviour 
change does not appear to be as promising as behaviour change related to nutrition. Of the 16 
studies that analyzed physical activity-related outcomes independently, only 2 (13%) found 
positive influences of genetic testing on physical activity (Egglestone, Morris, and O’Brien 2013; 
Kaufman et al. 2012), with follow-up periods ranging from 2 to 8 months in one study (Kaufman 
et al. 2012) and the periods not indicated in the other study (follow-up varied for each 
participant) (Egglestone, Morris, and O’Brien 2013). However, these articles rated poorly in their 
overall quality assessment, with “poor” to “fair” quality ratings of 3 (Egglestone, Morris, and 
O’Brien 2013) and 4 (Kaufman et al. 2012). 
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Smoking. Similar to nutrition, 4 (33%) of the 12 genetic intervention studies had a 
positive influence on smoking-related behaviours. However, improvements in smoking-related 
behaviours were generally only sustained over a short-term period. The overall quality of these 
studies was “fair.” 
 
Sleep. It is clear that sleep is an understudied area of genetic testing and behaviour change 
research, since our comprehensive search did not yield a single study that assessed sleep (sleep 
quality, hours of sleep, etc.) as a behaviour change outcome. 
 
Pooled Analyses. Two studies completed pooled analyses of changes in more than one 
lifestyle factor. Chao et al. did not find significant changes in nutrition or physical activity on 
their own, but when pooled together, there were significantly greater changes to nutrition and 
physical activity in the high-risk genetic testing group than in the non-risk and control groups 
(Chao et al. 2008). Additionally, in a pooled analysis of changes to nutrition, physical activity, or 
smoking, Egglestone et al. (Egglestone, Morris, and O’Brien 2013) found significant changes 
between the genetic testing group and the control group. However, their results should be 
interpreted with caution, as this study was awarded the lowest overall quality rating of 3 (Table 
3.2). 
Results from Controlled Intervention Trials 
While it is important to be comprehensive and consider all studies conducted on the topic 
of interest regardless of the research methods chosen, controlled interventions should be further 
highlighted and reviewed separately from other study designs given that this is the highest 
possible level of evidence for the original research included in the present review. 
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In total, 15 controlled intervention trials have been conducted over the past two decades. 
Approximately half of these studies (n = 7; 47%) found significant changes in nutrition and/or 
physical activity or in smoking at 1–3 time points included in the study. Consistent with the 
overall analysis, the controlled interventions found that nutrition was the most promising area of 
behaviour change, followed by smoking (short-term only). 
 
The genetic interventions in the controlled intervention trials overall ranked “fair,” 
demonstrating that in comparison to the result of the pooled analysis of all study designs, these 
studies provided their participants with higher-quality genetic interventions. This may help 
explain why 47% of the controlled intervention studies found significant changes in lifestyle 
habits resulting from the genetic intervention, compared to 36% of the studies using other study 
designs. The overall ranking of these studies was “fair,” with a mean rating of 5.6 out of the 
highest possible score of 9. Risk of bias overall was “fair” and consideration of the TPB was 
rated to be “poor,” which is consistent with the results of the analysis of all study designs 
combined. 
 
3.1.5 Discussion  
 
Given that decoding the entire human genome was the primary focus of genetic research 
until 2003 (National Institutes of Health 2015), it is not surprising to find that the majority of 
studies included in the present review were published after this time, with only 2 studies 
published before 2003. Since then, much greater focus has been placed on genetic testing 
behaviour change research pertaining to nutrition, physical activity, and smoking. However, 
47 
 
several studies included in the present review (46%) did not include a COI statement. Future 
research should ensure the inclusion of a COI statement given this concerning finding and given 
the increased emphasis in academia on the importance of considering COI in genetic testing and 
other research. 
 
Improving one or more of the four lifestyle behaviours of interest to this review has been 
shown to have a beneficial effect on chronic disease management and general health and well-
being (Dean and Söderlund 2015; Walker et al. 2010; B. Zhu et al. 2017; Wu, Zhai, and Zhang 
2014). The present review indicated that improvements to smoking habits were promising in the 
short-term. This finding was consistent with that of a previously published systematic review of 
the impact of genetic notification on smoking cessation (de Viron et al. 2012). 
 
While nutrition, physical activity, and smoking habits have been researched in multiple 
genetic intervention studies, sleep remains an understudied area of genetics and behaviour 
change. This is notable considering the substantial impact that sleep has on overall health and 
well-being. Current systematic reviews demonstrate a significant impact of sleep on cognition 
and emotion (Krause et al. 2017), glycemic control (Zhu et al. 2017), and overweight or obesity 
(Wu, Zhai, and Zhang 2014), to name a few. To our knowledge, little is known about the ability 
of sleep to modify genetic-associated health risks. Thus, future research should seek to first 
determine gene-sleep interactions that may influence health outcomes using methodologies 
similar to those of nutrigenomics research, as opposed to a genome-wide association study 
approach. Upon determining ways in which sleep may mitigate genetics-associated health risks, 
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future research should then seek to determine if genetic testing helps to motivate healthy sleep-
related behaviours. 
 
The considerable heterogeneity in studies (Tables 3.1 and 3.2) can be explained by a 
number of factors. Notably, the variation of statistical analyses between groups (i.e., genetic 
testing groups vs. control groups or high-risk genetic result groups vs. non-risk genetic result 
groups) would have impacted the findings and subsequent conclusions drawn. Consideration of 
theories in general to inform the study design was poor, and consideration of the TPB was 
absent, which further helps to explain the heterogeneity of findings, since several possible 
confounding factors were missed. Additionally, only 3 studies (Hietaranta-Luoma et al. 2014; 
Nielsen and El-Sohemy 2014; Roke et al. 2017) focused on nutrient metabolism. Therefore, a 
future focus is needed on genetic interventions related to nutrient metabolism and the subsequent 
disease risk through genetic testing of modifier genes (genetic risks that can be mitigated through 
specific lifestyle changes), rather than genetics-based disease risk estimates where there may be 
no known lifestyle modifications that can alter the genetic risk. It is possible that nutrition was 
the most promising lifestyle factor for promoting health behaviour change given that genetic 
testing of modifier genes typically leads to the provision of actionable recommendations [e.g., 
the recommendation to reduce sodium intake (Nielsen and El-Sohemy 2014)]. 
 
It is important to note that our risk-of-bias results are consistent with the previously 
published literature (Hollands et al. 2016; O’Donovan et al. 2017; French et al. 2017; Li et al. 
2016), providing validation for the NIH quality assessment process completed in the current 
review. Effect sizes were not included in this review due to heterogeneity of the genetic 
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interventions and study designs of the included articles that would have introduced potential 
flaws in effect size calculations and any conclusions drawn from such calculations. For 
randomized controlled trials, effect sizes have recently been presented elsewhere (Hollands et al. 
2016, although these should be interpreted with caution due to the significant heterogeneity of 
treatments (genetic interventions), measurements of outcomes, and populations studied. To our 
knowledge, we have developed and utilized the first quality assessment tool for evaluating and 
rating genetic interventions. Future research should seek to utilize this novel tool and significant 
contribution to the literature to assess the quality of genetic interventions in both primary 
research and systematic reviews. Furthermore, the components of this tool can be used in future 
genetic testing behaviour change study designs to improve the quality of genetic interventions 
provided to participants (Supplementary Table 3.4). Although the genetic intervention quality 
assessment was based on previously published robust research and critical commentaries 
(Nielsen and El-Sohemy 2014; Fenech 2008; Katsanis and Katsanis 2016; Witte, Meyer, and 
Martell 2001; Hall, Weinman, and Marteau 2004; Legenthal et al. 1997; Bloss, Schork, and 
Topol 2011; Bloss et al. 2013; Ferguson and Barnett 2012), assessing the quality of evidence 
supporting the genetic tests provided to participants was beyond the scope of the present review. 
This is an important area of future research and is a notable ethical concern of genetic testing. 
 
This review provides the most comprehensive analysis of genetic testing behaviour 
change research completed to date. However, some limitations to the present review exist. While 
this review summarized whether the genetic information was delivered direct to consumer or 
through a healthcare provider (Table 3.2), the practice of each provider is inevitably distinct. 
Some may incorporate behaviour change theory into their practice in order to maximally 
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promote health behaviour change, while others may simply provide an explanation of the genetic 
results. This limitation further highlights the complexity of genetic testing behaviour change 
research. Additionally, the TPB was chosen as the key theory of interest given that it is one of 
the most widely accepted and validated theories of behaviour change, with over 4,500 
publications referencing this theory and several meta-analyses finding that the key components 
of the TPB can be used to predict behavioural intentions with mean multiple correlations ranging 
from 0.59 to 0.67 (Ajzen 2011; Notani 1998; Rivis and Sheeran 2003; Wittmann 2003; Armitage 
and Conner 2001; Cheung and Chan 2000; Mceachan et al. 2016). However, a number of other 
theories have been validated and are frequently used in behaviour change research, such as the 
transtheoretical model (Prochaska and Velicer 1997). 
 
By improving upon genetic testing behaviour change studies, we anticipate the 
development of an algorithm that can be used to inform effective genetic testing behaviour 
change interventions for individuals who might benefit from this more personalized approach to 
healthcare. Indeed the limitations of genetic testing and the possible risk of harm (NIH: Genetics 
Home Reference 2018) should be considered prior to an individual’s decision to undergo genetic 
testing, especially in situations where one may learn about their risk of developing a disease, 
where actionable strategies for mitigating the risk are currently unknown (NIH: Genetics Home 
Reference 2018). Given that behaviour change is complex and multifactorial and studies have yet 
to robustly incorporate validated theory and high-quality genetic interventions into their 
methods, we cannot conclude with a broad statement about the impact of genetic testing on 
behaviour change. However, it is clear that it is possible to facilitate behaviour change through 
the provision of high-quality genetic interventions. Incorporating behaviour change theory into 
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future research is an important consideration to enhance our knowledge in this field. Specific 
recommendations for study design have recently been published elsewhere (Horne, Madill, and 
Gilliland 2017). An interdisciplinary research team with expertise in genomics as well as 
behaviour change may be the optimal approach given the complexities of this field of study. 
Considerable future research is needed in this promising and exciting area of lifestyle behaviour 
change research. 
 
3.1.6 Conclusion 
 
The use of validated theory to inform a robust study design (Horne, Madill, and Gilliland 
2017) and the provision of actionable, high-quality, genetic-based information and advice is 
recommended to test a behaviour change hypothesis in genetics research. Rather than using the 
traditional systematic review process of assessing solely risk of bias, we have demonstrated that 
factors beyond risk of bias influence research outcomes related to genetic testing and behaviour 
change. As more robust literature continues to be published, allowing for the determination of 
key components of genetic interventions that best facilitate behaviour change, lifestyle genomics 
behaviour change research has the potential to make a substantial impact on global health and 
well-being through the facilitation of personalized, health-promoting lifestyle behaviour change. 
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3.1.7 Tables and Figures  
 
Table 3.1: Summary of study characteristics and behaviour change findings 
                 
                 
                 
First 
author et 
al. date 
Participants 
(n baseline;  
n follow-up) 
 Interven
tion 
group(s) 
 Compar
ison 
group(s) 
 Target diseases/ 
conditions  
(genes tested) 
Follow-
up  
 Lifestyle habits 
assessed 
 Outcomes (p values); 
conclusions 
 Ranking of 
study design1 
COI 
                 
                 
Roke et al. 
2017  
Young 
female adults  
(n = 57;  
n = 56) 
 Genetic 
testing 
 No 
genetic 
testing 
 Health effects 
related to 
omega-3 intake 
(FADS1) 
 3 months  Nutrition 
(omega-3: EPA 
and DHA) 
 NS change in omega-3 
intake in the genetic 
testing group compared to 
the control group (no 
genetic testing) 
 1 No 
                                  Marsaux et 
al. 2016 
Adults  
(n = 265;  
n = 130) 
 High-
risk 
genetic 
result  
 Non-risk 
genetic 
result 
 Overweight/ 
obesity (FTO) 
 6 months  Physical activity  NS change in subjective or 
objective physical activity 
with provision of FTO 
genotype risk info 
 3 Yes 
                                  Meisel et 
al. 2015 
Young adults  
(n = 1,016;  
n = 279) 
Genetic 
testing 
 No 
genetic 
testing 
 Obesity (FTO)  1 month  Nutrition 
(adherence to a 
variety of eating 
behaviours) and 
physical activity 
 NS changes in nutrition 
and physical activity 
(pooled) between groups 
 1 No 
                                  Boeldt et 
al. 2015 
Adults 
working at 
health and 
technology 
companies 
(NR;  
n = 2,037) 
 Genetic 
testing 
 None  23 conditions 
including heart 
attack, 
Alzheimer 
disease, type 2 
diabetes, 
obesity, colon 
cancer, and 
cervical cancer 
(NR) 
 5.6±2.4 
months 
 Nutrition 
(dietary fat) and 
physical activity 
 NS (significance level NR) 
change in nutrition and 
physical activity following 
genetic testing2 
 4 No 
                 
                 Hietaranta-
Luoma et 
al. 2014 
Adults  
(n = 122;  
n = 113 at  
12 months) 
 Genetic 
testing 
 
and 
 
High-
risk 
genetic 
result 
 No 
genetic 
testing 
 
and 
 
Non-risk 
genetic 
result 
 Cardiovascular 
disease (apoE) 
 2 weeks 
6 months 
12 
months 
 Nutrition (fat 
quality, and 
consumption of 
vegetables, 
berries, fruits, 
and fatty and 
sugary foods) 
and physical 
activity 
 Improved dietary fat 
quality in the high-risk 
genetic result group vs. the 
control group at 2 weeks 
(p < 0.05) and 6 months of 
follow-up (p < 0.05); 
decreased intake of high-
fat, high-sugar foods in the 
non-risk genetic result 
group vs. the control group 
at 12 months (p < 0.05) 
 1 No 
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Voils et al. 
2015 
Veterans  
(n = 601;  
n = 506 at  
3 months,  
n = 472 at  
6 months) 
 Genetic 
testing 
 No 
genetic 
testing 
 Type 2 diabetes 
(TCF7L2, 
PPARγ, and 
KCNJ11) 
 3 months 
6 months 
 Nutrition 
(calories, 
carbohydrates, 
protein, fat, 
saturated fat, 
MUFA, and 
PUFA) and 
physical activity 
 Reduced calories and fat 
(MUFA and PUFA) in the 
genetic testing group vs. 
the no-genetic-testing 
group (p < 0.05) at 3 
months; NS changes in 
nutrition between the 
groups at 6 months; NS 
changes in physical 
activity at either time point 
 1 Yes 
                                  Marsaux et 
al. 2016 
Adults  
(n = 1,607;  
n = 1,233 
with 
subjective 
data at  
6 months,  
n = 730 with 
objective data 
at  
6 months) 
 Genetic 
testing 
 No 
genetic 
testing 
 Overweight/ 
obesity (FTO) 
 3 months 
6 months 
 Physical activity  NS changes in physical 
activity with the addition 
of genetic information 
 1 Yes 
                 
                 Nielsen et 
al. 2014 
Adults  
(n = 138;  
n = 130 at  
3 months,  
n = 123 at  
12 months) 
 High-
risk 
genetic 
result 
 
and 
 
Non-risk 
genetic 
result 
 No 
genetic 
testing 
 Caffeine 
metabolism 
(CYP1A2), 
vitamin C 
utilization 
(GSTT1 and 
GSTM1), sweet 
taste perception 
(TAS1R2), and 
sodium 
sensitivity 
(ACE) 
 3 months 
12 
months 
 Nutrition 
(caffeine, 
vitamin C, added 
sugar, and 
sodium) 
 The high-risk genetic 
result group (for the ACE 
gene) had reduced sodium 
intake to a greater extent 
than the control group by 
the 12-month follow-up (p 
= 0.008); NS changes in 
caffeine, vitamin C, and 
added sugar intake at each 
follow-up time point; NS 
changes in sodium intake 
at the 3-month follow-up 
 1 Yes 
                                  Egglestone 
et al. 2013 
Adults who 
had 
purchased a 
DTC genetic 
test or were 
considering 
purchasing a 
test or who 
were 
awaiting their 
results  
(n = 275) 
 Genetic 
testing 
 No 
genetic 
testing 
 NR (NR)  Varied  Nutrition 
(healthier diet, 
vitamins/ 
supplements, 
caffeine, fibre, 
salt, fat, and 
fruits/vegetables
), physical 
activity, and 
smoking 
 Greater health behaviour 
scores in the genetic 
testing group vs. the 
control group (p = 0.02 for 
pooled nutrition, physical 
activity, and smoking); the 
most common changes 
were “healthier diet,” 
“more exercise,” and 
“taking vitamins or 
supplements”; more often 
reported “sufficient fruit 
and vegetable intake” in 
the genetic testing group (p 
= 0.03); NS changes in 
smoking individually 
 2 NR 
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Bloss et al. 
2013 
Adults 
working at 
health and 
technology 
companies  
(n = 3,639;  
n = 2,037 at  
3 months,  
n = 1,325 at 
14 ± 1.3 
months) 
 Genetic 
testing 
 None  Deep vein 
thrombosis, 
melanoma, 
sarcoidosis, 
haemochromatos
is, lactose 
intolerance, 
breast cancer, 
prostate cancer + 
20 other 
conditions not 
listed (variable) 
 3 months  
14±1.3 
months 
 
 Nutrition 
(dietary fat) and 
physical activity 
 NS changes in nutrition or 
physical activity at 3 
months (significance level 
NR) or 14±1.3 months 
 4 No 
                                  Kaufman et 
al. 2012 
Adult 
customers of 
DTC genetic 
testing 
companies  
(n = 3,167;  
n = 1,048) 
 Genetic 
testing 
 
and 
 
High-
risk 
genetic 
result 
 Non-risk 
genetic 
result 
 Variable  
(variable) 
 2–8 
months 
 Nutrition 
(change diet) 
and physical 
activity 
 The participants who 
considered themselves at 
high risk of colon cancer 
were significantly more 
likely to change their diet 
(p = 0.02) and start 
exercising more (p = 0.01) 
than those who considered 
themselves at low risk of 
colon cancer; 10% of all 
participants reported they 
changed a supplement, 
33% reported being more 
careful about their diet, 
and 14% reported 
exercising more 
 2 NR 
                                  Hollands et 
al. 2012 
Adults with 
1st-degree 
relatives with 
Crohn’s 
disease  
(n = 497;  
n = 426) 
 Genetic 
testing 
 
and 
 
High-
risk 
genetic 
result 
 No 
genetic 
testing 
 
and 
 
Non-risk 
genetic 
result 
 Crohn’s disease 
(NOD2) 
 6 months  Smoking  NS changes in smoking 
cessation between the 
genetic testing and the no-
genetic-testing group; NS 
changes in smoking 
cessation between the 
high-risk and the non-risk 
genetic result group 
(significance level NR) 
 1 No 
                                  Bloss et al. 
2011 
Adults 
working at 
health and 
technology 
companies  
(n = 3,639;  
n = 2,037) 
 Genetic 
testing 
 None  23 conditions 
including breast 
and prostate 
cancer (NR) 
 5.6±2.4 
months 
 Nutrition 
(dietary fat) and 
physical activity 
 NS changes in nutrition 
and/or physical activity 
following genetic testing 
 4 NR 
                                  Vernarelli 
et al. 2010 
Adults with 
at least one 
parent who 
developed 
Alzheimer 
disease  
(n = 279;  
n = 272) 
 High-
risk 
genetic 
result 
 Non-risk 
genetic 
result 
 Alzheimer 
disease (apoE) 
 6 weeks  Nutrition 
(dietary 
supplement use) 
and physical 
activity 
 The high-risk genetic 
result group was more 
likely to take supplements 
than the non-risk genetic 
result group (p = 0.0001) 
 3 No 
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Hishida et 
al. 2010 
Adult 
smokers (n = 
562; n = 533) 
 Genetic 
testing 
 No 
genetic 
testing 
 Lung and 
oesophageal 
cancer  
(L-myc) 
 12 
months 
 Smoking  NS changes in smoking 
cessation between the 
genetic testing and the no-
genetic-testing group 
 1 No 
                                  Quach et 
al. 2009 
Adults with a 
personal 
and/or family 
history of 
breast and/or 
ovarian 
cancer  
(n = 120;  
NR) 
 Genetic 
testing 
 None  Breast and 
ovarian cancer 
(BRCA1/2) 
 6 months  Nutrition 
(healthy diet and 
vitamin use) and 
physical activity 
 NS changes in nutrition, 
vitamin use, or physical 
activity after genetic 
testing (significance level 
NR) 
 4 NR 
                                  O’Neill et 
al. 2008 
Adult 
females  
(NR;  
n = 115 at  
1 month and  
6 months) 
 High-
risk 
genetic 
result 
 Uninfor
mative 
genetic 
result 
 
and 
 
Non-risk 
genetic 
result 
 Breast cancer 
(BRCA1/2) 
 1 month 
6 months 
 Nutrition 
(saturated fat, 
fruit/vegetables) 
and physical 
activity 
 NS differences between 
groups in nutrition or 
physical activity at 
baseline and 1 month or 6 
months following genetic 
testing 
 3 NR 
                                  Chao et al. 
2008 
Adult with 
parent who 
developed 
Alzheimer 
disease  
(n =162;  
n = 147) 
 Genetic 
testing 
 
and 
 
High-
risk 
genetic 
result 
 No 
genetic 
testing 
 
and 
 
Non-risk 
genetic 
result 
 Alzheimer’s 
disease (apoE) 
 12 
months 
 Nutrition 
(changes in diet, 
changes in 
vitamin/ 
supplement use) 
and physical 
activity 
 The high-risk genetic 
result group was more 
likely to report a nutrition 
or physical activity change 
than the non-risk genetic 
result group (p = 0.003) 
and the no-genetic-testing 
group (p = 0.03); most 
common was a change in 
medication/supplement use 
(specifically vitamin E) 
 1 NR 
                                  Sanderson 
et al. 2008 
Adult 
smokers (NR;  
n = 61) 
 Genetic 
testing 
 
and 
 
High-
risk 
genetic 
result 
 No 
genetic 
testing 
 
and 
 
Non-risk 
genetic 
result 
 Lung cancer 
(GSTM1) 
 1 week 
2 months 
 Smoking  Fewer cigarettes smoked 
(p = 0.009) and greater 
quit rates (p = 0.009) at the 
1-week follow-up in the 
high-risk genetic result 
group than in the no-
genetic-testing group; NS 
differences at the 2-month 
follow-up between the 
groups for cigarettes 
smoked and quit rates 
 1 No 
                                  Rees et al. 
2007 
Adult 
females  
(n = 23) 
 Genetic 
testing 
 None  Breast cancer 
(BRCA1/2) 
 Varied – 
up to 18 
months 
 Nutrition 
(dietary 
changes), 
physical activity, 
and smoking 
 Few women reported a 
significant impact on 
nutrition, physical activity, 
and/or smoking as a result 
of receiving genetic testing 
results and counselling 
(significance level N/A) 
 Qualitative NR 
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Rief et al. 
2007 
Adults  
(n = 294) 
 Genetic 
testing 
and 
consultat
ion 
 No 
genetic 
testing – 
consultat
ion only 
 
and 
 
No 
genetic 
testing 
and no 
consultat
ion 
 Obesity (NR)  6 months  Nutrition 
(restraint eating) 
 NS changes to restraint 
eating in the genetic 
testing group compared to 
the no-genetic-testing 
groups 
 1 No 
                                  Carpenter 
et al. 2007 
Adult 
smokers (n = 
729; n = 199) 
 High-
risk 
genetic 
result 
 Non-risk 
genetic 
result 
 Emphysema 
(AAT) 
 3 months  Smoking  Those with high-risk 
genetic results made 
significantly greater quit 
attempts than the non-risk 
genetic result group (p = 
0.004) 
 3 NR 
                                  Ito et al. 
2006 
Adult 
smokers (n = 
697; n = 369 
with data for 
baseline,  
3 and 9 
months) 
 Genetic 
testing 
 No 
genetic 
testing 
 Lung and 
oesophageal 
cancer  
(L-myc) 
 3 months 
9 months 
 Smoking  NS differences in smoking 
cessation between groups 
at 3 months (significance 
level NR) or 9 months 
 1 NR 
                                  Marteau et 
al. 2004 
Adult 
probands and 
their adult 
relatives with 
familial 
hypercholeste
rolaemia (n = 
341;  
n = 275) 
 Genetic 
testing 
 No 
genetic 
testing 
 Familial 
hypercholesterol
aemia (NR) 
 6 months  Nutrition (total 
fat and 
unsaturated fat), 
physical activity, 
and smoking 
 NS impact on nutrition, 
physical activity, or 
smoking with genetic 
testing 
 1 NR 
                                  Mcbride et 
al. 2002 
Adult 
smokers (n = 
557; n = 412 
at  
6 months,  
n = 356 at  
12 months,  
n = 487 with 
data from all 
3 time points) 
 Genetic 
testing 
 No 
genetic 
testing 
 Lung cancer 
(GSTM1) 
 6 months 
12 
months 
 Smoking  Greater smoking cessation 
in the genetic testing group 
than in the no-genetic-
testing group (p < 0.006) at 
6 months; NS smoking 
cessation rates at 12 
months 
 1 NR 
Audrain et 
al. 1997 
Adult 
smokers (n = 
550; n = 426) 
 Genetic 
testing 
 No 
genetic 
testing 
 Lung cancer 
(CYP2D6) 
 12 
months 
 Smoking   Greater likelihood of quit 
attempts in the genetic 
testing group than in the 
no-genetic-testing group (p 
= 0.02); NS change in 30-
day cessation between 
groups 
 1 NR 
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Table 3.1 Legend: COI, conflict of interest; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; NS, not statistically significant (p > 0.05 unless otherwise 
stated); NR, not reported; DTC, direct to consumer; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid. 1 The rank of the study design is as 
follows, based on the categories of the NIH Quality Assessment Tools (NIH, 2014) in combination with consideration of the hierarchy of evidence (Evans et al. 
2003): 1 = controlled intervention study; 2 = observational cohort/cross-sectional study; 3 = case-control study; 4 = pre-post study with no control group. 2 Note: 
significance levels for this group of participants are reported in Bloss et al. 2011. 
        
        
 
Table 3.2: Summary of quality assessment ratings and impact of genetic testing on lifestyle factor(s) of interest 
        
        
Ranking of 
study 
design1 
First author, 
year 
Quality assessment rating  Key findings: impact of genetic testing on 
lifestyle factor(s) of interest 
 Source of genetic 
information 
Specific lifestyle factors with significant 
improvement 
    methods genetic 
info 
TPB overall 
quality 
score 
 nutrition PA smoking nutrition 
& PA 
 nutrition, 
PA, & 
smoking 
               
               
1 Roke et al. 
2017 
Good Fair Fair 7  Δ      Other N/A 
                              1 Hietaranta-
Luoma et al. 
2015 
Fair Good Poor 6  a  
(2 weeks) 

b  
(6 
months) 

c  
(12 
months) 
Δ     HCP Improved dietary fat quality (high-risk 
genotype vs. control at 2 weeks and 
baseline to 6-month follow-up in high-risk 
genotype group); decreased intake of high-
fat, high-sugar foods (in low-risk genotype 
vs. control at 12 months) 
                              1 Marsaux et al. 
2015 
Fair Fair Poor 5   Δ     DTC N/A 
                              1 Meisel et al. 
2015 
Poor Fair Fair 5  Δ Δ     DTC N/A 
                              1 Voils et al. 
2015 
Fair Good Poor 6  d  
(3 
months) 
Δ  
(6 
months) 
Δ     HCP Reduced calories and fat (MUFA and 
PUFA) 
                              1 Nielsen et al. 
2014 
Good Fair Poor 6  Δ  
(3 
months) 

a  
(12 
months) 
     DTC Reduced sodium intake 
                              1 Hollands et al. 
2012 
Good Good Poor 7    Δ    Other N/A 
                              1 Hishida et al. 
2010 
Poor Poor Poor 3    Δ    HCP N/A 
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1 Chao et al. 
2008 
Fair Poor Poor 4  Δ Δ  a, e   HCP General improvements to nutrition and PA; 
vitamin E supplementation was the most 
common change reported 
                              1 Sanderson et 
al. 2008 
Poor Fair Fair 5    a  
(1 week)  
Δ  
(2 
months) 
   HCP Fewer cigarettes smoked and greater 
smoking cessation 
                              1 Rief et al. 2007 Fair Good Poor 6  Δ      HCP N/A 
                              1 Ito et al. 2006 Poor Good Fair 6    Δ    Other N/A 
                              1 Marteau et al. 
2004 
Fair Fair Fair 6  Δ Δ Δ    HCP N/A 
                              1 McBride et al. 
2002 
Poor Good Fair 6    d  
(6 
months) 
Δ  
(12 
months) 
   Other Greater smoking cessation 
                              1 Audrain et al. 
1997 
Fair Fair Fair 6    d (quit 
attempts) 
Δ (30-day 
cessation) 
   HCP Greater likelihood of quit attempts 
                            Summary2 (n = 15) Fair Fair Poor 5.6  3/8 0/6 3/7 1/1    
                              2 Egglestone et 
al. 2013 
Poor Poor Poor 3  d d Δ  d  DTC Greater health behaviour scores; the most 
common changes were “healthier diet,” 
“more exercise,” and “taking vitamins or 
supplements”; more often reported 
“sufficient fruit and vegetable intake” 
               2 Kaufman et al. 
2012 
Fair Poor Poor 4  e e     DTC + optional 
HCP 
“Changed their diet” and “started 
exercising more” 
                            Summary2 (n = 2) Fair – 
poor 
Poor Poor 3.5  2/2 2/2 0/1  1/1   
                              3 Marsaux et al. 
2016 
Fair Fair Poor 5   Δ     DTC N/A 
                              3 Vernarelli et al. 
2010 
Good Poor Poor 5  e Δ     HCP Greater changes in supplement use; vitamin 
E, vitamin C, botanicals, multivitamins, 
vitamin B, and fish oil/omega were the 
most common changes reported 
                              3 O’Neill et al. 
2008 
Good Poor Poor 5  Δ Δ     HCP N/A 
                                             3 Carpenter et al. 
2007 
Fair Fair Poor 5    e    DTC + optional 
HCP 
Greater 24-h quit attempts 
                            Summary2 (n = 4) Good – 
fair 
Fair – 
poor 
Poor 5.0  1/2 0/3 1/1     
                              4 Boeldt et al. 
2015 
Fair Poor Fair 5  Δ Δ     DTC + optional 
HCP 
N/A 
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                              4 Bloss et al. 
2013 
Fair Poor Fair 5  Δ Δ     DTC + optional 
HCP 
N/A 
                              4 Bloss et al. 
2011 
Fair Poor Poor 4  Δ Δ     DTC + optional 
HCP 
N/A 
                              4 Quach et al. 
2009 
Fair Poor Fair 5  Δ Δ     HCP N/A 
                            Summary2 (n = 4) Fair Poor Fair 4.8  0/4 0/4      
                              Qualitative Rees et al. 
2007 
Good Poor Poor 5  Δ Δ     HCP N/A 
                            Summary2 (n = 1) Good Poor Poor 5.0  0/1 0/1      
                        Summary of all studies  
(n = 26) 
FAIR POOR POOR 5.2  Nutrition: 6/18 (33%) 
PA: 2/16 (13%) 
Smoking: 4/12 (33%) 
 Studies with significant beneficial health behaviour 
change(s): 
        7/93 (78%) provided actionable recommendations 
        Studies with null findings: 
7/14 (50%) provided actionable recommendations 
               
               
“Other” sources of genetic information: Roke et al. 2017, used a researcher; McBride et al. 2002, used “trained counsellors”; Ito et al. 2006, used a “trained interviewer”; 
Hollands et al. 2012, used a “trained research counsellor.” No studies found a detrimental effect of genetic testing on lifestyle change. Statistically significant beneficial behaviour 
change(s); Δ, no statistically significant behaviour change(s); blank cells, lifestyle factor(s) of interest was/were not assessed; N/A, not applicable; TPB, theory of planned 
behaviour; PA, physical activity; HCP, genetic intervention offered through a healthcare provider; DTC, genetic intervention offered direct to consumer; Other, another method 
was used to deliver the genetic intervention to the participants; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid. 1 The rank of the study design is as 
follows, based on the National Institutes of Health Quality Assessment Tools (National Institutes of Health n.d.) and the hierarchy of evidence pyramid (Evans 2003): 1 = 
controlled intervention study; 2 = observational cohort/cross-sectional study; 3 = case-control study; 4 = pre-post study with no control group. 2 n = x indicates the total number 
of studies included in the summary; modes are reported for each of the three quality assessment ratings; x/x indicates the number of beneficial behaviour change findings/the 
total number of studies (note: several studies included multiple analyses such as those with more than one follow-up time point, and those assessing more than 1 lifestyle factor 
of interest); the overall quality score is represented as a mean. 3 Three studies did not provide information about whether or not actionable recommendations were provided. 
a High-risk genotype vs. control group. b Baseline to 6-month follow-up in high-risk genotype group. c Non-risk genotype vs. control group. d Genetic testing group vs. control 
group. e High-risk genotype group vs. non-risk genotype group. 
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Table 3.3: Frequencies of genes tested in genetic interventions and their reported associated 
health outcomes 
   
   
Gene Frequency Health outcomes reported to be 
associated with the gene 
   
   
AAT 1 Emphysema 
ACE 1 Salt sensitivity 
apoE 3 Alzheimer disease 
Cardiovascular disease 
BRCA1 3 Breast cancer 
Ovarian cancer 
BRCA2 3 Breast cancer 
Ovarian cancer 
CYP1A2 1 Caffeine metabolism 
CYP2D6 1 Lung cancer 
FADS1 1 Omega-3 metabolism 
FTO 3 Overweight/obesity 
GSMT1 3 Lung cancer 
Vitamin C utilization 
GSTT1 1 Vitamin C utilization 
KCNJ11 1 Type 2 diabetes 
L-myc 2 Lung cancer 
Oesophageal cancer 
NOD2 1 Crohn’s disease 
PPARγ 1 Type 2 diabetes 
TAS1R2 1 Sweet taste preference 
TCF7L2 1 Type 2 diabetes 
   
   
Of the studies that reported the specific genes tested in the genetic 
intervention, single nucleotide polymorphisms in 16 unique genes were 
tested, with apoE, BRCA1/2, FTO, and GSTM1 having the highest 
frequencies of use in the genetic intervention. 
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Figure 3.1: Search terms 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Search strategy 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
*Several articles assessed behaviour change related to >1 lifestyle factor of interest; 
therefore, the total number of records included in the systematic review does not match 
the total number of articles by lifestyle category.  
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Supplementary Table 3.4: Quality assessment tool for genetic interventions 
Criteria Yes No Other (CD, 
NR, NA)* 
1. Were the results of the genetic test interpreted and explained by a trained 
healthcare professional? 
   
2. Was a copy of the genetic testing report provided to the participants?    
3. Were the results of the genetic test communicated to participants on more than 
one occasion (i.e. was there follow-up provided after the initial communication of 
the results)? 
   
4. Were the results provided in the report, or discussed in the genetic counselling 
session actionable (i.e. did the report contain specific recommendations or did the 
genetic counsellor communicate specific recommendations)? 
   
5. Were the participants provided with an opportunity to ask questions about their 
results? 
   
 
Other Comments: ___________________________________________________________________________________ 
Overall Rating:_____________________________________________________ (Good, Fair, Poor; if Poor state reasons) 
*CD, cannot determine; NA, not applicable; NR, not reported 
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Supplementary Table 3.5: Summary of behaviour change theories and models included in 
genetic intervention behaviour change research manuscripts  
Author (Year) Was reference 
made to the TPB? 
Was reference made to another 
behaviour change theory or 
model? 
Other Comments 
Roke (2017)  No Yes – Parallel Process Model*  
Marsaux (2016)  No No  
Meisel (2015)  No No  
Boeldt (2015)  No Yes – Health Belief Model and 
Parallel Process Model* 
 
Hieteranta-Luoma 
(2015)  
No No  
Voils (2015)  No No  Referred to “behaviour theories” in general 
Marsaux (2015)  No No  
Nielsen (2014)  No No  
Egglestone (2013)  No No  
Bloss (2013)  No No  
Kaufman (2012)  No No  
Hollands (2012) No No - Referred generally to “theories of attitude 
change” 
Bloss (2011)  No No  
Vernarelli (2010)  No No  
Hishida (2010)  No Yes – Transtheoretical Model**, 
Extended Parallel Process Model 
 
Quach (2009)  No Yes – Self-Regulation Model  
O’Neil (2008)  No Yes – Transtheoretical Model**   
Chao (2008)  No No  
Sanderson (2008)  No Yes – Extended Parallel Process 
Model 
 
Rees (2007)  No Yes – Transtheoretical Model** - Discussed that interventions based on 
behaviour change theories are more 
effective 
- Referenced a meta-analysis of Protection 
Motivation Theory 
- Referenced an article which referred to 
several theoretical perspectives including 
the TPB and Theory of Reasoned Action 
Rief (2007)  No No  
Carpenter (2007)  No Yes – Transtheoretical Model**  
Ito (2006)  No Yes – Transtheoretical Model**  
Marteau (2004)  No No Referenced a meta-analysis of Protection 
Motivation Theory 
McBride (2002)  No Yes – Transtheoretical Model** 
and Social Cognitive Theory 
 
Audrain (1997)  No Yes – Transtheoretical Model**  
 
*The Parallel Process Model is often referred to as The Common Sense Model 
**The Transtheoretical Model is often referred to as The Stages of Change  
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Supplementary Figure 3.3: Number of studies published annually by category 
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CHAPTER 4: A CRITICAL, SCOPING REVIEW OF GENETIC-
BASED INTERVENTIONS FOR WEIGHT MANAGEMENT 
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4.1 Title: Assessing the effectiveness of actionable nutrigenomics and lifestyle 
genomics interventions for weight management: A critical, scoping review with 
directions for future research 
 
4.1.1 Abstract 
 
The use of nutrigenomics and lifestyle genomics in clinical practice has the potential to 
optimize weight-related outcomes for patients. A scoping review was conducted to summarize 
and evaluate the current body of knowledge related to the effectiveness of providing DNA-based 
lifestyle advice on weight-related outcomes, with the aim of providing direction for future 
research. Primary studies were included if they were written in English, evaluated weight-related 
and/or body composition outcomes, and provided participants with an actionable genetic-based 
lifestyle intervention. Interventions that only provided information on genetic risk for 
diseases/conditions were excluded. Data were extracted from each article meeting inclusion 
criteria (n=3) and the studies were critically appraised for methodological quality. Research in 
this area is promising, but limited. One study demonstrated that a nutrigenetic intervention 
resulted in greater long-term weight loss compared to a standard intervention, while another 
found no significant improvements in weight-related outcomes with genetically-tailored advice. 
The third study found that individuals with high-risk FTO genotypes had greater changes in 
markers of adiposity compared to a group receiving standard/non-personalized advice, but no 
differences were observed between the genetic group and groups receiving other levels of 
personalization that did not include the provision of genetic information and advice. With limited 
existing research, the effectiveness of nutrigenomics and lifestyle genomics interventions for 
weight management in clinical practice cannot yet be conclusively determined. 
Recommendations for future research are detailed in the present manuscript.  
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4.1.2 Background 
 
Consumers have expressed considerable interest in nutrigenetic testing (Vallée Marcotte 
et al. 2019; Nielsen and El-Sohemy 2014). As a result, many companies are offering 
personalized DNA-based lifestyle advice, most of which provide specific recommendations to 
optimize weight management practices (Nutrigenomix Inc., n.d.; MyDNA 2019; Pathway 
Genomics, n.d.; 23andMe n.d.). With increasing epidemiological and interventional research 
demonstrating relationships between genetics, nutrition and physical activity, and weight-related 
outcomes (Garaulet et al. 2011; Phillips et al. 2012; Zhang et al. 2012; Corella et al. 2009), 
personalized lifestyle recommendations based on genetics are beginning to be established. For 
example, evidence from a 2-year randomized controlled trial (RCT) reported that variation in the 
FTO gene at rs9939609 can predict weight loss response to a lower vs. higher protein diet 
(Zhang et al. 2012).   
 
Weight loss continues to be a priority for the general public (Sui et al. 2019). As such, 
nutrigenomics and lifestyle genomics testing for weight management are attractive tools, as they 
promote more personalized strategies for individuals to optimize their weight loss response to a 
particular dietary plan (Garaulet et al. 2011; Phillips et al. 2012; Zhang et al. 2012; Corella et al. 
2009). While the scientific evidence for personalized weight management strategies continues to 
grow, long-term behaviour change and weight management remains a challenge and weight loss 
outcomes in clinical practice often do not satisfy the wants or needs of patients (Soleymani, 
Daniel, and Garvey 2016; Field, Camargo, and Ogino 2013; Rogerson, Soltani, and Copeland 
2016). Moreover, weight loss is often followed by weight regain above and beyond baseline 
weight. Research has demonstrated that such weight “yo-yoing” (the constant and recurring 
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decrease and increase in weight over time) could be more harmful to health than maintenance of 
a higher body mass index (BMI) (Rhee 2017).  
 
Research demonstrates that individual responses to nutritional intake for weight 
management differ based on genetic variation (Garaulet et al. 2011; Phillips et al. 2012; Zhang et 
al. 2012; Corella et al. 2009). Some studies have also shown that individuals are more motivated 
to follow nutrition advice when it is based on their genetics (Nielsen and El-Sohemy 2014; 
Horne et al. 2018; Kaufman et al. 2012). Thus, it is possible that the provision of nutrigenomics 
and lifestyle genomics interventions could be used as tools to support long-term weight 
management. However, multiple factors beyond genetics, nutrition, and physical activity 
contribute to the development and management of obesity including the social determinants of 
health, built environment, food access and availability, medications, certain diseases/conditions 
such as polycystic ovarian syndrome, sleep, stress and others (Moore et al. 2010; Finkelstein, 
Ruhm, and Kosa 2005; Seabrook and Avison 2010; Gilliland et al. 2012; Naderpoor et al. 2015; 
Maina et al. 2004). Thus, managing overweight and obesity is multi-factorial. Nutritional 
genomics and lifestyle genomics are not the only considerations of weight management, but they 
remain important components of the overall picture, alongside other factors.  
 
With the robust and growing research foundation on the science of nutrigenomics, 
lifestyle genomics, and differing weight loss responses to the same nutrition plans, this review 
aims to summarize and evaluate the current body of knowledge related to the effectiveness of 
providing DNA-based lifestyle advice on weight-related outcomes, with the aim of providing 
direction for future research.  
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4.1.3 Methods 
 
A scoping review was conducted with guidance from Arksey and O’Malley’s 
methodological framework (Arksey and O’Malley 2005). The purpose of this review was to 
identify, summarize and review the existing literature on the efficacy of using genetic-based 
lifestyle interventions to enhance weight loss and/or improve body composition. Furthermore, 
we aimed to use these results to provide direction for future research. English articles assessing 
the impact of providing genetic-based lifestyle advice on weight-related, BMI and/or body 
composition outcomes were included. Non-English articles, and articles assessing the impact of 
providing information on genetic risk (i.e. without actionable lifestyle advice) were excluded. To 
capture studies only assessing the pragmatic use of genetic-based lifestyle interventions, articles 
were also excluded if they aimed to identify or replicate gene-nutrient-health outcome/weight 
interactions. PubMed and Google Scholar were searched for relevant studies using different 
combinations of the following search terms: nutrigenomics, nutrigenetics, nutritional genomics, 
lifestyle genomics, weight, BMI, body composition, intervention, nutrition, lifestyle, and/or 
physical activity. Reference lists of included articles were reviewed for relevant articles.  
 
The following data from each study were charted: author(s), year of publication, 
intervention type and comparator, duration of intervention, study population, methods, relevant 
outcome measures, single nucleotide polymorphisms (SNPs) included in genetic reports, genetic 
testing company (where applicable), and relevant results related to the effectiveness of genetic-
based weight management interventions. Each article was critically appraised for key limitations 
70 
 
of the employed scientific methods to determine gaps in the existing literature and provide 
direction for future research.  
 
4.1.4 Results 
 
A summary of studies meeting the inclusion criteria (n=3) is presented in Table 4.1.  This 
review found that overall research in this area is minimal, with only three studies assessing the 
practical impact of providing actionable genetic-based lifestyle information on weight-related 
and/or body composition outcomes. While two RCTs have been conducted, one was a feasibility 
study (Frankwich et al. 2015), which has not yet been followed up with a larger, adequately 
powered trial and in the other, change in a weight-related outcome was not the primary outcome 
of interest (Celis-Morales et al. 2017; Newcastle University 2016).   
 
The retrospective chart review by Arkadianos et al. (2007) was an informative first step 
for this body of knowledge. The authors concluded that individuals receiving the nutrigenomics 
intervention were more likely to maintain weight loss and experienced significantly greater BMI 
reductions over the long-term, compared to individuals who were advised to follow a low 
glycemic-index, Mediterranean diet. However, several methodological limitations should be 
noted. First, due to the nature of the study methods (retrospective chart review), cause and effect 
relationships cannot be drawn. Furthermore, the nutrition recommendations provided to 
participants were not specific to weight management; rather, they provided recommendations for 
general health and wellbeing. For example, SNPs in tumor necrosis factor alpha (TNFα), 
interleukin 6 (IL6) and nitric oxide synthase 3 (NOS3) were tested to provide nutrition 
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recommendations such as “Add supplement Omega 3 (700-1400 mg). Make sure weekly diet 
contains portions of oily fish” (Arkadianos et al. 2007).  Additionally, intervention durations 
were not standardized and therefore varied substantially in both total length and the amount of 
follow-up. Of note, income was not considered as a confounding factor, and given that patients 
either chose to purchase a nutrigenetic test (out of pocket) or did not purchase a nutrigenetic test 
in this study, it is plausible that income levels differed significantly between groups. This is an 
important confounding factor to consider given that income is a well-established social 
determinant of health (Government of Canada 2019; Seabrook and Avison 2012). The authors 
noted several other limitations including the lack of placebo, modest sample (n=93) size, and a 
sample consisting of Caucasian individuals from Greece with a history of difficulty losing 
weight, thus limiting generalizability (Arkadianos et al. 2007).  
 
Frankwich and colleagues conducted the first RCT in this area (Frankwich et al. 2015). 
This was a feasibility RCT. Feasibility trials are distinguished by their focus on assessing the 
viability or capability of conducting a larger trial, rather than assessing effectiveness or efficacy 
of an intervention with adequate power  (Eldridge et al. 2016). The percent of participants 
achieving 5% weight loss was the primary outcome, and this study found that there was no 
significant difference between groups in the percent of participants achieving 5% weight loss 
(Frankwich et al. 2015). However, typically estimates of participant outcomes such as weight 
loss would be reported as estimates with 95% confidence intervals (without p-values) given that 
feasibility trials are not adequately powered to assess the effectiveness of an intervention 
(Eldridge et al. 2016).  In fact, the authors noted limitations related to the small sample size 
(n=32), and determined that a sufficiently powered trial would require 336 participants per group 
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using a sample size calculation with 80% power and an alpha-level of 0.05 (Frankwich et al. 
2015).  
 
Finally, Celis-Morales et al. (2017) conducted the second RCT on this topic, which was a 
sub-study within the larger Food4Me RCT. This was a significant contribution to the body of 
knowledge in this area. In total, participants were provided with information and advice related 
to five gene-lifestyle-health outcome interactions (FTO, physical activity and weight; FADS1 
omega-3 and cardiovascular health; TCF7L2 dietary fat and weight; ApoE(e4), saturated fat and 
cholesterol/cardiovascular health; MTHFR, folate and cardiovascular health). This study 
compared weight and waist circumference (WC) outcomes between a control group and different 
levels of personalized advice (as outlined in Table 4.1), and further compared risk and non-risk 
FTO genotype groups (Celis-Morales et al. 2017). Participants randomized to receive FTO 
genetic information/advice were informed that “A specific variation of this gene is associated 
with a greater need to maintain a healthy body weight and engage in physical activity. A healthy 
weight combined with exercise may provide added health benefits for these individuals.” 
Carriers of the high-risk FTO allele were further advised to “[reduce their] body weight and 
waist circumference to a healthy normal range because [they] have a genetic variation that can 
benefit by reducing these two obesity-related markers.” Furthermore, participants randomized to 
receive genetic-based advice were provided with weight-related information and advice 
according to a variant within the TCF7L2 gene. They were informed that “a specific variation of 
this gene is associated with improved weight loss when consuming a low-fat diet compared with 
the effect of other weight-loss diets” and that “reducing dietary fat may enhance weight loss in 
these individuals” (Celis-Morales et al. 2017). While the RCT was well-designed and is 
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reflective of direct-to-consumer (DTC) lifestyle genomics testing, there are some considerable 
limitations to note. First, the height, weight, and waist circumference (WC) data were all self-
reported. While the authors point out that these measures are reliable (Celis-Morales et al. 2015), 
certainly measured data would still have improved validity and reliability. Another notable 
limitation of this study was that the FTO-related advice provided to participants was borderline 
actionable. Given the complexity of weight management (Moore et al. 2010; Finkelstein, Ruhm, 
and Kosa 2005; Seabrook and Avison 2010; Gilliland et al. 2012; Naderpoor et al. 2015; Maina 
et al. 2004), simply advising individuals to “maintain a healthy body weight” does not provide 
specific direction on how to achieve this aside from a broad statement advising individuals to 
exercise. While the TCF7L2-related advice to consume a low-fat diet was actionable, the exact 
amount of dietary fat was not well-defined and only individuals with the high-risk genotype of 
TCF7L2 received an actionable recommendation. Therefore, it is not surprising that individuals 
provided with genetic-based information/advice did not reduce their weight or WC to a greater 
extent than those receiving other forms of personalized advice (Table 4.1). The authors do 
mention this as a limitation, stating that the feedback was “only a positive reinforcement” (Celis-
Morales et al. 2017). Lastly, a weight-related outcome was not the predetermined primary 
outcome of this study and therefore it is possible that the statistical power for this study was 
inadequate, which is also noted by the authors (Celis-Morales et al. 2017). 
 
Overall, study limitations in the current body of knowledge are related to study design, 
the nature of the recommendations provided to participants, small (underpowered) sample sizes, 
the use of self-reported weight-related data, and lack of consideration of important confounding 
factors. 
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Table 4.1: Summary of studies meeting inclusion criteria  
Author, 
year 
Methodology Intervention 
Duration 
(data 
collection 
follow-ups) 
Intervention 
Type and 
Comparator 
Study 
Population 
(number of 
participants 
completing 
study) 
Information on Genes, SNPs, 
Dietary/Lifestyle Advice 
Provided, and Company 
(where applicable) 
Outcome* Results Related to the Effectiveness of Genetic-
Based Interventions for Weight Management 
Arkadianos 
et al. 2007  
Retrospective 
Chart Review 
90 to >365 
days 
(duration 
differed by 
patient) 
Nutrigenetic-
guided diet vs. 
low glycemic-
index, 
Mediterranean 
diet 
Patients with 
history of 
unsuccessful 
weight loss 
attempts 
(n=93) 
24 variants in 19 genes to 
provide advice for: folic acid, 
vitamin B6, vitamin B12, 
cruciferous vegetables, vitamin 
A, vitamin C, vitamin E, 
caffeine, dairy, vitamin D, 
calcium, omega-3, exercise 
Weight, 
BMI 
• Nutrigenetic diet group was more likely to have 
maintained some weight loss 
• Nutrigenetic diet group had significantly greater 
BMI reduction long-term (>300 days) 
Frankwich 
et al. 2015  
RCT 
(feasibility 
trial) 
24 weeks 
(follow-up at 
8 weeks and 
24 weeks) 
Nutrigenetic-
guided diet vs. 
standard 
balanced diet  
U.S. veterans 
(n=32) 
Balanced, low-carbohydrate, 
low-fat or Mediterranean based 
on SNPs of 7 genes (APOA2 
rs5082, ADIPOQ rs17300539, 
FTO rs9939609, KCTD10 
rs10850219, LIPC rs1800588, 
MMAB rs2241201, and PPARG 
rs1801282) used in Pathway 
FIT®’s proprietary algorithm 
Weight*, 
BMI 
• Nutrigenetic intervention did not enhance weight 
loss 
• Adherence to nutrigenetic intervention was 
correlated with weight loss (adherence to standard 
diet was not) 
Celis-
Morales et 
al. 2017  
RCT 6 months 
(follow-up at 
3 and 6 
months) 
Diet + phenotype 
+ genotype vs. 
diet + phenotype 
vs. diet vs. 
control; and FTO 
high-risk 
genotype vs. 
FTO non-risk 
genotype 
Overweight/ 
obese 
individuals 
from 7 
European 
countries 
(n=583) 
Individuals with high-risk FTO 
genotype advised to engage in 
physical activity and reduce 
weight and waist circumference 
to maintain a healthy body 
weight; individuals with high-
risk TCF7L2 genotype advised 
to consume a low-fat diet 
Weight, 
WC 
• High-risk FTO genotype group had greater 
reductions in weight and WC compared to the 
control group (standard, non-personalized 
lifestyle advice) 
• No significant differences in weight loss and WC 
reductions between diet + phenotype + genotype 
group and different levels of personalized advice 
(i.e. diet + phenotype group that received advice 
based on weight, diet, physical activity level, 
blood work and WC; and diet only group that 
received advice based on weight, diet and 
physical activity level) 
*denotes primary outcome indicated in manuscript  
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4.1.5 Discussion 
 
To our knowledge, this is the first review that summarized and assessed the current body 
of knowledge related to the impact of providing patients with genetic-based lifestyle 
interventions for managing weight, BMI and/or body composition. It is clear that significant gaps 
exist in the literature.  
 
Critically analyzing the level of evidence available to support the genes tested and 
subsequent dietary advice provided was beyond the scope of this review. However, it should be 
noted that the lack of regulation in the genetic testing industry allows for tests to go to market 
without any accountability to base such tests on robust or any level of scientific evidence 
(Caulfield and McGuire 2012); as such, guidelines have been developed to assess the scientific 
validity and evidence for various nutrigenomics interactions (Grimaldi et al. 2017). It is 
interesting to note that one of the three conducted studies provided genetic-based 
recommendations for following low-carbohydrate nutrition plans for weight loss, when the 
evidence to support such genetic-based advice has been scrutinized. Recent research has assessed 
whether genetic-based alignment to low-carbohydrate nutrition plans is effective for predicting 
weight loss outcomes. These studies (Coletta et al. 2018; Gardner et al. 2018) do not assess the 
effectiveness of providing patients/consumers with genetic-based lifestyle advice and therefore 
were not included in the present review. However, based on the results from these two studies, it 
is clear that our knowledge of using genetics to predict weight loss response to low-carbohydrate 
diets is lacking as both studies concluded that dietary alignment to the particular genetic profiles 
did not correlate with greater weight loss outcomes (Coletta et al. 2018; Gardner et al. 2018). 
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This simply demonstrates that the genes tested, and genetic-based nutrition advice provided were 
not based on robust evidence; it does not necessarily imply that all nutrigenomics interventions 
will be ineffective at reducing weight and/or improving body composition. Until further research 
provides better insights for tailoring carbohydrate intake based on genetics, it remains 
inappropriate to use nutrigenetic testing to provide information in response to low-carbohydrate 
nutrition plans for weight loss. While we work towards improving knowledge in this area, 
perhaps interventions providing genetically-tailored weight management advice should be 
focused on other nutrients such as protein and saturated fat (Zhang et al. 2012; Casas-Agustench 
et al. 2013; Corella et al. 2009).  
 
From a consumer genetic testing perspective, with the current lack of industry regulation, 
companies are free to provide any genetically-guided advice regardless of the level of scientific 
evidence (Caulfield and McGuire 2012). Until regulation catches up with industry practices, the 
development of clinical practice guidelines in nutrigenomics would help to provide guidance to 
researchers and clinicians for incorporating evidence-based nutrigenomics advice into research 
and clinical practice.  Ultimately, this would enhance the potential for nutrigenomics to improve 
health outcomes for the general public. 
 
Overall, weight management remains a challenging area of clinical practice. Research 
evaluating the effectiveness of genetic-based weight management interventions has been 
minimal, and results have been variable thus far. While there were some promising findings by 
Arkadianos et al. (2007), this study had significant methodological flaws. Similarly, while 
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Frankwich et al. (2015) completed the first RCT in this area, this was a feasibility RCT, which 
has not yet been followed up with a larger, adequately powered clinical trial. Lastly, Celis-
Morales (2017) completed a second RCT, but the genetic-based advice provided to participants 
was minimal, and borderline actionable, and the study may not have been adequately powered 
statistically.  
 
Based on this review, future research should seek to use evidence-based nutrigenetic 
interventions, employ an RCT methodology, be adequately powered to detect significant 
differences for a predetermined weight-related primary outcome, consider important 
confounding factors, be at least 12 months in duration, and follow established processes for 
clinical trials such as the SPIRIT and CONSORT guidelines (Chan et al. 2013; Zwarentein et al. 
2008). Furthermore, this future work should provide a genetic-based intervention that is likely to 
facilitate behaviour change; a quality assessment tool for genetic-based interventions has been 
developed and should be used to help researchers design appropriate interventions (Horne et al. 
2018). This work should also use previously developed study quality assessment tools to inform 
study design and reduce any risk of bias (National Institutes of Health n.d.). 
 
4.1.6 Conclusion 
 
Research assessing the impact of providing genetically-tailored information and advice 
on weight management outcomes is minimal. Notable limitations exist in the study methods 
employed in the current body of knowledge. Future research should address these limitations 
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before we can thoroughly answer the important research question: Can the use of nutrigenomics 
and lifestyle genomics interventions enhance weight-related outcomes?   
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CHAPTER 5: STUDY DESIGN 
 
As published* in BMC Public Health: 
 
Horne J, Gilliland J, O’Connor C, Seabrook J, Hannaberg P, Madill J. 2019. “Study protocol of 
a pragmatic randomized controlled trial incorporated into the Group Lifestyle Balance™ 
Program: The Nutrigenomics, Overweight/Obesity and Weight Management Trial (The NOW 
Trial).” BMC Public Health 19(1): 310. 
*Sub-heading numbers, table/figure numbers and reference formatting have been modified for consistency with the 
present dissertation. 
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5.1 Title: Study Protocol of a pragmatic randomized controlled trial incorporated into the 
Group Lifestyle Balance™ Program: The Nutrigenomics, Overweight/Obesity and Weight 
Management Trial (The NOW Trial) 
 
5.2 Abstract 
 
Background: The nutrigenomics, overweight/obesity and weight management trial (NOW Trial) 
is a pragmatic randomized controlled trial of community-dwelling adults recruited from the 
Group Lifestyle Balance™ (GLB) Program. The GLB Program (formerly referred to as the 
Diabetes Prevention Program) is an evidence-based, intensive weight management program, 
which was offered to overweight/obese patients (BMI ≥ 25.0 kg/m2) in a rural Ontario 
community. 
Methods: Patients enrolled in the GLB Program were invited to participate in this study. GLB 
groups were randomized 1:1 to receive either the standard GLB program + population-based 
lifestyle advice for weight management, or a modified GLB program + personalized, genetic-
based lifestyle advice for weight management. The purpose of this study is to determine if the 
provision of genetic-based lifestyle guidelines is superior to the provision of population-based 
guidelines in a pragmatic clinical setting to promote changes in: body composition, weight, body 
mass index, dietary and physical activity habits, as well as attitudes, subjective norms, and 
behavioural control. The 12-month intervention protocol consists of 23 group-based sessions and 
4 one-on-one sessions. Data collection time points include baseline in addition to 3, 6, and 12-
month follow up. The comprehensive study design is described in the present manuscript, using 
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both the extended CONSORT checklist for reporting pragmatic trials and the SPIRIT checklist 
as guidance during manuscript development. 
Discussion: Overall, this study seeks to pragmatically determine if the provision of DNA-based 
lifestyle advice leads to improved health and lifestyle outcomes compared to the provision of 
standard, population-based lifestyle advice. The results of this trial can be used to inform clinical 
and community nutrition practice guidelines. 
Trial Registration: This study was registered with clinicaltrials.gov: NCT03015012 on January 
9, 2017. 
 
5.3 Introduction 
 
Lifestyle modification of nutrition and physical activity are often recommended to help 
manage overweight and obesity (Jensen et al. 2014). Despite increased knowledge of beneficial 
lifestyle strategies for weight management, rates of overweight and obesity continue to climb 
among adults in Canada and the United States (Devito, French, and Goldacre 2018; Statistics 
Canada 2014). The Group Lifestyle Balance™ (GLB) program is one of the most successful 
lifestyle-based weight management programs and is currently offered in over 80 primary care 
settings in the United States and is now becoming increasingly prevalent in Canada (University 
of Pittsburgh, c2017). The GLB program was originally intended only for individuals with 
prediabetes and was formerly referred to as The Diabetes Prevention Program (DPP). In patients 
with prediabetes, the DPP lifestyle intervention reduced the risk of progressing to type 2 diabetes 
by 58%, while the biguanide antihyperglycemic agent, Metformin, reduced the risk of type 2 
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diabetes by 31% when compared to a placebo pill (Diabetes Prevention Program Research Group 
2002). Given the documented success of the DPP, the Ontario Ministry of Health and Long-
Term Care encouraged program expansion through broader eligibility criteria (Ontario Ministry 
of Health and Long-Term Care 2018), and as such some clinics are now offering this program 
for general weight management (regardless of receiving a prediabetes diagnosis), since 
overweight and obesity are considered risk factors for the development of type 2 diabetes 
(Diabetes Canada, c2019).  
 
Although the GLB program has proven to be successful (Kramer et al. 2010; Diabetes 
Prevention Program Research Group 2002; Piatt et al. 2012), a “one-size fits all” approach to 
weight management has been critiqued by experts, who argue that this generalized approach 
yields minimal weight loss outcomes that do not satisfy the wants and needs of clinicians, 
researchers and patients alike (Field et al. 2013). Genetic testing is an innovative tool, which has 
the potential to facilitate positive lifestyle changes and enhance patient outcomes, though this has 
been widely debated in the literature in recent years (Horne et al. 2018; Hollands et al. 2016; 
O’Donovan et al. 2017; French et al. 2017). A systematic review found that actionable lifestyle 
recommendations (e.g., “reduce your consumption of sodium”) facilitated behaviour change 
greater than the provision of simple genetic-based disease-risk estimates, and that nutrition was 
the most promising lifestyle habit that could be motivated by lifestyle genomics testing (Horne et 
al. 2018). 
 
A few studies have assessed change in weight from the provision of genetic-based 
information compared to a standard intervention (Arkadianos et al. 2007; Frankwich et al. 2015; 
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Celis-Morales et al. 2017). Two studies reported that genetic testing was superior to a standard 
intervention for changes in weight or BMI (Arkadianos et al. 2007; Celis-Morales et al. 2017), 
and one study showed that adherence to a genetic-based diet was correlated with greater weight 
loss, whereas adherence to a standard diet was not (Frankwich et al. 2015).  
 
There have been considerable scientific advancements in knowledge pertaining to 
nutrition and physical activity recommendations, which can be personalized based on an 
individual’s genetic variation. Nutrigenomics is a science that explores the interaction between 
nutrition, genetics, and health outcomes (Gibney and Walsh 2013). The science exploring how 
nutrition and physical activity, alongside other lifestyle components, can impact health outcomes 
can be referred to as lifestyle genomics (Horne et al. 2018). Single nucleotide polymorphisms 
(SNPs) located within the genes FTO, MC4R, TCF7L2, UCP1, APOA2, and PPARg2 can 
impact physical activity and dietary approaches to weight management and/or nutritional habits 
(Corella et al. 2010; Nagai et al. 2011; Zhang et al. 2012; Grau et al. 2010; Mattei et al. 2012; 
Phillips et al. 2012; Garaulet et al. 2011; Stutzmann et al. 2009; Andreasen et al. 2008). 
Furthermore, SNPs located within the genes ACTN3, NFIA-AS2, ADRB3, NRF2 and GSTP1 
have been shown to impact genetic predisposition to excel in either endurance or strength-based 
activities (Ma et al. 2013; Ahmetov et al. 2015; Zarebska et al. 2014; He et al. 2006; Santiago et 
al. 2011). These genetic variants were used in the genetic test provided in the present study as 
they are currently offered through commercial genetic testing (Nutrigenomix Inc., n.d.), thus 
optimizing the pragmatic nature of this trial.  
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While genetics certainly play a role in obesity, there are multiple factors contributing to 
the current obesity epidemic, including diminished energy expenditure, increased energy intake, 
rising food costs, the built environment, socioeconomic status, and other social determinants of 
health (Moore et al. 2010; Eriksson et al. 2003; Finkelstein, Ruhm, and Kosa 2005; Seabrook 
and Avison 2010; Gilliland et al. 2012; Sarma et al. 2014). Several of these factors can be 
modified such as energy intake and energy expenditure.  
 
The Theory of Planned Behaviour (TPB) posits that attitudes towards a behaviour, 
subjective norms, perceived behavioural control and actual behavioural control can be used to 
predict intentions and behaviours (Ajzen 1991). Although the TPB is one of the most widely-
accepted behaviour change theories, it has yet to be incorporated into genetic testing behaviour 
change research (Horne, Madill, and Gilliland 2017; Horne et al. 2018), despite a recent call to 
incorporate this theory into personalized healthcare research (Horne, Madill, and Gilliland 2017). 
By considering this theory, we can account for many contributors impacting behaviour change 
and therefore account for several confounding factors, which could influence study results. The 
present randomized controlled trial is the first study to intentionally incorporate the TPB into 
genetic testing behaviour change research.  
 
The proposed extended CONSORT checklist for reporting pragmatic trials (Zwarentein et 
al. 2008) was used to guide the development of the current manuscript. The complete checklist 
can be reviewed in Supplementary Table 5.2, with items 1 through 16 being relevant for 
purposes of this paper.  
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5.4 Methods/Design 
 
5.4.1 Objectives 
 
The primary objective of this study is to determine if the provision of genetic-based lifestyle 
advice reduces body fat percentage to a greater extent than the provision of population-based 
lifestyle advice. Secondary objectives include determining whether the provision of genetic-
based lifestyle advice (a) helps to motivate healthful changes to dietary intake and physical 
activity, (b) leads to greater improvements in anthropometric measures such as weight, BMI, 
lean mass, fat mass (kg), and water weight, and (c) influences attitudes, subjective norms, 
behavioural control, and intention to make lifestyle changes. The tertiary objective is to 
determine if there is a nutrigenomics interaction between ACE rs4343 genetic variation, sodium 
and water intake, and water weight. 
 
5.4.2 Hypotheses 
 
Compared to the provision of population-based lifestyle advice, providing DNA-based 
lifestyle advice will lead to significantly greater improvements in: body fat percentage, attitudes 
and intentions towards behaviour change, the adoption of healthier dietary and physical activity 
habits, as well as improved weight, and BMI. Furthermore, ACE rs4343 genetic variation will 
lead to increased water weight when sodium intake is high.   
 
5.4.3 Material and Methods 
 
The flow of the study protocol for this parallel group, superiority randomized controlled 
trial is outlined in Figures 5.1, 5.2 and 5.3. Further details are provided below.  
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5.4.4 Sample Size Calculation 
 
Seventy-four participants (n = 37 per group) are needed in this study to detect a clinically 
meaningful difference of 4% in body fat percentage, assuming 80% power, an alpha of 5%, and a 
standard deviation of 6.1% (Smilowitz et al. 2009). We aimed to recruit 88 participants (n = 44 
per group) to account for the potential dropout rate of 20%. While minimal research exists 
outlining a clinically meaningful change in body fat percentage, a 5% change in weight (which 
would come from fat mass, water weight and/or muscle mass) is often reported to be clinically 
meaningful (Williamson et al. 2015). Furthermore, clinical experience from the registered 
dietitians involved in this study helped to determine the clinically meaningful 4% difference 
mentioned above. This difference has also been supported in published reference standards of 
body fat percentage in Caucasian adults indicate that a 4% change in body fat percentage is 
associated with a 1 – 2 decile change on the reference standards charts (Imboden et al. 2017). 
 
5.4.5 Cohort Randomization  
 
A cohort randomization model was used rather than subject randomization to allow all 
participants in a given GLB group to obtain the same intervention. At the time of randomization, 
12 cohorts (GLB groups) were randomized 1:1 to either the personalized lifestyle intervention 
(PLI) based on genetics, or the standard lifestyle intervention (SLI) based on population-based 
guidelines. It was anticipated that 12 groups of approximately 7 participants each would be 
needed to obtain the desired sample size of 88 participants. Prior to obtaining informed consent 
from participants, randomly permuted blocks were generated using the original generator on an 
87 
 
internet-based randomization program (Dallal 2017). Since participant recruitment was quicker 
than anticipated and there was an even 1:1 split of a PLI and a SLI group in the last two 
randomized groups, only 10 of the randomized groups (5 PLI groups, 5 SLI groups) were used, 
resulting in a total of N = 140 participants in the study (mean number of study participants per 
group ± SD = 14.0 ± 4.1).   
 
5.4.6 Recruitment 
 
Participants were recruited from the GLB program at the East Elgin Family Health Team 
(EEFHT). There were two primary methods of recruitment into this program: [1] adults from 
Elgin and Middlesex Counties in Ontario, Canada were referred to the GLB program by 
healthcare professionals in the area such as registered dietitians (RDs), physicians, nurses, nurse 
practitioners, and physical therapists; and [2] adults joined the program through word-of-mouth 
referrals from members of the community. Participants expressing interest in joining the GLB 
program were invited to the EEFHT for an in-person meeting to learn about the NOW Trial, and 
to provide written, informed consent if they decided to take part in the study. Therefore, 
participants are highly reflective of typical patients in the GLB program. Recruitment occurred 
from April 2017 until September 2018.  This study is registered with clinicaltrials.gov 
(NCT03015012) and was approved by the Western University Research Ethics Board (108511). 
 
5.4.7 Participants: Screening & Informed Consent 
 
Screening and informed consent were completed in person at The EEFHT during the in-
person meeting. Inclusion criteria were as follows: BMI ≥ 25.0 kg/m2, ≥18 years of age, English-
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speaking, willing to undergo genetic testing, having access to a computer with internet at least 
one day per week, and not seeing another healthcare provider for weight loss advice outside of 
the study.  Pregnancy and lactation were considered exclusion criteria.  
 
5.4.8 Run-In 
 
Upon obtaining written, informed consent, participants were scheduled for in-person 
baseline data collection, within approximately 14 days (mean ± SD = 9.3 ± 5.7) prior to the 
intervention start date. Participants were not given any lifestyle advice during the run-in period.  
 
5.4.9 Baseline Data Collection 
 
All data were entered into the database using unique study codes for each participant and 
were securely stored in a locked cabinet, in a locked office. Baseline data consisted of a 
combination of in-person, online, and telephone data collection methods.  
 
Trained research assistants collected 3-day food records over the phone using the 
validated multiple-pass method (Conway et al. 2003). To reduce participant burden, each 
participant chose to have either three separate phone calls (one for each day of intake), or one 
phone call (for all three days of intake). One weekend day and two weekdays were collected. In a 
few cases where research assistants were unable to reach participants over the phone, the food 
records were collected in-person at the EEFHT. The food records were then analyzed using the 
Canadian Nutrient File within the nutritional analysis software program ESHA Food Processor 
(version 11.1).   
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Participants also completed a self-administered past-month, semi-quantitative, online 
food frequency questionnaire, the Canadian Diet History Questionnaire II (CDHQII). This 
questionnaire is a modified version of the United States Diet History Questionnaire adapted for 
Canadian data (National Institutes of Health 2018). Most participants completed this 
questionnaire away from the EEFHT, but in cases where participants did not have internet access 
at home (n = 3), the CDHQII was self-administered at the EEFHT. 
 
In-person baseline data collection included: measured height and weight (to calculate 
BMI), a BIA assessment to obtain body composition data (using the Body Stat 1500MDD; see 
further detail in methodological Appendix B), a past-week physical activity recall (to calculate 
metabolic equivalents), a baseline demographic questionnaire, a list of medications, and a TPB 
questionnaire. To optimize reliability, weight and height measurements were taken on the same 
Health O Meter Professional weigh scale and stadiometer, and body composition was assessed 
using the same BIA machine. The TPB questionnaire was developed based on Ajzen’s Guide to 
Constructing a TPB Questionnaire (Ajzen 2006). The results for weight, body fat percentage, 
body fat amount, lean weight, and water weight from the BIA were communicated to participants 
during their in-person baseline data collection visit.  
 
To assess possible short-term changes in components of the TPB (e.g., attitudes towards 
nutrition, physical activity, genetic testing, etc.), the TPB questionnaire was administered twice 
during the baseline assessment period: once during the one-on-one, in-person meeting (pre-
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intervention), and once immediately after the group-based intervention was delivered (post-
intervention).  
 
5.4.10 Blinding and Allocation Concealment 
 
During informed consent meetings, baseline data collection and the run-in period, 
participants were blinded to their group assignment. However, participants were not blinded to 
their group assignment during the administration of the second baseline TPB survey (completed 
immediately after the first group session in order to assess possible changes short-term in key 
components of the TPB upon receiving either population-based advice or genetic-based advice). 
Research assistants collecting and analyzing food intake data were also blinded to the study 
group of the participants and the statistician will be blinded to the group assignments. Since our 
outcomes included changes in attitudes related to genetic testing for personalized lifestyle 
advice, as well as change in nutrition and physical activity habits, it was inappropriate to blind 
the participants throughout the entire duration of the study. Therefore, participants were 
informed of their group assignment during the first group intervention meeting, as further 
outlined in section 5.4.12, below. One author (JH) generated the allocation sequence, enrolled 
participants, facilitated group and one-on-one interventions, collected data, entered data into the 
database and scheduled participants, and therefore could not be blinded. Allocation was 
concealed for the other five co-authors.  
 
5.4.11 Staggered Cohorts 
 
Staggered cohorts have been used to reduce the impact of confounding by indication and 
have previously been successful in studies comparing active and passive treatment groups 
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(Blackburn et al. 2017). In the present study, staggered cohorts were pre-planned in order to 
maximize study efficiency and effectiveness. Seasonality and timing of groups were considered 
in the planning phase to ensure that there was a similar amount of SLI groups and PLI groups 
offered during the day and evening. Three SLI groups were offered during the day, and 2 SLI 
groups were offered in the evenings. Likewise, 3 PLI groups were offered during the day, and 2 
PLI groups were offered in the evenings. 1 SLI group began in the spring, 2 in the summer, and 2 
in the fall. Similarly, 1 PLI group began in the spring, 2 in the summer, 1 in the fall, and 1 in the 
winter.  
 
5.4.12 Interventions 
 
Given its previously documented success (Kramer et al. 2010; Diabetes Prevention 
Program Research Group 2002; Piatt et al. 2012), the GLB program was chosen as the gold 
standard comparator for this RCT. Furthermore, given that this study is taking place within 
routine community/clinical practice, it is highly pragmatic with a mean overall PRECIS-2 score 
of 4.4 (Table 5.1) (Loudon et al. 2015).  
 
Participants joined the GLB group session that best suited their availability, and were 
blinded to the group intervention assignment at this time. As previously detailed, groups were 
pre-randomized 1:1 to receive either the standard 12-month GLB Program curriculum + a 
summary report of population-based lifestyle recommendations (SLI/Control Group), or a 
modified 12-month GLB Program + a summary report of DNA-based lifestyle recommendations 
(PLI Group). All participants underwent a group-based weight management program in addition 
to four one-on-one sessions (one baseline and three follow-up) with a RD. Group sizes ranged 
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from 7 - 20 participants per group at baseline, with a mean group size of 14 participants. At the 
three follow-up one-on-one sessions, the RD reviewed the information provided in the summary 
report (population-based recommendations for the SLI group and DNA-based recommendations 
for the PLI group; refer to Supplementary Tables 5.3 and 5.4, respectively, for sample reports). 
One-on-one sessions lasted approximately 30 minutes. The same RD who completed the one-on-
one sessions was also the lead trained lifestyle coach for the GLB Program group sessions. This 
allowed for optimization of intervention reliability in all group and one-on-one sessions. These 
sessions were highly standardized as outlined in Supplementary Table 5.5. No additional 
healthcare professionals above and beyond standard practice were hired to run the intervention at 
the EEFHT. Interventions took place between May 2017 and September 2019.  
 
SLI Group Meetings (Control Group) 
The standard GLB Program curriculum involves group-based education on a sustainable 
healthy lifestyle and a low-fat, calorie-controlled diet as further detailed elsewhere (University of 
Pittsburgh 2017).  Standard GLB group sessions were 1 hour long. The EEFHT expanded the 
eligibility criteria for this program and offered it to adults with a BMI ≥25 kg/m2.  In addition to 
the standard GLB Program, participants were provided with an extra 1.5 hour group session (the 
first session), where they were given an overview of population-based information and 
recommendations for calories, protein, total fat, saturated fat, total unsaturated fat, 
monounsaturated fat, polyunsaturated fat, and physical activity. This information is further 
detailed in Supplementary Table 5.3. Upon completion of the 12-month study, participants in the 
SLI group were given the results of their lifestyle genomics test if they were interested in 
receiving it.  
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PLI Group Meetings (Intervention Group) 
The modified GLB Program curriculum is outlined in Supplementary Table 5.5. The 
modifications allowed participants in this group to follow their DNA-based recommendations, 
rather than the standard population-based guidelines. For example, if an individual possessed a 
genetic variant in the FTO gene whereby a moderately high protein diet can enhance weight loss 
(Zhang et al. 2012), they were given a target for protein, and were taught how to count daily 
grams of protein (in addition to calories). In comparison, for the standard GLB program, every 
participant was provided with a target for total fat intake and were taught how to count daily fat 
grams (in addition to calories). Modified GLB group sessions were 1 hour long. In addition to 
the modified GLB Program, participants were provided with an extra 1.5 hour group session (the 
first session), where they were given an overview of personalized DNA-based information and 
recommendations for calories, protein, total fat, saturated fat, total unsaturated fat, 
monounsaturated fat, polyunsaturated fat, and physical activity. This information is further 
detailed in Supplementary Table 5.4. It should be noted that the genetic intervention is rated to 
be high-quality based on a recently developed genetic intervention quality assessment tool 
(Horne et al. 2018). The quality assessment is outlined in Supplementary Table 5.6.  
 
5.4.13 Follow-Up Data Collection 
 
Similar to baseline data collection, follow-up data collection involved a combination of 
in-person, online and telephone data collection methods. All participants were invited to 
complete follow-up data collection, regardless of their compliance to their intervention’s lifestyle 
recommendation. Complete follow-up data included: BMI, 3-day food records, the CDHQII 
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past-month online food frequency questionnaire, BIA, a past-week physical activity recall, a 
follow-up demographic survey and medication list, and a TPB questionnaire. Further details of 
these measures are indicated above in section 5.4.9. The TPB questionnaire was administered 
once at each follow-up time point during the one-on-one in-person sessions. In addition, at the 
12-month follow-up, participants were asked one open-ended question: How has your life 
changed since you started participating in this program/study (if at all)? Follow-up data 
collection commenced in August 2017 and is ongoing until September 2019.  
 
5.4.14 Statistical Analysis Plan 
 
We plan to use SPSS Version 23.0 to conduct all statistical analyses, and the data will be 
analyzed on an intention-to-treat basis. Generalized linear mixed-effects models will be used to 
test between group differences from baseline to each follow-up period for each outcome 
indicator. If significant mean differences are detected, a Tukey’s post hoc test will be used to 
compare differences by group. General linear regression models will be used to assess 
interactions between a given genotype of interest and dietary component of interest on BMI and 
body composition. General linear regression models will further be used to assess interactions 
between TPB components, study group, and anthropometric measures of weight and body 
composition. No interim analyses will be completed.  
 
5.4.15 Outcomes 
 
The primary outcome in this study is change in percent body fat. Secondary outcome 
measures include changes in: dietary intake (calories, fat, protein, carbohydrates, unsaturated fat 
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including mono- and poly-unsaturated fat, saturated fat, and sodium), physical activity, attitudes, 
subjective norms, behavioural control, intention to make lifestyle changes, weight and BMI.  
 
5.4.16 Dissemination 
 
We plan to disseminate the findings from this trial through: a community presentation to 
the participants involved in the study, presentations at relevant conferences for researchers and 
healthcare professionals, as well as in peer-reviewed publications. 
 
5.5 Discussion 
The overarching aim of this study is to determine if patients have improved health and 
lifestyle outcomes with the provision of DNA-based lifestyle information and recommendations, 
compared to the provision of standard, population-based lifestyle advice. Furthermore, it aims to 
test the aforementioned hypotheses, based on lifestyle genomics weight management advice 
available to consumers globally through commercial genetic testing. This highlights the 
pragmatic nature of this trial, and optimizes the potential for knowledge translation on a global-
scale. 
 
The NOW Trial protocol differs from previous research in that it was designed 
pragmatically, using a knowledge translation approach. Furthermore, the NOW Trial aims to 
compare a DNA-based lifestyle change program to the gold standard, population-based lifestyle 
change program (the GLB Program), while considering and accounting for major confounding 
factors of behaviour change. It is also the first lifestyle genomics weight management and 
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behaviour change study to incorporate the TPB into the study design; this may help target a sub-
set of the population that may benefit most from genetic testing for weight management. This 
trial is also unique because the genetic information was presented to participants in a group 
setting, thus demonstrating the feasibility of this more efficient approach to the delivery of 
genetic information. 
 
Pragmatic clinical trials are distinguished by their focus on informing clinical practice 
rather than confirming a physiological or clinical hypothesis. Notably, pragmatic trials help to 
inform real-world research questions that are applicable to broad patient groups (Ford et al. 
2016). Given the novel and pragmatic nature of the study, the NOW Trial provides several 
original contributions to the literature. Overall, the NOW Trial will provide important, 
innovative health knowledge relevant to researchers, academia, consumers, the genetic testing 
industry, clinicians and public health authorities. 
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5.6 Tables and Figures 
 
Table 5.1: PRECIS-2 Scoring Tool 
PRECIS-2 Domain Score [Likert scale 1 
(very explanatory) - 
5 (very pragmatic)] 
1. Eligibility: To what extent are the participants in the trial similar 
to those who would receive this intervention if it was part of usual 
care? 
5 
2. Recruitment: How much extra effort is made to recruit 
participants over and above what would be used in the usual care 
setting to engage with patients?  
5 
3. Setting: How different are the settings of the trial from the usual 
setting?  
5 
4. Organization: How different are the resources, provider 
expertise, and the organization of care delivery in the intervention 
arm of the trial from those available in usual care?  
4 
5. Flexibility (delivery): How different is the flexibility in how the 
intervention is delivered and the flexibility anticipated in usual 
care?   
4 
6. Flexibility (adherence): How different is the flexibility in how 
participants are monitored and encouraged to adhere to the 
intervention from the flexibility anticipated in usual care? 
4 
7. Follow-up: How different is the intensity of measurement and 
follow-up of participants in the trial from the typical follow-up in 
usual care?  
3 
8. Primary outcome: To what extent is the trial’s primary outcome 
directly relevant to participants?  
5 
9. Primary analysis: To what extent are all data included in the 
analysis of the primary outcome?  
TBD 
 
Mean score:  4.4 
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Figure 5.1: Flow of study protocol 
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Figure 5.2: CONSORT 2010 Flow Diagram 
 
  
 
 
  
Assessed for eligibility (n=141) 
Excluded (n=1) 
   Not meeting inclusion criteria (n=1) 
   Declined to participate (n=0) 
   Other reasons (n=0) 
Analysed  (TBD) 
 Excluded from analysis (give reasons) (TBD) 
Lost to follow-up (give reasons) (TBD) 
Discontinued intervention (give reasons) (TBD) 
Allocated to SLI (n=70) 
 Received allocated intervention (n=68) 
 Did not receive allocated intervention (n=2, 
lost to follow-up during run-in period) 
Lost to follow-up (give reasons) (TBD) 
Discontinued intervention (give reasons) (TBD) 
Allocated to PLI (n=70) 
 Received allocated intervention (n=69) 
 Did not receive allocated intervention (n=1, 
lost to follow-up during run-in period) 
Analysed  (TBD) 
 Excluded from analysis (give reasons) (TBD) 
 
Allocation 
Analysis 
Follow-Up 
Randomized (n=140) 
Enrollment 
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Figure 5.3: SPIRIT flow diagram of the NOW trial study protocol at the EEFHT 
 STUDY PERIOD 
 
Enrolment 
 Baseline 
Data 
Collection 
Post-allocation Close-out 
TIMEPOINT SE Run-In Day 1 3 Mo. 6 Mo. 12 Mo. 12 Mo. 
ENROLMENT:        
Eligibility screen X       
Informed consent  X       
Allocation Revealed 
to Participants 
  X     
INTERVENTIONS:        
Personalized 
Lifestyle Intervention 
 
       
Standard Lifestyle 
Intervention 
(Control) 
 
       
Lifestyle Genomics 
Results Provided to 
Control Group 
 
      X 
ASSESSMENTS:        
Body Composition 
 X  X X X  
Weight/Height/BMI 
 X  X X X  
TPB Survey 
 
 X X X X X  
Demographic 
Questionnaire + Med 
List 
 X  X X X  
Past-Week Physical 
Activity Recall 
 X  X X X  
3-Day Food Records 
 X  X X X  
Past-Month CDHQII 
 X  X X X  
Qualitative 
Component 
     X  
SE: study entry      Mo: month 
101 
 
Supplementary Table 5.2: Proposed extended CONSORT checklist of items for reporting 
pragmatic trials 
Section Item Standard CONSORT description Extension for pragmatic trials Checklist 
Title and abstract 1 
How participants were allocated to 
interventions (eg, “random allocation,” 
“randomised,” or “randomly assigned”) 
 
 
Introduction     
Background 2 
Scientific background and explanation of 
rationale 
Describe the health or health 
service problem that the 
intervention is intended to address 
and other interventions that may 
commonly be aimed at this 
problem 
 
Methods     
Participants 3 
Eligibility criteria for participants; 
settings and locations where the data 
were collected 
Eligibility criteria should be 
explicitly framed to show the 
degree to which they include 
typical participants and/or, where 
applicable, typical providers (eg, 
nurses), institutions (eg, 
hospitals), communities (or 
localities eg, towns) and settings 
of care (eg, different healthcare 
financing systems) 
 
Interventions 4 
Precise details of the interventions 
intended for each group and how and 
when they were actually administered 
Describe extra resources added to 
(or resources removed from) 
usual settings in order to 
implement intervention. Indicate 
if efforts were made to 
standardise the intervention or if 
the intervention and its delivery 
were allowed to vary between 
participants, practitioners, or 
study sites 
 
Describe the comparator in 
similar detail to the intervention 
 
Objectives 5 Specific objectives and hypotheses   
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Section Item Standard CONSORT description Extension for pragmatic trials Checklist 
Outcomes 6 
Clearly defined primary and secondary 
outcome measures and, when applicable, 
any methods used to enhance the quality 
of measurements (eg, multiple 
observations, training of assessors) 
Explain why the chosen outcomes 
and, when relevant, the length of 
follow-up are considered 
important to those who will use 
the results of the trial 
 
Sample size 7 
How sample size was determined; 
explanation of any interim analyses and 
stopping rules when applicable 
If calculated using the smallest 
difference considered important 
by the target decision maker 
audience (the minimally 
important difference) then report 
where this difference was 
obtained 
 
Randomisation—
sequence 
generation 
8 
Method used to generate the random 
allocation sequence, including details of 
any restriction (eg, blocking, 
stratification) 
 
 
Randomisation—
allocation 
concealment 
9 
Method used to implement the random 
allocation sequence (eg, numbered 
containers or central telephone), 
clarifying whether the sequence was 
concealed until interventions were 
assigned 
 
 
Randomisation—
implementation 
10 
Who generated the allocation sequence, 
who enrolled participants, and who 
assigned participants to their groups 
 
 
Blinding 
(masking) 
11 
Whether participants, those 
administering the interventions, and 
those assessing the outcomes were 
blinded to group assignment 
If blinding was not done, or was 
not possible, explain why 
 
Statistical methods 12 
Statistical methods used to compare 
groups for primary outcomes; methods 
for additional analyses, such as subgroup 
analyses and adjusted analyses 
 
 
Results     
Participant flow 13 
Flow of participants through each stage 
(a diagram is strongly recommended)—
specifically, for each group, report the 
The number of participants or 
units approached to take part in 
the trial, the number which were 
 
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Section Item Standard CONSORT description Extension for pragmatic trials Checklist 
numbers of participants randomly 
assigned, receiving intended treatment, 
completing the study protocol, and 
analysed for the primary outcome; 
describe deviations from planned study 
protocol, together with reasons 
eligible, and reasons for non-
participation should be reported 
Recruitment 14 
Dates defining the periods of recruitment 
and follow-up 
 
 
Baseline data 15 
Baseline demographic and clinical 
characteristics of each group 
 
TBD 
Numbers analysed 16 
Number of participants (denominator) in 
each group included in each analysis and 
whether analysis was by “intention-to-
treat”; state the results in absolute 
numbers when feasible (eg, 10/20, not 
50%) 
 
TBD 
Outcomes and 
estimation 
17 
For each primary and secondary 
outcome, a summary of results for each 
group and the estimated effect size and 
its precision (eg, 95% CI) 
 
TBD 
Ancillary analyses 18 
Address multiplicity by reporting any 
other analyses performed, including 
subgroup analyses and adjusted analyses, 
indicating which are prespecified and 
which are exploratory 
 
TBD 
Adverse events 19 
All important adverse events or side 
effects in each intervention group 
 
TBD 
Discussion     
Interpretation 20 
Interpretation of the results, taking into 
account study hypotheses, sources of 
potential bias or imprecision, and the 
dangers associated with multiplicity of 
analyses and outcomes 
 
TBD 
Generalisability 21 
Generalisability (external validity) of the 
trial findings 
Describe key aspects of the 
setting which determined the trial 
results. Discuss possible 
TBD 
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Section Item Standard CONSORT description Extension for pragmatic trials Checklist 
differences in other settings where 
clinical traditions, health service 
organisation, staffing, or 
resources may vary from those of 
the trial 
Overall evidence 22 
General interpretation of the results in 
the context of current evidence 
 
TBD 
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Supplementary Table 5.3: Sample report for standard lifestyle intervention (GLB group)  
 
 
  
Lifestyle Component Population-Based Recommendations  
Calories Aim for a 500 calorie deficit per day for weight loss. 
Protein Consume 10-35% of calories from protein.  
Total Fat Consume 20-35% of calories from fat.  
Saturated Fat Limit your saturated fat intake to less than 10% of total calories. 
Unsaturated Fat Consume a balance of monounsaturated and polyunsaturated fat to meet your total fat 
needs. 
Monounsaturated Fat Consume a balance of monounsaturated and polyunsaturated fat to meet your total fat 
needs. Polyunsaturated Fat 
Sodium Consume less than 2300 mg sodium daily.  
Eating Between 
Meals 
Do not go longer than six hours without eating throughout the day. Ensure snacks and 
meals are calorie-controlled. 
Physical Activity  Aim for 150 minutes/week of physical activity with muscle strengthening activities at 
least 2 days/week. 
Endurance Find an endurance-based activity that you enjoy – meet the physical activity guidelines 
stated above. 
Strength and Power Find a strength/power based activity that you enjoy – meet the physical activity 
guidelines stated above. 
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Supplementary Table 5.4: Sample report for personalized lifestyle intervention (GLB+NGx) 
Lifestyle Component Gene(s), rs 
number(s) 
Your 
Genetic 
Variant 
Your 
Risk/ 
Response 
DNA-Based Recommendations and Implication 
Calories UCP1, rs1800592 AA Typical Your resting metabolism is typical. Aim for a 500 calorie deficit per day for weight 
loss. 
Protein FTO, rs9939609 AA Enhanced You can enhance your weight loss if you consume 25-35% of calories from 
protein. 
Total Fat TCF7L2, rs7903146 TC Typical Consume 20-35% of calories from fat. 
Saturated Fat APOA2, rs5082 CC Enhanced You can enhance your weight loss if you consume less than 10% of calories from 
saturated fat. 
Unsaturated Fat FTO, rs9939609 AA Enhanced You can enhance your weight loss if you limit your intake of saturated fat to less 
than 10% of calories and consume at least 5% of calories from polyunsaturated 
fat. 
Monounsaturated Fat PPARg2, rs1801282 CC Typical Consume a balance of monounsaturated and polyunsaturated fat to meet your 
total dietary fat intake goal.  
Sodium ACE, rs4343 GG Typical Limit your sodium intake to less than 2300 mg per day for heart health. 
Eating Between Meals MC4R, rs17782313 TT Typical You have a typical likelihood of eating between meals. Do not go longer than six 
hours without eating.  
Physical Activity FTO, rs9939609 AA Enhanced You can enhance your weight loss if you complete at least 30-60 minutes/day of 
cardio activity, 6 days/week and muscle-strengthening activities at least 2 
days/week. 
Endurance ADRB, rs4994 TT Typical You have a typical genetic predisposition to excel in endurance-based physical 
activity.  NRF2, rs12594956 CA 
GSTP1, rs1695 AA 
NFIA-AS2, rs1572312 CC 
Strength and Power ACTN3, rs1815739 TC Enhanced You have an enhanced genetic predisposition to excel in strength and power 
based physical activity. 
     
Participant Number X 
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Supplementary Table 5.5: GLB program/NOW trial curriculum and modifications for genetic 
testing intervention groups 
Class 
Number 
Class Topic Modifications for Genetic Testing Intervention Groups1 
1 General 
Overview of 
Nutrition and 
Physical Activity 
Targets2 
• Genetic information and recommendations provided to 
participants 
2 Welcome to the 
Group Lifestyle 
Balance™ 
Program3 
• The physical activity goal was verbally modified 
whereby participants were asked to refer to their 
personalized physical activity goals from their genetic 
report. 
3 Be a Calorie 
Detective 
• Any reference made to counting fat grams was verbally 
modified. Participants were reminded about how 
response to different diets for weight loss differ from 
person to person. Based on their personalized genetic 
report, participants were advised and taught how to 
count a nutrient that would benefit their personal weight 
loss (i.e. some counted protein, others counted saturated 
fat, and/or total fat, etc). 
• The calorie goals remained the same, but participants 
with the “diminished” result in their genetic report for 
calories were advised to be especially mindful of 
meeting their calorie goal, and were advised to aim for a 
650 kcal deficit to lose 1 lb per week. 
4 Healthy Eating • When reference was made to a nutrient included in the 
genetic report, participants were instructed to refer back 
to their genetic report to recall how this nutrient might 
be particularly important to them. The information in 
the genetic reports was then reviewed. 
5 Move Those 
Muscles 
• The physical activity goal was verbally modified 
whereby participants were asked to refer to their 
personalized physical activity goals from their genetic 
report. 
• Genetic predisposition to excel in endurance and/or 
strengthening activities (outlined in the genetic report) 
was reviewed.  
6 Tip the Calorie 
Balance 
• For the daily calorie deficit for weight loss, participants 
were advised to refer to their genetic report to determine 
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if they should aim for a 500 kcal deficit/day or a 650 
kcal deficit/day.  
• When reference was made to a nutrient included in the 
genetic report, participants were instructed to refer back 
to their genetic report to recall how this nutrient might 
be particularly important to them. The information in 
the genetic reports was then reviewed. 
7 Take Charge of 
What’s Around 
You  
• No1 modifications were made. Some participants 
discussed components of their genetic report.  
8 Problem Solving • No1 modifications were made. Some participants 
discussed components of their genetic report.  
9 Step Up Your 
Physical Activity 
Plan 
• The physical activity goal was verbally modified 
whereby participants were asked to refer to their 
personalized physical activity goals from their genetic 
report. 
• Genetic predisposition to excel in endurance and/or 
strengthening activities (outlined in the genetic report) 
was reviewed.  
• Participants with the “enhanced” weight loss response 
to physical activity (from the genetic report), were 
advised to continue working up to 30-60 mins/day, 6 
days/week of moderate intensity physical activity.  
10 Manage Slips & 
Self-Defeating 
Thoughts 
• The step goal was verbally modified for individuals 
with the “enhanced” weight loss response to physical 
activity; these individuals were advised to aim for 
10,000 steps/day.  
• When reference was made to a nutrient included in the 
genetic report, participants were instructed to refer back 
to their genetic report to recall how this nutrient might 
be particularly important to them. The information in 
the genetic reports was then reviewed. 
11 Four Keys to 
Healthy Eating 
Out 
• No1 modifications were made. Some participants 
discussed components of their genetic report.  
12 Make Social 
Cues Work for 
You 
• No1 modifications were made. Some participants 
discussed components of their genetic report.  
13 Ways to Stay 
Motivated 
• The physical activity goal was verbally modified 
whereby participants were asked to refer to their 
109 
 
personalized physical activity goals from their genetic 
report. 
• The step goal was verbally modified for individuals 
with the “enhanced” weight loss response to physical 
activity; these individuals were advised to aim for 
10,000 steps/day.  
14 Strengthen Your 
Physical Activity 
Plan 
• The physical activity goal was verbally modified 
whereby participants were asked to refer to their 
personalized physical activity goals from their genetic 
report. 
• The step goal was verbally modified for individuals 
with the “enhanced” weight loss response to physical 
activity; these individuals were advised to aim for 
10,000 steps/day. Genetic predisposition to excel in 
endurance and/or strengthening activities (outlined in 
the genetic report) was reviewed.  
15 Take Charge of 
Your Lifestyle 
• Reference made to fat grams was verbally modified. 
Participants were reminded about how response to 
different diets for weight loss differ from person to 
person. Based on their personalized genetic report, 
participants were advised to count a nutrient that would 
benefit their personal weight loss (i.e. some counted 
protein, others counted saturated fat, and/or total fat, 
etc). 
16 Mindful Eating, 
Mindful 
Movement 
• No1 modifications were made. Some participants 
discussed components of their genetic report.  
17 Manage Your 
Stress 
• No1 modifications were made. Some participants 
discussed components of their genetic report.  
18 Sit Less for Your 
Health 
• No1 modifications were made. Some participants 
discussed components of their genetic report.  
19 More Volume, 
Fewer Calories 
• When reference was made to a nutrient included in the 
genetic report, participants were instructed to refer back 
to their genetic report to recall how this nutrient might 
be particularly important to them. The information in 
the genetic reports was then reviewed. 
20 Stay Active • No1 modifications were made. Some participants 
discussed components of their genetic report.  
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21 Balance Your 
Thoughts 
• No1 modifications were made. Some participants 
discussed components of their genetic report.  
22 Heart Health • When reference was made to a nutrient included in the 
genetic report, participants were instructed to refer back 
to their genetic report to recall how this nutrient might 
be particularly important to them. The information in 
the genetic reports was then reviewed. 
• The physical activity goal was verbally modified 
whereby participants were asked to refer to their 
personalized physical activity goals from their genetic 
report. 
• The step goal was verbally modified for individuals 
with the “enhanced” weight loss response to physical 
activity; these individuals were advised to aim for 
10,000 steps/day. Genetic predisposition to excel in 
endurance and/or strengthening activities (outlined in 
the genetic report) was reviewed.  
23 Look Back & 
Look Forward  
• The physical activity goal was verbally modified 
whereby participants were asked to refer to their 
personalized physical activity goals from their genetic 
report. 
• The step goal was verbally modified for individuals 
with the “enhanced” weight loss response to physical 
activity; these individuals were advised to aim for 
10,000 steps/day. Genetic predisposition to excel in 
endurance and/or strengthening activities (outlined in 
the genetic report) was reviewed.  
1. The physical activity goal and references to fat grams were verbally modified in the “To Do” lists at the end of 
sessions. Participants were reminded about how response to different diets and physical activity for weight loss 
differ from person to person. Based on their personalized genetic report, participants were advised and taught how to 
reach their personal nutrition and physical activity goals. This modification occurred throughout the GLB Program’s 
“To Do” lists and is not included in this table.  
2. The GLB curriculum begins in class 2. Class 1 allows for an overview of nutrition and physical activity guidelines 
either based on 1) the Acceptable Macronutrient Distribution Ranges and population-based health information and 
recommendations or 2) genetic-based information and recommendations. Refer to Supplementary Tables 5.3 and 5.4 
for sample reports provided in class 1.  
3. Participants were informed about how the program is typically used for individuals with pre-diabetes, since our 
population consisted of overweight/obese adults who may or may not have pre-diabetes or type 2 diabetes.  
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Supplementary Table 5.6: Quality assessment tool for genetic interventions 
Criteria Yes No Other (CD, 
NR, NA)* 
1. Were the results of the genetic test interpreted and explained by a 
trained healthcare professional? 
   
2. Was a copy of the genetic testing report provided to the 
participants? 
   
3. Were the results of the genetic test communicated to participants 
on more than one occasion (i.e. was there follow-up provided after 
the initial communication of the results)? 
   
4. Were the results provided in the report, or discussed in the genetic 
counselling session actionable (i.e. did the report contain specific 
recommendations or did the genetic counsellor communicate 
specific recommendations)? 
   
5. Were the participants provided with an opportunity to ask 
questions about their results? 
   
 
Other Comments: N/A ______________________________________________________________ 
Overall Rating (Good, Fair, Poor; if Poor state reasons): Good  
*CD: cannot determine, NR: not reported, NA: not applicable 
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CHAPTER 6: DIETARY ADHERENCE AND CHANGE IN 
DIETARY INTAKE 
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6.1 Title: Enhanced long-term dietary change and adherence in a 
nutrigenomics-guided lifestyle intervention program compared to a population-
based (GLB/DPP) lifestyle intervention for weight management: Results from 
the NOW randomized controlled trial 
 
6.1.1 Abstract 
 
Background: Adherence to nutritional guidelines for chronic disease prevention and 
management remains a challenge in clinical practice. Innovative strategies are needed to help 
optimize dietary behaviour change. 
Objective: The objective of this study was to determine if a nutrigenomics-guided lifestyle 
intervention program could be used to motivate greater dietary adherence and change in dietary 
intake short-term, moderate-term, and long-term compared to the gold-standard population-based 
weight management intervention [Group Lifestyle Balance™ (GLB)/Diabetes Prevention 
Program (DPP)]. 
Design: The nutrigenomics, overweight/obesity, and weight management randomized controlled 
trial is a pragmatic, parallel-group, superiority clinical trial (N=140), which was conducted at the 
East Elgin Family Health Team (EEFHT). GLB weight management groups were pre-
randomized 1:1 to receive either the standard GLB program, or a modified GLB + nutrigenomics 
(GLB+NGx) program. Three-day food records were collected at baseline, 3, 6 and 12 months 
using the validated multiple pass method. Researcher assistants collecting 3-day food records 
were blinded to the participants’ group assignments. Statistical analyses included: split plot 
analyses of variance (ANOVAs), two-way ANOVAs, binary logistic regression, chi-square and 
Fisher’s exact tests. Using the Theory of Planned Behaviour as guidance, important confounding 
factors of behaviour change were considered in the analyses. 
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Results: Only the GLB+NGx group significantly reduced their total fat intake from baseline to 
12-month follow-up (36.0±4.8%kcal to 30.2±8.7%kcal, p=0.02). Long-term dietary adherence to 
total fat and saturated fat guidelines were also significantly (p<0.05) greater in the GLB+NGx 
group compared to the standard GLB group. 
Conclusions: Nutrigenomics weight management interventions can motivate long-term 
improvements in dietary fat intake above and beyond standard guidelines. 
 
6.1.2 Introduction  
 
The science of nutrigenomics, which explores interactions between individual genetic 
variation, dietary intake and changes in gene expression, structure and function (Subbiah 2008), 
has garnered significant attention in recent years with consumers and healthcare professionals 
alike expressing overall positive attitudes towards genetic testing for personalized nutrition 
(Valée Marcotte et al. 2019; Nielsen and El-Sohemy 2014; Cormier et al. 2014). As such, a 
number of companies are offering nutrigenetic testing for weight management (Saukko 2013; 
Drabsch and Holzapfel 2019). 
A recent review reported that personalized nutrition recommendations are of great potential 
for optimizing outcomes of weight management interventions, while also noting that research in 
this area is lacking and human intervention studies are needed (Drabsch and Holzapfel 2019). 
The potential value of personalized nutrition for weight management stems from studies 
indicating positive consumer attitudes towards genetic-based dietary advice (Nielsen and El-
Sohemy 2014; Morin 2009), several indications that a one-size-fits all approach to weight 
management is not optimal (Drabsch and Holzapfel 2019), and the potential for genetically-
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guided, actionable nutrition recommendations to help motivate changes in dietary intake (Horne 
et al. 2018).  
According to the most recent systematic review on genetic testing behaviour change 
research, nutrition was found to be the most promising lifestyle component that could be 
motivated as a result of undergoing genetic testing, especially when the genetic intervention 
provided actionable recommendations (Horne et al. 2018). Furthermore, this review found that 
genetic testing behaviour change research has yet to incorporate the Theory of Planned 
Behaviour (TPB), and incorporation of behaviour change theory in general is fundamentally 
lacking (Horne et al. 2018). This is concerning given that the TPB is one of the most widely 
accepted behaviour change theories. It suggests that attitudes, subjective norms and behavioural 
control are the three key factors affecting human behaviour (Ajzen 1991). Furthermore, 
researchers in the field of genetic testing behaviour change research have called to action 
academia to incorporate this theory into genetic testing behaviour change studies to account for 
potential confounding factors; this has been further detailed elsewhere (Horne et al. 2017). 
Behaviour change theories provide important guidance for the development of interventions that 
are more likely to facilitate changes in lifestyle habits. Thus, failing to consider established 
behaviour change theories can lead to findings that do not demonstrate changes in dietary 
behaviours. As such, it is not surprising that the current limited knowledge related to change in 
dietary intake and eating habits in genetic-based weight management interventions does not 
appear to be promising (Horne et al. 2018; Meisel et al. 2015). Overall, the field of 
nutrigenomics and behaviour change is highly complex and warrants further investigation.  
The purpose of this study was to address the limitations of previous work by considering the 
TPB in the dietary intervention and statistical analyses, providing a high-quality, personalized, 
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genetic-based lifestyle intervention, and ultimately determining if the provision of a nutrigenetic-
based weight management intervention motivates greater dietary changes and adherence 
compared to a population-based weight management intervention.  
 
6.1.3 Subjects and Methods  
 
 The current study is a sub-study within the nutrigenomics, overweight/obesity and weight 
management trial (NOW trial), which is a parallel-group, superiority, randomized, controlled 
clinical intervention study (N=140) incorporated into the Group Lifestyle Balance™ (GLB) 
program (formerly referred to as the Diabetes Prevention Program). The GLB program is one of 
the most effective public health weight management programs (Xiao et al. 2013; Diabetes 
Prevention Program Research Group 2002; McTigue et al. 2009; Piatt et al. 2012); it is offered in 
numerous clinics in the United States and Canada (University of Pittsburgh c2019) and has been 
extensively researched for long-term weight management and diabetes prevention (Xiao et al. 
2013; Diabetes Prevention Program Research Group 2002; McTigue et al. 2009; Piatt et al. 
2012). Detailed study methods for the NOW trial have been published elsewhere (Horne et al. 
2019).  One author (JH) conducted 1:1 computer-generated cohort randomization (Dallal 2017) 
of 12 GLB groups as this was the anticipated number of groups required to achieve the target 
sample size. A cohort randomization model was used rather than subject randomization to ensure 
that all participants in each GLB group received the same intervention [standard GLB or GLB + 
nutrigenomics (GLB + NGx)]. This study was approved by the Western University Research 
Ethics Board and registered with clinicaltrials.gov (NCT03015012).  
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Participants  
 Patients were recruited into the GLB program at the East Elgin Family Health Team 
(EEFHT) in Aylmer, Ontario, Canada through healthcare professional referrals and word-of-
mouth referrals from members of the community from April 2017 – September 2018. Patients 
expressing interest in the GLB program were then invited to participate in the study if they met 
the following inclusion criteria: BMI ≥ 25.0 kg/m2, ≥ 18 years of age, English-speaking, willing 
to undergo genetic testing, having access to the internet, and not seeing another healthcare 
provider for weight loss advice outside of the study. Pregnancy and lactation were exclusion 
criteria. The target total sample size was 74 participants (after dropout) in order to detect a 4% 
change in body fat percentage (primary outcome), using a standard deviation of 6.1%, with 80% 
power and an alpha of 5%. Since recruitment was quicker than anticipated, recruitment ended 
after 10 cohorts since there was an even 1:1 split of a GLB and GLB+NGx group in the last two 
pre-randomized cohorts as further detailed previously (Horne et al. 2019). Four of the five 
researchers (JG, JS, CO, JM) and all research assistants collecting 3-day food records (3DFRs) 
were blinded to participant group allocation. It was not possible to blind the researcher 
responsible for organizing and facilitating all intervention sessions (JH) and given the nature of 
the intervention, it was inappropriate to blind participants to their allocated intervention. The 
participants, setting and healthcare provider facilitating the interventions (JH) were all highly 
representative of typical/standard care. All interventions were delivered by one healthcare 
provider (JH) in order to standardise their delivery and enhance reliability and no additional 
resources were required to implement the interventions; the healthcare provider is a registered 
dietitian (RD) who has previous training in nutritional genomics.  
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Interventions 
Staggered cohorts participated in the 12-month intervention and data collection occurred 
from May 2017 – September 2019. Participants received specific targets for eight nutrients: 
calories, protein, saturated fatty acids (SFAs), monounsaturated fatty acids (MUFAs), 
polyunsaturated fatty acids (PUFAs), total unsaturated fat, total fat, and sodium. These targets 
were derived from genetics for half of the participants, and were derived from population-based 
guidelines (Health Canada 2010) for the other half of participants; the nutrition reports provided 
to participants have been previously published (Horne et al. 2019). For the standard GLB 
intervention, participants were advised primarily to follow a calorie-controlled, moderately-low 
fat (25% kcal) nutrition plan (University of Pittsburgh c2017). Both intervention groups followed 
the standard GLB program overall calorie intake targets (University of Pittsburgh c2017). For the 
personalized GLB+NGx group, individuals received information related to resting metabolism 
and subsequent personalized calorie deficits recommended for weight loss (Horne et al. 2019). 
Participants in the GLB+NGx group were advised to focus on the macronutrient 
recommendation(s) that was/were highlighted in their genetic report to enhance weight loss 
response. For example, an individual with the AA variant of FTO (rs9939609) was advised to 
focus on following a higher-protein nutrition plan to optimize weight loss, whereas an individual 
with the CC variant of APOA2 (rs5082) was advised to focus on following a low saturated fat 
(<10% kcal) nutrition plan to optimize weight loss (rather than all participants following the 
standard moderately-low total fat GLB nutrition intervention). Participants randomized to the 
GLB+NGx group were also informed of their genetic predisposition to eat more frequently 
during the day based on MC4R (rs17782313) genetic variation. If an individual had multiple 
genetic variants and genetic-based nutrition recommendations highlighted in their genetic report, 
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they were advised to focus on achieving one of the nutrition targets (of their choosing), and then 
work on another when they perceived that they were ready to engage in further dietary changes. 
A sample NOW trial genetic report has been previously published elsewhere; this report was 
selected for the present study based off commercially available nutrigenetic testing accessible by 
the general public through healthcare professionals (Horne et al. 2019).  
All participants were advised to track their food and beverage intake closely (by completing 
food records/journals) for the first two to three months of the intervention while working towards 
their nutrition targets. They were further advised to measure their food and beverage intake for at 
least the first week of the intervention in order to increase awareness and accuracy of the portion 
sizes indicated in their dietary tracking. In the second week of the intervention, participants were 
educated on counting and tracking calories and nutrients (total fat for the standard GLB group; 
individualized nutrients for the GLB+NGx group).  With weekly meetings for the first three 
months and meetings approximately once per month for the remainder of the 12-month 
intervention, participants had several opportunities to ask questions about their nutrition 
recommendations to ensure comprehension. These recommendations were also reviewed at a 3-
month, 6-month and 12-month one-on-one follow-up appointment with an RD. 
Incorporation of the TPB  
  This is the first study to intentionally incorporate the TPB into a genetic testing behaviour 
change study. Both interventions aimed to positively impact key components of the TPB 
(attitudes, subjective norms, and behavioural control).  The interventions aimed to impact 
attitudes by informing individuals of the health benefits associated with engaging in a healthy 
lifestyle and providing education on positive mindsets and mindfulness (University of Pittsburgh 
c2017). The group-based nature of the intervention aimed to affect subjective norms. A stepwise, 
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goal-setting approach was used to help positively impact behavioural control. In the GLB+NGx 
group, the intervention aimed to further impact attitudes through the provision of more 
personalized dietary guidance. All participants completed a baseline TPB questionnaire. The 
TPB was used to guide the analyses of possible attrition bias and subsequently control for 
possible confounding factors of behaviour change as further indicated below.  
Genotyping 
 Oragene ON-500 saliva collection kits (DNA Genotek, Ottawa, Ontario, Canada) were 
used to collect DNA saliva samples of participants at the EEFHT. The saliva samples were 
shipped and stored at -80°C at the University of Toronto until they were analysed. The iPLEX 
Gold assay with mass-spectrometry-based detection on the Sequenom MassARRAY® platform 
was used for all genotyping. This genotyping method has been utilized in previous research 
(Jenkins et al. 2018; Josse et al. 2012; Banks et al. 2019). The following single nucleotide 
polymorphisms (SNPs) of interest to the current study were analyzed: UCP1 (rs1800592), FTO 
(rs9939609), TCF7L2 (rs7903146), APOA2 (rs5082), PPARγ2 (rs1801282), MC4R 
(rs17782313).  
Dietary Intake and Adherence  
 Dietary intake and adherence are important outcomes to address in a pragmatic 
randomized controlled trial given that altering nutrition-related behaviour change is a challenge 
in clinical practice. As such, dietary intake was a predetermined secondary outcome of the NOW 
trial (Madill 2016) and was measured using the validated multiple pass method (Conway et al. 
2003) to collect three 24-hour recalls [i.e. three-day food records (3DFRs)] consisting of one 
weekend day and two week days. Data collection occurred at baseline (during a 14-day run-in 
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period), 3-month, 6-month and 12-month follow-up in order to assess short-term, moderate-term, 
and long-term changes. Trained research assistants who were blinded to participants’ group 
allocations collected 3DFRs over the phone. In some rare cases where a participant could not be 
reached over the phone, 3DFRs were collected in-person at the EEFHT. Dietary adherence was 
measured by analyzing the quantity of participants adhering to the calorie, saturated fat, total fat 
and protein recommendations. ESHA Food Processor version 11.3.285 (ESHA Research, Salem, 
OR, United States) was used to analyze all 3DFRs. 
Statistical Analyses  
 The mean and standard deviation (SD) were used to report continuous variables and 
percentages were used for categorical variables. Estimates of the different sources of attrition 
bias were conducted using two-way analysis of variance (ANOVA) models. The TPB (Ajzen 
1991) was used to guide this analysis with data collected from a baseline TPB survey. The 
following possible confounding factors were analyzed to determine if there were significant 
differences between drop-outs in each group: attitudes towards changing their intake of calories, 
fat, and protein (attitudes); friends eating a healthy diet, family eating a healthy diet (subjective 
norms); stage of change/transtheoretical model; perceived difficulty altering calorie, fat, and 
protein intake (perceived behavioural control); income and education (actual behavioural 
control/social determinants of health). 
Chi-square tests were used to analyze categorical variables (dietary adherence). In cases 
where there were fewer than five expected counts, Fisher’s exact tests were used. To assess 
dietary adherence at 3 months while controlling for income, binary logistic regression was 
conducted. Split-plot ANOVAs were used to compare differences between groups (GLB vs. 
GLB+NGx) for change in dietary intake from baseline to 3-, 6-, and 12-month follow-up 
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(prespecified outcome). Repeated measures ANOVAs were used to assess within-group changes 
in dietary intake from baseline to 3-, 6-, and 12-month follow-up (prespecified outcome). SPSS 
Version 26.0 (IBM Corporation, Armonk, NY, United States) was used for all statistical 
analyses, which took place in October – November 2019. The analyses were by originally 
assigned groups. 
Hypotheses 
 It was hypothesized that the GLB+NGx group would engage in greater dietary changes 
and better adhere to the dietary advice compared to the standard GLB group.  
 
6.1.4 Results  
 
Overall, mean values from demographic and TPB characteristics (Tables 6.1 and 6.2) 
indicated that the study population consisted of highly motivated, college-educated, middle-aged 
female subjects with obesity, who had positive attitudes towards changing their dietary intake, 
with neutral subjective norms related to friends/family consuming a healthy diet, and neutral 
perceived behavioural control for changing their dietary intake. The genetic results of 
participants in the GLB+NGx group are summarized in Table 6.3. There was significant attrition 
bias for one TPB component, income (p=0.02), at the 3-month follow-up only (Table 6.2) and 
therefore this was controlled for as a confounding factor in the 3-month analyses. There were no 
differential attrition rates between groups. At baseline, 112 participants completed the 3DFRs, 
with 86 completing the 3-month follow-up data collection (77% retention), 74 completing 6-
month food records (66% retention) and 59 completing the 12-month food records (53% 
retention). No adverse events were reported. 
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Table 6.1: Baseline demographic and clinical characteristics of participants  
 
GLB Group 
Mean ± SD 
GLB+NGx Group 
 Mean ± SD 
Age (years) 56.4 ± 12.1  53.5 ± 13.6  
Gender 84.3% female 89.9% female 
Ethnicity 98.6% Caucasian 97.1% Caucasian 
Annual household income (CDN $) 73,943 ± 41,403 71,389 ± 44,301 
Weight (lbs) 217.3 ± 49.0 215.4 ± 51.8 
BMI (kg/m2) 36.7 ± 7.3 37.3 ± 9.7 
Body fat (%) 46.7 ± 7.0 45.7 ± 7.9  
N=140 (n=70 participants per group) 
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Table 6.2: Baseline scores and values for components of the Theory of Planned Behaviour for dropouts and stayers 
TIME 
POINT 
AND 
PARTICIP-
ANT TYPE  
TYPE OF 
GROUP 
ATTITUDES SUBJECTIVE NORMS 
PERCEIVED BEHAVIOURAL CONTROL 
(PBC) 
ACTUAL 
BEHAVIOURAL 
CONTROL  
  
Attitudes 
(Calories) 
Attitudes 
(Fat) 
Attitudes 
(Protein) 
Friends Eat a 
Healthy Diet 
Family Eats a 
Healthy Diet 
PBC 
(Calories) 
PBC (Fat) 
PBC 
(Protein) 
Stage of 
Change 
Income 
(CDN$) 
Level of 
Education 
3-MONTH 
STAYERS 
GLB 6.39 ± 0.75 6.27 ± 0.94 6.30 ± 0.73 4.06 ± 1.69 5.06 ± 1.64 4.45 ± 1.28 4.73 ± 1.38 4.76 ± 1.39 3.70 ± 1.05 
70,619 ± 
37,561a 
3.97 ± 0.73 
GLB+NGx  6.49 ± 0.98 6.23 ± 1.03 6.31 ± 1.05 4.57 ± 1.31 5.06 ± 1.32 4.31 ±1.60 4.37 ± 1.65 4.80 ± 1.57 4.00 ± 1.06 
85, 059 ± 
44,460a 
4.06 ± 0.79 
3-MONTH 
DROP-
OUTS 
GLB  6.16 ± 0.99 5.89 ± 1.50 5.76 ± 1.28 4.19 ± 1.65  4.65 ±1.58 4.25 ± 1.46 4.31 ± 1.60 4.56 ± 1.48 3.42 ± 1.00 
76,806 ± 
44,778a 
3.75 ± 0.84 
GLB+NGx  6.24 ± 1.10 6.26 ± 0.93 6.29 ± 0.91 4.18 ± 1.31 5.00 ± 1.30 4.50 ± 1.64 4.71 ± 1.51 5.35 ± 1.59 3.67 ± 0.88 
56, 865 ± 
39,852a 
3.97 ± 0.76 
6-MONTH 
STAYERS 
GLB 6.50 ± 0.67 6.22 ± 0.97 6.31 ± 0.78 4.31 ± 1.60 5.06 ± 1.61 4.28 ± 1.28 4.63 ± 1.43 4.78 ± 1.39 3.59 ± 1.04 
68,006 ± 
33,432 
3.97 ± 0.65 
GLB+NGx  6.51 ± 0.95 6.31 ± 1.00 6.41 ± 0.98 4.48 ± 1.30 5.00 ± 1.39 4.38 ± 1.68 4.41 ± 1.57 4.54 ± 1.48 3.93 ± 1.10 
74,893 ± 
45,009 
4.04 ± 0.96 
6-MONTH 
DROP-
OUTS 
GLB 6.01 ± 1.00 5.95 ± 1.49 5.76 ± 1.24 3.97 ± 1.72 4.66 ± 1.62 4.41 ± 1.46 4.52 ± 1.70 5.21 ± 1.66 3.51 ± 1.02 
79,056 ± 
47,079 
3.76 ± 0.89 
GLB+NGx  6.36 ± 1.04 6.24 ± 0.98 6.23 ± 0.97 4.30 ± 1.34 5.05 ± 1.26 4.43 ± 1.58 4.55 ± 1.50 4.98 ± 1.56 3.78 ± 0.89 
68,808 ± 
44,197 
4.00 ± 0.82 
12-MONTH 
STAYERS 
GLB  6.57 ± 0.60 6.43 ± 0.87 6.29 ± 0.85 4.43 ± 1.66 5.24 ± 1.44 4.38 ± 1.36 4.57 ± 1.60 4.81 ± 1.50 3.67 ± 1.11 
68,760 ± 
31,195 
4.05 ± 0.67 
GLB+NGx  6.39 ± 1.10 6.21 ±1.07 6.18 ± 1.12 4.53 ± 1.35 5.07 ± 1.39 4.57 ± 1.73 4.68 ± 1.76 5.18 ± 1.70 4.04 ± 1.10 
81,574 ± 
42,411 
4.00 ± 0.92 
12-MONTH 
DROP-
OUTS 
GLB 6.14 ± 0.96 5.92 ± 1.40 5.90 ± 1.16 4.00 ± 1.66 4.67 ± 1.66 4.33 ± 1.39 4.48 ± 1.47 4.58 ± 1.41 3.50 ± 0.99 
76,149 ± 
45,177 
3.77 ± 0.83 
GLB+NGx 6.34 ± 1.02 6.27 ± 0.92 6.39 ± 0.86 4.27 ± 1.30 5.00 ± 1.26 4.29 ± 1.54 4.44 ± 1.45 5.00 ± 1.53 3.71 ± 0.87 
64,338 ± 
44,740 
4.02 ± 0.85 
Mean scores for attitudes, subjective norms, and PBC (calories, fat, protein) on a Likert scale of 1 (negative attitude/subjective norms/PBC) to 7 (positive 
attitude/subjective norms/PBC); Mean scores for stage of change on Likert scale of 1 to 6 (pre-contemplation, contemplation, motivation, action of <3 months, 
action of 3-6 months, maintenance of >6 months); Mean scores for highest level of education on a Likert scale of 1 to 5 (elementary school, middle school, high 
school, college, university); ‘Stayers’ were defined as individuals completing baseline and 3/6/12 month food records; a. p-interaction < 0.05. 
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Table 6.3: Nutrition-related genetic variation among participants in the GLB+NGx group 
n=70
Nutrient, Gene 
(rs number) 
Genotype 
Distribution 
(n, %) 
Participants with Elevated 
Risk/Enhanced Response 
Genotype (n, %) 
Associated 
Risk/Response 
Calories, UCP1 
(rs1800592) 
AA (44, 62.9) 
AG (19, 27.1) 
GG (7, 10.0) 
Elevated Risk (26, 37.1) 
Lower resting 
metabolic rate 
Protein, FTO 
(rs9939609) 
AA (21, 30.0) 
TA (27, 38.6) 
TT (22, 31.4) 
Enhanced Response (21, 30.0) Weight loss 
Total Fat, TCF7L2 
(rs7903146) 
TT (6, 8.6) 
CT (28, 40.0) 
CC (36, 51.4) 
Enhanced Response (6, 8.6) Weight loss 
SFA, APOA2 
(rs5082) 
TT (21, 30.0) 
TC (44, 62.9) 
CC (5, 7.1) 
Enhanced Response (5, 7.1) Weight loss 
PUFA:SFA, FTO 
(rs9939609) 
AA (21, 30.0) 
TA (27, 38.6) 
TT (22, 31.4) 
Enhanced Response (48, 68.6) Weight loss 
MUFA, PPARg2 
(rs1801282) 
CC (53, 75.7) 
CG (17, 24.3) 
GG (0, 0.0) 
Enhanced Response (17, 24.3) Weight loss 
Snacking/Appetite, 
MC4R 
(rs17782313) 
TT (30, 42.9) 
TC (35, 50.0) 
CC (5, 7.1) 
Elevated Risk (40, 57.1) 
Greater snacking/eating 
frequency 
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Change in Dietary Intake 
Change in dietary intake from baseline to 3-, 6-, and 12-month follow-up is detailed in 
Table 6.4. For the analysis of overall change in dietary intake throughout the entire duration of 
the study, a total of 32 participants completed the food records at all four time points. As further 
depicted in Figures 6.1 and 6.2, only the GLB+NGx group significantly reduced total dietary fat 
intake from baseline to 12-month follow-up (36.0±4.8%kcal to 30.2±8.7%kcal, p=0.02). 
Furthermore, as depicted in Figure 6.3, the GLB+NGx group experienced a clinically meaningful 
reduction in SFA intake (11.9±3.3%kcal to 9.3±3.3%kcal, p=0.13) and statistically significant 
reduction in grams, but not percent of calories (%kcal), of unsaturated fat. Overall, there were 
long-term (12-month) changes in dietary fat intake when participants in the GLB program 
received the addition of nutrigenetic information and advice compared to receiving only 
population-based dietary information and advice. 
Dietary Adherence 
As further detailed in Table 6.5, with more broad %kcal ranges, participants in the standard 
GLB group had significantly (p<0.01) greater adherence to the group-specific target for protein 
intake at all four time points (baseline, 3, 6 and 12 months) indicating that the group-specific 
targets in the GLB+NGx group were more difficult to achieve from the beginning. Similarly, 
with more broad %kcal ranges for total fat intake in the GLB+NGx ‘typical response’ group, 
participants in the GLB+NGx group had significantly (p<0.01) greater adherence to the group-
based targets for total fat at all four time points, indicating that the target for total fat intake in the 
standard GLB group was more difficult to achieve. Interestingly, the GLB+NGx group had 
significantly greater long-term (12-month) adherence to the targets of <25%kcal from total fat 
(p<0.01) and <10%kcal from saturated fat (p=0.02), compared to the standard GLB group.  
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Table 6.4: Overall change in dietary intake from baseline to 3-, 6- and 12-month follow-up 
 Baseline 3-Months 6-Months 12-Months 
RM-
ANOVA 
RM-
ANOVA 
Split-Plot 
ANOVA 
NUTRIENT GLB GLB+NGx GLB GLB+NGx GLB GLB+NGx GLB GLB+NGx 
p-value 
GLB 
p-value 
GLB+NGx 
p-
interaction 
Calories (kcal 
± SD) 
1709.2±502.9 1873.9±528.2 1473.2±358.5 1662.9±543.4 1566.2±394.1 1713.2±602.6 1473.5±339.6 1639.1±680.8 0.17 0.30 0.99 
Calories (% 
change ± SD) 
0.0 ± 0.0 0.0 ± 0.0 -9.9±2.3 -7.7±3.2 -1.8±4.3 -6.7±2.6 -8.5±2.7 -12.9±3.1 0.49 0.39 0.22 
Protein (g ± 
SD) 
70.7±23.3 86.6±23.5 73.6±26.7 77.1±25.8 75.1±28.4 80.6±29.3 68.6±29.0 72.3±24.2 0.63 0.20 0.44 
Protein (%kcal 
± SD) 
16.7±2.8 19.1±5.3 20.3±6.1 19.1±4.8 19.2±5.0 19.7±7.1 18.6±5.8 18.6±5.8 0.11 0.91 0.35 
Total Fat (g ± 
SD) 
74.1±33.6 75.0±22.6 53.3±20.8 61.2±28.3 62.8±27.9 60.6±28.3 59.7±19.1 55.4±29.4 0.14 0.01a 0.63 
Total Fat 
(%kcal ± SD) 
37.7±8.2 36.0±4.8 31.2±8.3 31.9±7.4 35.5±10.1 31.4±9.2 36.2±7.2 30.2±8.7 0.12 0.02b 0.24 
SFA (g ± SD) 24.6±12.3 24.4±8.1 18.6±9.7 19.7±11.1 21.1±8.8 21.3±12.8 19.7±6.5 17.6±10.8 0.22 0.08 0.85 
SFA (%kcal ± 
SD) 
12.2±3.1 11.9±3.3 10.8±4.4 10.2±3.7 11.7±3.9 10.8±4.6 11.9±3.1 9.3±3.3 0.64 0.13 0.45 
Total UnSFA 
(g ± SD) 
48.7±22.4 49.6±17.2 33.7±13.0 40.5±18.7 41.1±23.1 38.2±16.4 38.6±14.7 36.8±19.2 0.17 0.02c 0.56 
Total UnSFA 
(%kcal ± SD) 
24.5±6.1 23.3±3.8 20.2±5.7 20.8±5.6 22.7±8.4 19.7±5.4 22.8±5.2 19.7±6.0 0.23 0.05 0.35 
GLB Group: n=16, GLB+NGx Group: n=18 (total n=32). Bold values are significant at p<0.05. Effect sizes: a. 0.190; b. 0.187; c. 0.191 
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Table 6.5: Differences between groups for dietary adherence at baseline, 3, 6 and 12 months  
 
Baseline (n, % 
achieving target) 
Significance 
3-Months (n, % 
achieving target) 
Significance 
6-Months (n, % 
achieving target) 
Significance 
12-Months (n, % 
achieving target) 
Significance 
NUTRIENT GLB GLB+NGx p-value GLB GLB+NGx p-value* GLB GLB+NGx p-value GLB GLB+NGx p-value 
Individualized 
Calorie Target1 
20, 
37.7% 
26, 44.8% 0.45 
22, 
50.0% 
22, 52.4% 0.86 
23, 
57.5% 
15, 44.1% 0.25 16, 57.1% 17, 56.7% 0.97 
<25% kcal from 
total fat 
6, 11.3% 5, 8.4% 0.61 
6, 
13.6% 
7, 16.7% 0.87 
6, 
15.0% 
6, 17.6% 0.76 0, 0.0% 8, 25.8% <0.01a 
Group-based 
total fat target2 
6, 11.3% 23, 39.0% <0.01b 
6, 
13.6% 
27, 64.3% <0.01c 
6, 
15.0% 
19, 55.9% <0.01d 0, 0.0% 18, 58.1%  <0.01e 
10-35% kcal 
from protein 
52, 
98.1% 
59, 
100.0% 
0.47 
43, 
97.7% 
42, 
100.0% 
0.99 
40, 
100.0% 
34, 
100.0% 
1.00 25, 89.3% 
31, 
100.0% 
0.10 
Group-based 
protein target3 
52, 
98.1% 
44, 74.6% <0.01f 
43, 
97.7% 
31, 70.5% 0.01g 
40, 
100.0% 
25, 73.5% <0.01h 27, 96.4% 22, 71.0% 0.01i 
<10% kcal from 
saturated fat 
14, 
26.4% 
14, 23.7% 0.74 
21, 
47.7% 
22, 52.4% 0.57 
15, 
37.5% 
15, 44.1% 0.56 8, 28.6% 18, 58.1% 0.02j 
 
1. Calorie targets were individualized based on baseline weight as outlined in the GLB Program curriculum (University of Pittsburgh, c2017) 
2. Group-based total fat targets were: ≤25% of calories from total fat in the standard GLB group, 20-35% of calories from total fat in the GLB+NGx ‘typical 
response’ group and 20-25% of calories in the GLB+NGx ‘enhanced response’ group 
3. Group-based protein targets were: 10-35% if calories in the standard GLB group and in the GLB+NGx ‘typical response’ group and 25-35% of calories in the 
GLB+NGx ‘enhanced response’ group 
Odds ratios: a. NA; b. 5.00; c. 11.40; d. 7.18; e. NA; f. 17.727; g. 15.258; h. NA; i. 11.045; j. 3.46 
*binary logistic regression, controlling for income 
Baseline: GLB Group: n=53, GLB+NGx Group: n=59 (total n=112; n=111 for calories analysis as baseline weight data missing for n=1) 
3-Months: GLB Group: n=44, GLB+NGx Group: n=42 (total n=86) 
6-Months: GLB Group: n=40, GLB+NGx Group: n=34 (total n=74) 
12-Months: GLB Group: n=28, GLB+NGx Group: n=31 (total n=59; n=58 for calories analysis as baseline weight data missing for n=1) 
Fisher’s exact test used when expected counts were less than 5  
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Figure 6.1: Flow diagram of participants from baseline to 3-, 6- and 12-month follow-up 
 
 
 
 
130 
 
 
 
 
Figure 6.2: Change in percent of calories from total fat 
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Figure 6.3: Change in percent of calories from saturated fat  
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6.1.5 Discussion  
 
This study demonstrates that a nutrigenomics weight management intervention can 
motivate greater long-term dietary change compared to population-based recommendations in 
one of the most effective public health weight management and diabetes prevention programs. 
Notably, this is the first genetic testing behaviour change study to incorporate the TPB and thus 
control for important confounding factors of behaviour change and is the first study to assess 
changes in calorie and macronutrient intake resulting from a genetic-based weight management 
intervention. It is also the first study to assess change in dietary intake when the GLB/DPP 
program is extended to patients with overweight/obesity, regardless of having a prediabetes 
diagnosis - a recommended program expansion by public health officials (Ontario Ministry of 
Health and Long-Term Care 2018).  
 Previous research has assessed change in dietary intake in participants diagnosed with 
prediabetes enrolled in the GLB/DPP program. Over the course of 12 months, it appears that the 
participants with prediabetes made greater overall dietary changes (-452 calories and -6.6% total 
fat) compared to the population of adults with overweight/obesity in the NOW trial who received 
the standard GLB program (-236 calories and -1.5% total fat), although different tools were used 
to measure dietary intake, therefore the results cannot be compared with complete accuracy 
(Mayer-Davis et al. 2004). Theoretical concepts of behaviour change support this finding; the 
extended parallel process model suggests that if individuals’ perceptions about susceptibility to a 
threat (e.g., developing type 2 diabetes) and the magnitude of the threat are high, they are more 
likely to take action to control the threat (e.g., improve their nutrition) (Popova 2012). 
Interestingly, the NOW trial GLB+NGx group (with overweight/obesity but not necessarily a 
prediabetes diagnosis) changed their dietary intake to a similar extent as those in the original 
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GLB/DPP cohort, all of whom had a diagnosis of prediabetes, whereas the NOW trial standard 
GLB group made fewer changes to their diet (Mayer-Davis et al. 2004). In comparing these 
findings to the extended parallel process model, it is possible that the addition of genetic-based 
nutrition information and advice positively impacted response efficacy (beliefs about the 
effectiveness of the advice to improve weight management), and elicited greater danger control 
responses (beliefs, attitudes, intentions, and behaviours to manage weight) (Popova 2012). 
Future research should explore this concept further. Future research should also assess change in 
dietary intake in the GLB program (with and without the addition of nutrigenomics 
information/advice) in various locations across North America, and with a more ethnically 
diverse study sample in order to improve generalizability. The current study is primarily 
generalizable to Caucasian females with overweight and obesity enrolled in a weight 
management program. Notably, given the highly pragmatic nature of the NOW trial (Table 6.6), 
overall, this study has strong external validity. 
 In terms of the dietary analyses, while both grams and %kcal are reported in the present 
study, %kcal is a more accurate comparison between groups given that calorie intakes between 
groups were not identical. As such, differences in %kcal from macronutrients should be 
weighted more highly in the interpretation of the overall results compared to grams of nutrients. 
Given that the %kcal from protein recommendations for the GLB+NGx ‘enhanced response’ 
group proved to be challenging to achieve, and that a large proportion of the GLB+NGx group 
were advised to limit their SFA intake to <10%kcal to enhance weight loss (Table 6.3), it is not 
surprising that there was significantly greater dietary adherence to the SFA recommendations in 
the GLB+NGx group as many participants were focusing on reducing their SFA intake. This 
would also contribute to the significant reduction in total fat intake in the GLB+NGx group only 
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(in addition to a reduction in unsaturated fat). It was, however, surprising to see minimal change 
in total fat intake and poor dietary adherence to the total fat recommendations in the standard 
GLB group at 12-month follow-up since this was the focus of the standard program. While 
clinically meaningful (though not statistically significant) reductions in total fat intake occurred 
from baseline to 3-, and 6-month follow-up, these were not sustained after 12-months.  As 
further explained above, it appears individuals with overweight/obesity, but not necessarily 
having a prediabetes diagnosis, have a more difficult time maintaining long-term dietary changes 
in the standard GLB program compared to those diagnosed with prediabetes (Mayer-Davis et al. 
2004). According to the NOW trial findings, the addition of genetic-based dietary advice could 
help to mitigate this. Indeed, previous research has indicated that weight control is a motivator 
for the intention to adopt personalized nutrition strategies (Rankin et al. 2018). 
 Our finding that GLB+NGx group participants who dropped out at 3 months had a 
significantly lower income, on average, compared to 3-months dropouts from the standard GLB 
group was interesting. It is possible that purchasing food in order to adhere to the nutrigenomics 
intervention was perceived as, or in reality was, more expensive (e.g. 30% of participants were 
advised to follow a higher protein nutrition plan) and cost may have been prohibitive to 
following the dietary advice. Studies have reported cost is a barrier to consumption of higher 
protein foods (Appleton 2016; Best and Appleton 2013). However, the finding that dropouts 
from the GLB+NGx group tended to have lower incomes was not consistent after 6 and 12 
months, and therefore, future research should explore this phenomenon further.   
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Table 6.6: PRECIS-2 Scoring Tool 
PRECIS-2 Domain Score [Likert scale 1 
(very explanatory) - 5 
(very pragmatic)] 
1. Eligibility: To what extent are the participants in the trial similar to 
those who would receive this intervention if it was part of usual care? 
5 
2. Recruitment: How much extra effort is made to recruit participants 
over and above what would be used in the usual care setting to engage 
with patients?  
5 
3. Setting: How different are the settings of the trial from the usual 
setting?  
5 
4. Organization: How different are the resources, provider expertise, 
and the organization of care delivery in the intervention arm of the trial 
from those available in usual care?  
4 
5. Flexibility (delivery): How different is the flexibility in how the 
intervention is delivered and the flexibility anticipated in usual care?   
4 
6. Flexibility (adherence): How different is the flexibility in how 
participants are monitored and encouraged to adhere to the intervention 
from the flexibility anticipated in usual care? 
4 
7. Follow-up: How different is the intensity of measurement and follow-
up of participants in the trial from the typical follow-up in usual care?  
3 
8. Primary outcome: To what extent is the trial’s primary outcome 
directly relevant to participants?  
5 
9. Primary analysis: To what extent are all data included in the analysis 
of the primary outcome?  
N/A (the present study 
provides an analysis of 
secondary outcome 
data) 
 
Mean score:  4.4 
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Strengths and Limitations 
 There are several specific strengths and limitations of the present work that should be 
noted. This was novel to the field, as it was one of only four randomized controlled trials (RCTs) 
to assess change in dietary intake resulting from a nutrigenetic intervention over a 12-month 
period. Previously, Hietaranta-Luoma et al. (2014) similarly found that a nutrigenetic 
cardiovascular disease intervention motivated greater long-term changes in dietary intake, and 
further motivated greater short-term and moderate-term changes compared to a control group. 
Nielsen and El-Sohemy’s (2014) and Chao et al.’s (2008) 12-month RCTs also found that 
nutrigenomics interventions motivated greater long-term (12-month) changes in dietary intake. 
There have been no RCTs demonstrating that nutrigenomics is ineffective at motivating changes 
in dietary intake after 12-month follow-up (Horne et al. 2018). Thus, taken together, the body of 
evidence highly suggests that nutrigenomics is a useful tool for motivating positive nutritional 
intake over the long-term. 
Consistent with the vast majority of nutrition research, there were limitations related to 
the methods used to collect dietary intake data such as possible recall bias and underreporting of 
intake (Shim, Oh, and Kim 2014). However, 3DFRs were collected using the multiple-pass 
method, which has been validated against direct observation in a similar population (Conway et 
al. 2003). Additionally, these food records provided highly detailed nutritional intake data, which 
is a strength of this dietary collection method (Shim, Oh, and Kim 2014). Nonetheless, 3DFRs 
are time consuming leading to respondent burden (Shim, Oh, and Kim 2014), which helps to 
explain why a smaller subset of the NOW trial sample participated in 3DFR collection 
throughout the entire duration of the study. In addition, 3DFRs were collected over the phone, 
whereas other NOW trial outcome data (e.g. weight and body composition) were collected in-
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person (Horne et al. 2019; Madill 2016), leading to slightly different samples as some 
participants completed only the 3DFRs, while others completed only the in-person data 
collection, and others completed both.   
 Since the dietary analysis was a secondary outcome of the NOW trial, the sample size 
may not have been large enough to detect statistical significance in some cases. For example, 
while adherence to SFA was significantly greater (p=0.02) in the GLB+NGx group compared to 
the standard GLB group, a 12-month clinically meaningful reduction in SFA was observed in the 
GLB+NGx group only (11.9±3.3%kcal to 9.3±3.3%kcal), but this change was not statistically 
significant (p=0.13). Nonetheless, this was a notable observation given that in addition to 
possible weight-related outcomes resulting from a decrease in SFA to <10% kcal from saturated 
fat (Corella et al. 2009), achieving <10% kcal from SFA can have further beneficial effects on 
LDL-cholesterol and other cardiovascular disease risk factors (Anderson et al. 2016). Future 
research should seek to replicate this study in a RCT adequately powered to detect significant 
differences in %kcal from SFA. Nonetheless, this long-term 22% reduction in SFA observed in 
the GLB+NGx group is notable, and relates to the statistically significant greater adherence to 
the SFA guidelines after 12 months in the GLB+NGx group compared to the standard GLB 
group. 
Lastly, baseline portion sizes were likely underreported given that baseline data 
collection occurred during the run-in period and participants learned how to measure their food 
and beverage intake in the first week of the intervention. This may have affected results for 
calories and grams of nutrients (but not percent of intake from macronutrients). However, since 
participants were advised to measure all food and beverages for one week and track their intake 
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for two to three months, this likely improved the accuracy of the follow-up 3DFRs. Thus, the 
actual change in dietary intake may in fact have been greater than the data suggest. 
 
6.1.6 Conclusion  
 
Overall, the NOW trial provides important, novel insights into genetic testing behaviour 
change research, grounded in fundamental theoretical concepts. The results of this study provide 
convincing evidence that the addition of nutrigenomics to one of the most effective public health 
weight management and diabetes prevention programs can help motivate and optimize long-
term, clinically meaningful differences in nutritional intake and adherence to dietary guidelines. 
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CHAPTER 7: CHANGE IN WEIGHT, BMI AND BODY 
COMPOSITION 
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7.1 Title: Change in weight, BMI and body composition after 3, 6 and 12 months 
in a population-based intervention vs. genetic-based intervention: Results from 
the NOW randomized controlled trial  
 
7.1.1 Abstract 
 
Importance: Nutrigenomics testing for weight management is widely available to the general 
public through direct-to-consumer testing and via healthcare professionals, but limited research 
has assessed its effectiveness. 
Objective: To compare changes in body fat percentage (BFP), weight and body mass index 
(BMI) between a standard intervention and a nutrigenomics intervention.  
Design: The nutrigenomics, overweight/obesity and weight management (NOW) trial is a 
parallel group, pragmatic, randomized, controlled clinical trial incorporated into the Group 
Lifestyle Balance (GLB)/Diabetes Prevention Program. Participants were followed from baseline 
to 3, 6, and 12 months through staggered cohorts occurring between April 2017 and September 
2019. Statistical analyses included two-way analyses of variance (ANOVAs) for analyses of 
potential attrition bias, and split plot ANOVAs to assess between-group differences from 
baseline to 3-, 6-, and 12-month follow-up.  
Setting: This study took place at the East Elgin Family Health Team in Aylmer, Ontario, 
Canada. 
Participants: Participants enrolled in the GLB/Diabetes Prevention Program were invited to 
participate if they had a BMI ≥25.0 kg/m2, were ≥18 years of age, English-speaking, willing to 
undergo genetic testing, had internet access and were not seeing another healthcare provider for 
weight loss advice outside of the study. Pregnancy and lactation were exclusion criteria. Only 
one participant declined study participation, with a total of 140 enrolling.  
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Interventions: GLB groups were randomized 1:1 to receive either the standard 12-month GLB 
program or a modified 12-month program (GLB+NGx), which included the provision of 
nutrigenomics information and advice for weight management.  
Main Outcome(s) and Measure(s): The primary study outcome was change in BFP. Change in 
weight and BMI were secondary outcomes.  
Results: The sample consisted primarily of middle-aged Caucasian females with class II obesity 
(n=75). The GLB+NGx group experienced significantly (p<0.05) greater reductions in percent 
and absolute BFP at the 3-month follow-up (percent BFP change: -4.95±5.52%, 95% CI: -3.3 to 
-6.6; absolute BFP change: -2.12±1.96%, 95% CI: -1.5 to -2.8) and percent BFP at 6-month 
follow-up (-7.76±6.33%, 95% CI: -5.8 to -9.6) compared to the standard GLB group (3-month 
percent BFP change: -2.24±4.13%, 95% CI: -0.5 to -3.9; 3-month absolute BFP change: -
1.02±1.89, 95% CI: -0.4 to -1.7; 6-month percent BFP change: -4.80±4.85%, 95% CI: -2.8 to -
6.8, respectively).  
Conclusions and Relevance: The nutrigenomics intervention used in the NOW trial is a valuable 
intervention for optimizing body composition, especially over the short- and moderate-term. 
Trial Registration: This trial is registered with clinicaltrials.gov (NCT03015012). 
 
7.1.2 Introduction 
 
Weight management is an ongoing challenge for a substantial proportion of the 
population. It is estimated that two-fifths of the adult population worldwide are attempting to 
lose weight, with another quarter of the population attempting to maintain weight (Santos et al. 
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2017). Patients’ motivations for weight control are broad and include desires to improve health, 
well-being, physical appearance, fitness, and self-esteem (Santos et al. 2017).  
 
The most current American Heart Association/American College of Cardiology/Task 
Force on Practice Guidelines and the Obesity Society (AHA/ACC/TOS) clinical practice 
guidelines for overweight and obesity management state that there is “strong evidence” (NHLBI 
Grade A) for the effectiveness of several interventions in achieving sustained weight loss (Jensen 
et al. 2014). Despite this knowledge, successful long-term weight loss still proves to be 
challenging, with many interventions demonstrating weight regain after long-term follow-up 
(Aller et al. 2014; Miura et al. 1989; Brock et al. 2010; Wadden and Sarwer 1999). While there 
are numerous weight management programs available to the public, the Group Lifestyle 
Balance™ (GLB) program (formerly referred to as the Diabetes Prevention Program) can be 
considered the gold standard weight management intervention for long-term, sustainable weight 
loss and diabetes prevention (Diabetes Prevention Program Research Group 2002; McTigue et 
al. 2009; Piatt et al. 2012; Xiao et al. 2013). This program meets all of the criteria from the 
AHA/ACC/TOS clinical practice guidelines, while addressing various modifiable health and 
lifestyle behaviours (Jensen, Ryan, Apovian, et al. 2014).  
 
Complex factors affect weight and body composition. Factors contributing to the 
development and management of overweight/obesity include stress, sleep, nutrition, physical 
activity (PA), social determinants of health, the built environment, medications, certain 
diseases/conditions and genetics (Moore et al. 2010; Eriksson et al. 2003; Finkelstein, Ruhm, and 
Kosa 2005; Seabrook and Avison 2010; Gilliland et al. 2012; Sarma et al. 2014). With increasing 
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knowledge of how individual genetic variation affects nutrient metabolism, absorption, and other 
physiological processes, genetics are an important factor to consider in weight management 
interventions. The science of nutrigenomics explores interactions between nutrition, genetics, 
and health outcomes (Subbiah 2008). The science of lifestyle genomics is broader, and explores 
interactions between various lifestyle components (such as smoking, PA, sleep, and nutrition), 
genetics, and health outcomes (Horne et al. 2018). 
 
Consumers have demonstrated consistently positive attitudes towards nutrigenetic testing 
(Vallée Marcotte et al. 2019; Morin 2009; Stewart-Knox et al. 2009; Nielsen and El-Sohemy 
2012). As such, many consumer nutrigenomics and lifestyle genomics tests are available to the 
general public, often including personalized weight management lifestyle advice. While primary 
research has demonstrated several relationships between genetic variation, weight/body 
composition and specific dietary and PA strategies (Zhang et al. 2012; Eller et al. 2008; Paniagua 
et al. 2007; Corella et al. 2010; Corella et al. 2011; De Luis, Aller, and Pacheco 2015; Phillips et 
al. 2012; Memisoglu et al. 2003; Garaulet et al. 2011; Sonestedt et al. 2011; J. Zhu et al. 2014; 
Xi et al. 2011; Rampersaud et al. 2008), the efficacy of the practical application of this science in 
a clinical setting has yet to be thoroughly explored. To date, only three studies have assessed the 
efficacy of using nutrigenomics and lifestyle genomics to optimize weight management 
(Arkadianos et al. 2007; Frankwich et al. 2015; Celis-Morales et al. 2017). These studies 
provided a solid starting point for enhancing our knowledge on this topic, but exhibit notable 
limitations related to statistical power, methodology and the quality of the interventions 
delivered to study participants.  Nonetheless, findings have been variable (Arkadianos et al. 
2007; Frankwich et al. 2015; Celis-Morales et al. 2017) with some promise for the use of 
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genetic-based advice to optimize weight management (Arkadianos et al. 2007). The present 
randomized controlled trial (RCT) aimed to address the limitations of the current body of 
knowledge in order to answer the important research question, does the provision of 
personalized genetic-based lifestyle information and advice enhance weight loss and improve 
body composition to a greater extent than the gold-standard, population-based weight 
management program?  
 
7.1.3 Methods 
 
The nutrigenomics, overweight/obesity and weight management (NOW) trial is a 
pragmatic, parallel-group, superiority randomized controlled trial. Complete details of the study 
methods for this clinical trial, including a SPIRIT flow diagram, have been published elsewhere 
(Horne et al. 2019). Briefly, a personalized genetic-based lifestyle intervention program was 
compared (1:1) to the gold standard, population-based lifestyle intervention program (GLB) for 
weight management. Inclusion criteria consisted of having a BMI ≥25.0 kg/m2, being ≥18 years 
of age, English-speaking, willing to undergo genetic testing, having internet access, and not 
seeing another healthcare provider for weight loss advice outside of the study. Pregnancy and 
lactation were considered exclusion criteria. This study took place at the East Elgin Family 
Health Team (EEFHT) in Aylmer, Ontario, Canada and was registered with clinicaltrials.gov 
(NCT03015012) (Madill 2016). 
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Recruitment  
 
Adults from Elgin and Middlesex Counties in Ontario, Canada were either referred to the 
GLB program by healthcare professionals in the area, or signed up for the program through 
word-of-mouth referrals from members of the community. Participants expressing interest in 
joining the GLB program were invited to the EEFHT for an in-person NOW trial information 
meeting, and provided written, informed consent if they decided to take part in the study.  
 
Primary and Secondary Outcomes 
 
The primary outcome of this RCT was percent change in body fat percentage (BFP). 
Changes in weight and body mass index (BMI) were secondary outcomes as indicated on 
clinicaltrials.gov (Madill 2016). 
 
Sample Size 
 
As indicated in the study protocol (Horne et al. 2019), in order to detect a 4% change in 
BFP, using a standard deviation of 6.1%, the sample size calculation indicated that a total of 74 
participants (37 participants per group) were needed to test the primary outcome of this trial with 
80% power and an alpha of 5%. 
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Randomization and Blinding  
 
For the cohort randomization, randomly permuted blocks were generated by one author 
(JH) using the original generator on an internet-based randomization program (Dallal 2017). This 
allowed for pre-randomization of GLB groups in order to determine if the group intervention 
sessions would be population-based, or genetic-based as further detailed in ‘Interventions and 
Data Collection,’ below. Participants selected a GLB group that best suited their schedule and 
were blinded to the group assignment at this time. Four authors were blinded throughout the 
duration of the study, with one author unblinded (JH) for logistical reasons as this investigator 
was responsible for scheduling participants, arranging the genetic testing, facilitating all group 
and one-on-one sessions and completing data collection.  
 
Run-In 
Baseline data collection occurred within approximately 14 days (mean ± SD = 9.3 ± 5.7) 
prior to the intervention start date. No lifestyle advice was provided to participants during this 
run-in period.  
Interventions and Data Collection  
 
Participant recruitment took place between April 2017 and September 2018. Recruitment 
ended in September 2018 given the allocated timeline for this project and given that the target 
recruitment sample number had been achieved. One author (JH) was responsible for enrolling 
participants and assigning them to interventions (based on their availability and the GLB group 
times/dates selected by the blinded participants). Data collection and lifestyle interventions 
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occurred between May 2017 and September 2019, with staggered cohorts throughout this period. 
Group allocation was concealed for the participants until the first group intervention session 
(after baseline data collection). Those randomized to the population-based lifestyle intervention 
(GLB) group participated in the standard 22-session, 12-month GLB program (University of 
Pittsburgh, c2017). They also received an additional information session detailing population-
based guidelines for 11 nutrition and PA-related items: calories, protein, total fat, saturated fat, 
monounsaturated fat, polyunsaturated fat, sodium, snacking, overall PA, endurance and 
strength/power as previously published (Horne et al. 2019). Individuals randomized to the 
standard GLB program received their nutrigenomics/lifestyle genomics report after the 12-month 
study was complete. 
 
Individuals randomized to the personalized, genetic-based nutrition and PA-intervention 
(GLB+NGx) received information/advice on the 11 nutrition and PA-related items listed above, 
with their advice based on individual genetic variation in 12 unique genetic variants: FTO 
(rs9939609), UCP1 (rs1800592), TCF7L2 (rs7903146), APOA2 (rs5082), PPARg2 (rs1801282), 
ACE (rs4343), MC4R (rs17782313), ADRB (rs4994), NRF2 (rs12594956), GSTP (rs1695), 
NFIA-AS2 (rs1572312), and ACTN3 (rs1815739). These genetic variants were chosen as they 
are reflective of currently available consumer nutrigenetic testing. Participants were also 
involved in the 12-month GLB program, which was modified by the program facilitator (JH) 
throughout its duration to highlight nutrition and PA guidelines that may differ according to 
genetic variation (Horne et al. 2019). In addition to the 22 GLB program group sessions, a 
supplementary group session occurred at the beginning of the program, which consisted of an 
overview of the nutrition and PA advice, based on genetics. Furthermore, all participants’ 
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nutrition and PA guidelines (for both the GLB and GLB+NGx groups) were reviewed during 
their three follow-up data collection appointments (occurring at months 3, 6, and 12) with a 
registered dietitian (RD).  
 
Baseline and follow-up anthropometric data included weight and height (used to calculate 
BMI) and body composition conducted using the Bodystat 1500MDD (Bodystat, Douglas, Isle of 
Man, United Kingdom) bioelectrical impedance analysis (BIA) device.  
 
Genotyping 
 
Oragene ON-500 saliva collection kits (DNA Genotek, Ottawa, Ontario, Canada) were 
used to collect DNA saliva samples of participants at the EEFHT. The saliva samples were 
shipped to the University of Toronto and stored at -80°C.  The iPLEX Gold assay with mass-
spectrometry-based detection on the Sequenom MassARRAY® platform was used for 
genotyping of the 12 single nucleotide polymorphisms (SNPs) listed above. This method of 
genotype analysis has been used in previous research (Jenkins et al. 2018; Josse et al. 2012; 
Banks et al. 2019).  
 
Statistical Analysis 
 
All statistical analyses were completed using IBM SPSS Statistics version 26.0 (Armonk, 
NY: IBM Corp.). Two-way analyses of variance (ANOVAs) facilitated the analysis of potential 
attrition bias for the following participant characteristics: level of education, annual household 
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income (CDN dollars), age (years), baseline stage of change (transtheoretical model), and 
perceived difficulty managing weight (behavioural control construct of the theory of planned 
behaviour [TPB]) (Ajzen 2011). To account for potential BIA equipment error, descriptive 
statistics were used to identify far-out outliers, which were then removed from the final analyses 
(Figure 7.1). Split plot ANOVAs were used to assess between-group changes in anthropometric 
data from baseline to 3-, 6-, and 12-month follow-up. Hypothesis tests were 2-sided and a p-
value < 0.05 was considered statistically significant.  
 
7.1.4 Results 
 
Baseline participant demographic and clinical characteristics were outlined in Chapter 6, 
Table 6.1. A total of 140 participants enrolled in the study with 75 participants completing 
anthropometric data collection for all four time points (Figure 7.1). No statistically significant 
sources of attrition bias were revealed for level of education, annual household income (CDN 
dollars), age (years), baseline stage of change (transtheoretical model), and perceived difficulty 
managing weight (TPB). There were no reported harms or unintended consequences reported in 
either group.   
 
Far-out (extreme) outliers (n=2) were removed from the body composition data (one in 
the standard GLB group and one in the personalized GLB+NGx group). Results from the 
analyses of changes in anthropometric characteristics are outlined in Tables 7.1 and 7.2, as well 
as Figure 7.2. After 3- and 6-month follow-up, the GLB+NGx group had significantly (p<0.05) 
greater reductions in percent BFP change compared to the standard GLB group. The GLB+NGx 
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group additionally had significantly (p<0.05) greater reductions in absolute BFP change after 3 
months. There were no significant interactions between group and BFP (percent and absolute) 
after 12-month follow-up (p>0.05). Furthermore, while the GLB+NGx group had clinically 
meaningful, greater reductions in weight and BMI after 3 and 6 months (percent and absolute) 
compared to the standard GLB group, there were no significant interactions between group and 
weight or BMI at 3-,6-, and 12-month follow-up (p>0.05). 
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Table 7.1: Anthropometric measurements at baseline, 3, 6, and 12 months 
  
Anthropometric 
Measures 
Baseline  
(Mean ± SD, 
95% CI) 
3 Months 
(Mean ± SD, 
95% CI) 
6 Months 
(Mean ± SD, 
95% CI) 
12 Months 
(Mean ± SD, 
95% CI) 
GLB Group:     
Body Fat (%)  48.18 ± 6.60,  
45.6 to 50.7 
47.16 ± 7.18,a 
44.5 to 49.9 
45.91 ± 6.97,b 
43.3 to 48.9 
44.70 ± 7.02,  
42.1 to 47.4 
Weight (lbs) 219.83±49.71, 
206.1 to 233.5 
212.97±49.36, 
199.4 to 226.6 
211.72±51.41, 
197.7 to 225.8 
213.51±51.64, 
199.2 to 227.8 
BMI (kg/m2) 37.82 ± 7.70, 
35.6 to 40.1 
36.65 ± 7.91, 
34.3 to 39.0 
36.38 ± 8.12, 
34.0 to 38.7 
36.68 ± 8.07, 
34.2 to 39.1 
GLB+NGx Group:     
Body Fat (%) 44.93 ± 7.95,  
42.5 to 47.4 
42.77 ± 8.29,a 
40.2 to 45.4 
41.55 ± 8.24,b 
39.0 to 44.1 
42.32 ± 8.15,  
39.7 to 44.9 
Weight (lbs) 203.34±32.29, 
189.8 to 216.9 
194.56±32.10, 
181.1 to 208.0 
192.48 ± 32.60, 
178.6 to 206.4 
196.85±34.16, 
182.7 to 211.0 
BMI (kg/m2) 35.22 ± 6.06, 
33.0 to 37.5  
33.72 ± 6.13, 
31.4 to 36.0 
33.36 ± 6.20, 
31.0 to 35.7 
34.11 ± 6.46, 
31.8 to 36.5 
p-interaction for body fat (%) = 0.002, effect size = 0.087; a. p = 0.023; b. p = 0.022 
Standard GLB Group: Weight and BMI, n=37; Body Fat, n=33 
GLB+NGx Group: Weight and BMI, n=38; Body Fat, n=35 
Analyses were all by originally assigned groups. 
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Table 7.2: Change in anthropometric measurements at 3, 6, and 12 months 
 
Anthropometric 
Measure 
3-Month 
(Absolute ∆ ± 
SD, 95% CI) 
3-Month 
(Percent ∆ ± SD,  
95% CI) 
6-Month 
(Absolute ∆ ± 
SD, 95% CI) 
6-Month 
(Percent ∆ ± SD,  
95% CI) 
12-Month 
(Absolute ∆ ± 
SD, 95% CI) 
12-Month 
(Percent ∆ ± 
SD, 95% CI) 
GLB Group:       
Body Fat (%) -1.02 ± 1.89,a 
-0.4 to -1.7 
-2.24 ± 4.13,b 
-0.5 to -3.9 
-2.27 ± 2.26, 
-1.4 to -3.2  
-4.80 ± 4.85,c 
-2.8 to -6.8  
-3.48 ± 2.55,  
-2.6 to -4.4  
-7.31 ± 5.35, 
-5.4 to -9.2 
Weight (lbs) -6.86 ± 7.36,  
-4.5 to -9.2 
-3.23 ± 3.57,  
-2.1 to -4.4 
-8.11 ± 9.11,  
-4.7 to -11.5 
-3.96 ± 4.70,  
-2.3 to -5.7 
-6.32 ± 9.25,  
-2.6 to -10.0 
-3.13 ± 4.81,  
-1.3 to -4.9  
BMI (kg/m2) -1.12 ± 1.28,  
-0.8 to -1.6  
-3.27 ± 3.60,  
-2.1 to -4.4 
-1.44 ± 1.64,  
-0.9 to -2.0  
-4.06 ± 4.70,  
-2.4 to -5.8  
-1.14 ± 1.67, 
-0.5 to -1.8 
-3.22 ± 4.79,  
-1.4 to -5.0 
GLB+NGx Group:       
Body Fat (%) -2.12 ± 1.96,a 
-1.5 to -2.8  
-4.95 ± 5.52,b 
-3.3 to -6.6 
-3.38 ± 2.83, 
-2.5 to -4.2  
-7.74 ± 6.33,c 
-5.8 to -9.6 
-2.61 ± 2.66, 
-1.7 to -3.5 
-6.00 ± 5.76, 
-4.1 to -7.9 
Weight (lbs) -8.77 ± 7.04,  
-6.4 to -11.1 
-4.37 ± 3.44, 
-3.2 to -5.5 
-10.86 ± 11.48, 
-7.5 to -14.2 
-5.38 ± 5.57,  
-3.7 to -7.0 
-6.48 ± 12.91,  
-2.8 to -10.1 
-3.26 ± 6.03,  
-1.5 to -5.0 
BMI (kg/m2) -1.50 ± 1.19,  
-1.1 to -1.9 
-4.35 ± 3.45, 
-3.2 to -5.5 
-1.86 ± 1.97,  
-1.3 to -2.4 
-5.35 ± 5.62, 
-3.7 to -7.0 
-1.11 ± 2.24,  
-0.5 to -1.7  
-3.24 ± 6.06,  
-1.5 to -5.0 
∆: change 
p-interaction for absolute BFP∆ = 0.002, effect size = 0.087; a. p = 0.018  
p-interaction for percent BFP∆ = 0.003; effect size = 0.076; b. p = 0.026; c. 0.036 
Standard GLB Group: Weight and BMI, n=37; Body Fat, n=33 
GLB+NGx Group: Weight and BMI, n=38; Body Fat, n=35 
Note: Differences is percent weight and BMI change are due to rounding. 
Analyses were all by originally assigned groups. 
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Figure 7. 1: CONSORT 2010 Flow Diagram  
Assessed for eligibility (n=141) 
Excluded  (n=1) 
   Not meeting inclusion criteria (n=1) 
   Declined to participate (n=0) 
   Other reasons (n=0) 
Analyzed  (n=37)  
 Excluded from analysis (participant had 
spinal stimulator placed and therefore could 
not conduct BIA to measure body fat 
percentage, n=1; extreme outlier due to BIA 
machine error, n=1; weight and BMI were still 
measured for both participants therefore both 
remain included in the total number analysed) 
Lost to follow-up (n=21) (busy 
schedule/participant burden, n=3; could not 
reach participant, n=18)  
Discontinued intervention (total, n=10) 
(schedule changed, n=1; family member 
became ill or deceased, n=3; participant 
became ill, n=3, participant reported losing 
interest in program, n=3) 
Allocated to standard GLB (n=70) 
 Received allocated intervention (n=68) 
 Did not receive allocated intervention (lost to 
follow-up during run-in period, n=2) 
Lost to follow-up (n=24) (busy 
schedule/participant burden, n=7; could not 
reach participant, n=17)  
Discontinued intervention (total, n=7) 
(schedule changed, n=3; participant moved to 
different city or country, n=2; family member 
became ill or deceased, n=2) 
 
Allocated to GLB+NGx (n=70) 
 Received allocated intervention (n=69) 
 Did not receive allocated intervention (lost to 
follow-up during run-in period, n=1) 
Analyzed  (n=38) 
 Excluded from analysis (participant had 
pacemaker and therefore could not conduct 
BIA to measure body fat percentage, n=1; 
extreme outlier due to BIA machine error, n=1; 
weight and BMI were still measured for both 
participants therefore both remain included in 
the total number analysed) 
Allocation 
Analysis 
Follow-Up (3, 6 and 12 Month) 
Randomized (n=140) 
Enrollment 
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Figure 7.2: Change in anthropometric measures after 3-, 6-, and 12-month follow-up  
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7.1.5 Discussion  
 
This study provides several notable, novel contributions to the literature. From a public 
health perspective, it is the first study to explore short-, moderate- and long-term anthropometric 
changes resulting from the standard GLB program in a population of adults with a baseline BMI 
≥ 25.0 kg/m2 regardless of having a prediabetes diagnosis. While originally piloted and intended 
for diabetes prevention in individuals diagnosed with prediabetes (Diabetes Prevention Program 
Research Group 2002), public health officials have since encouraged the GLB program 
expansion to more broad patient populations such as those with a BMI ≥ 25.0 kg/m2 (Ontario 
Ministry of Health and Long-Term Care 2018). This study demonstrates that a clinically 
meaningful 3-5% sustained weight loss (Jensen et al. 2014) can be achieved with program 
expansion to this broader population, thus supporting public health authority recommendations. 
However, it should be noted that weight-related outcomes in patients with prediabetes appear to 
be even greater (Diabetes Prevention Program Research Group 2002). Additionally, to our 
knowledge this is the first study to explore body composition changes within the GLB program. 
Measures of body composition are superior to weight and BMI given that body composition 
accounts for changes in fat, water and muscle mass as opposed to overall weight changes (Nuttall 
2015).  
 
Gold-standard clinical practice guidelines for weight management interventions indicate 
that such interventions should include: calorie restriction; participation in a comprehensive 
lifestyle program for ≥6 months with at least 14 sessions in 6 months; counselling on the 
cardiovascular benefits associated with ≥3-5% weight loss; participation in long-term (≥12-
month) weight loss maintenance programs; and regular contact with an ‘interventionist’ who 
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assists with engagement in PA and monitoring body weight regularly (Jensen et al. 2014). Both 
the standard GLB and GLB+NGx interventions adhered to these guidelines. A minimum of 3-
5% sustained weight loss is clinically meaningful in order to produce several health benefits 
including reduced triglycerides, reduced blood glucose and hemoglobin-A1C, as well as a 
reduced risk of developing type 2 diabetes; higher weight loss is associated with greater benefits 
(Jensen et al. 2014). Both the standard GLB and GLB+NGx groups achieved such sustained 
weight loss over a 12-month period demonstrating the success of both the standard and modified 
(personalized) versions of the GLB program. Clinically meaningful changes in BFP are not as 
well-established as changes in weight, but population reference standard charts of BFP have been 
published (Imboden et al. 2017). Women tend to experience an approximate 2% absolute 
increase in BFP per decade from ages 20-29 until ages 50-59. From ages 60-69 to 70-79, less 
than a 1% absolute BFP increase is observed (Imboden et al. 2017). In comparing the percentiles 
for reference standards of women’s BFP (given that the current study consisted primarily of 
female participants) to the current study, the NOW trial participants exhibited a 1-2 decile 
change in BFP throughout the GLB and GLB+NGx programs across various study time points 
(3, 6, and 12 months) and long-term reductions of approximately 3% absolute BFP. Given that 
overall, BFP tends to increase with time (Imboden et al. 2017), this 3% reduction represents a 
clinically meaningful change. Moreover, as there were clinically meaningful changes observed 
for weight at all time points, this further demonstrates that the overall change in BFP would also 
be considered clinically meaningful. Furthermore, with body fat mass specifically having major 
impacts on health outcomes (Nuttall 2015), a 3-5% change in BFP is likely of greater clinical 
benefit than a 3-5% change in overall weight, which may also include reductions in muscle 
and/or fat mass.  
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Notably, the GLB+NGx group experienced significantly greater reductions in BFP after 3 
and 6 months compared to the standard GLB group. This speaks to the scientific validity and/or 
clinical utility of the nutrigenetic and lifestyle genomics information and advice provided to 
participants. The precise details of the genetic information provided, including a sample genetic 
report, have been previously detailed elsewhere (Horne et al. 2019). There are many clinical 
cases where short- and moderate-term weight loss and/or achieving a specific BMI cut-off have 
demonstrated positive impacts on major and critical patient outcomes. Examples include: pre-
transplant weight loss to reduce the risk of organ rejection, reduce the risk of wound 
complications, reduce hospital length-of-stay and increase chances of survival (Clausen et al. 
2018; Knoll et al. 2005); pre-surgery to reduce the risk of complications after hernia repair 
(Menzo et al. 2018); in kidney, heart, liver, and lung disease patients for transplant listing 
(Mehra et al. 2006; Knoll et al. 2005; Martin et al. 2014); to be eligible as a living organ donor at 
most transplant centres (UNOS Transplant Living c2019); improvement in pregnancy rates in 
patients with infertility (Best, Avenell, and Bhattacharya 2017); prior to total joint arthroplasty to 
increase chances of implant survivorship and postoperative functional scores (Bookman et al. 
2018); and pre-surgery weight loss to reduce the risk of dislocation following total hip 
replacement (Annan et al. 2018). With this in mind, studying the effectiveness of nutrigenomics 
and lifestyle genomics interventions for these specific clinical cases, and others where short-to-
moderate-term reductions in weight-related outcomes are beneficial, is an important 
recommended next step for the field of precision nutrition. Interestingly, a recent study found 
that only 6% of clinical dietitians working in the public health setting participated in 
nutrigenomics training, as opposed to 33% of industry dietitians and 14% of private practice 
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dietitians (Cormier et al. 2014). This suggests that there is likely minimal uptake of 
nutrigenomics in acute-care settings, such as hospitals, where the abovementioned cases are 
more prevalent; perhaps these are the clinical settings in which patients could benefit most from 
nutrigenomics and lifestyle genomics weight management interventions? 
 
 Our finding of significant differences in BFP between groups diminishing at the 12-
month follow-up is intriguing, especially given that the GLB+NGx group made significantly 
greater dietary changes and better adhered to specific dietary advice compared to the standard 
GLB group at 12 months. There are multiple possible explanations for these findings. First, 
biological mechanisms promote weight regain after periods of weight loss. Over time, 
physiological mechanisms including adipose cellularity, endocrine function, energy metabolism, 
neural responsivity and addiction-like neural mechanisms promote weight regain after a period 
of weight loss (Ochner et al. 2013). Decades of research have demonstrated that increased energy 
(calorie) intake can lead to increased fat cell size and fat cell number (Martinsson 1969; Hirsch 
and Batchelor 1976; Tchoukalova et al. 2010), and while weight loss may reduce the size of fat 
cells, it may not reduce the number of fat cells (Martinsson 1969; Björntorp et al. 1975; Hirsch 
and Han 1969; Arner and Spalding 2010; Gurr et al. 1982; Löfgren et al. 2005). Furthermore, 
preliminary research has demonstrated that this could encourage weight regain following periods 
of weight loss due to a reduction in the rate of fat oxidation and increased retention of ingested 
energy (MacLean et al. 2006; Jackman et al. 2008; Knittle and Hirsch 1968; Kelley et al. 1999; 
Berggren et al. 2008). In addition, some research has demonstrated a decrease in thyroid function 
(and thus, a decrease in metabolic rate) after weight loss in individuals with obesity (Rosenbaum 
et al. 2000; Kozłowska and Rosołowska-Huszcz 2004; Moreno et al. 2008). Moreover, the 
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activity of the hypothalamic-pituitary-adrenal axis, which regulates cortisol levels, is heightened 
following weight loss and this can lead to increased appetite and fat accumulation (Björntorp 
2001). In terms of changes in metabolic rate, a decrease in fat mass and lean mass will both lead 
to reductions in energy output/expenditure (Gallagher et al. 1996; Leibel, Rosenbaum, and 
Hirsch 1995). While a reduction in metabolic rate is normal and expected, studies have 
demonstrated that weight loss occurring from lifestyle interventions results in ‘metabolic 
adaptation.’ Metabolic adaptation refers to the concept that following weight loss, individuals 
experience a greater reduction in metabolic rate than would be expected based on an individual’s 
body composition (Leibel, Rosenbaum, and Hirsch 1995; Gallagher et al. 1996; Astrup et al. 
1999; Rosenbaum and Leibel 2010; Johannsen et al. 2012; Camps, Verhoef, and Westerterp 
2013; Tremblay and Chaput 2009). This decrease in resting metabolic rate following weight loss 
leads to biological challenges with weight loss maintenance. The classic Minnesota semi-
starvation experiment was one of the first studies to demonstrate a reduced resting metabolic rate 
during a period of weight regain following weight loss (Keys 1950), with several later studies 
corroborating these findings (Leibel, Rosenbaum, and Hirsch 1995; Astrup et al. 1999; 
Rosenbaum and Leibel 2010; Johannsen et al. 2012; Camps, Verhoef, and Westerterp 2013; 
Tremblay and Chaput 2009). Ultimately, there are a number of biological mechanisms leading 
the body to resist weight loss, and drive weight regain.  This could explain why results from the 
NOW trial demonstrated weight regain occurring from 6-month to 12-month follow-up in both 
the GLB and GLB+NGx groups. It is further interesting to notice the continued trend towards 
decreasing BFP (but not weight) in the standard GLB group only. Although differences were not 
significant between groups for BFP at 12-months, it is possible that the faster rate of BFP loss 
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experienced in the GLB+NGx group led to an earlier onset of the biological responses promoting 
weight regain. Indeed, research supports this idea (MacLean et al. 2011).  
 
 Second, while the abovementioned biological mechanisms promoting weight regain 
provide a plausible explanation for our findings, it is also possible that participants noticed some 
weight regain occurring between 6 and 12 months, and thus at 12 months became increasingly 
motivated to follow the genetically-guided advice. Given that weight and BFP losses take time, if 
participants were followed beyond 12 months, it is plausible that we would, again, observe 
significant differences between the standard GLB and GLB+NGx groups for BFP changes, as we 
observed at 3 and 6 months. Indeed, this is an important future research endeavour. Since data 
collection did not occur between 6- and 12-months, it is not possible to comprehend how well 
participants were following the dietary guidelines in between these two time points.  
 
There are some limitations of the present work that should be noted. Difficulty with 
participant retention and thus reduced statistical power may have limited the ability to detect 
statistical significance for the secondary outcomes, weight and BMI. Additionally, while the 
target dropout rate for an RCT is <20% (National Institutes of Health n.d.), studies demonstrate 
that this is typically challenging for long-term weight loss studies (Hillmer et al. 2017; Truby et 
al. 2006; Jebb et al. 2011; Wadden et al. 2004; Gill et al. 2012; Foster et al. 2003). Thus, the 
dropout rate for the NOW trial was not remarkable. Reasons for reduced participant retention can 
include scheduling conflicts, dissatisfaction with treatment, and lack of time to meet the study 
requirements (Wadden et al. 2004). Having a lower education level (less than university level), 
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and higher level of obesity are also risk factors for dropping out of weight loss programs/studies 
(Michelini et al. 2014; Hadžiabdić et al. 2015). These factors contributed to participant dropout 
in the NOW trial as further indicated in Figure 7.1, Table 7.1 and Chapter 6, Table 6.2. Given the 
higher dropout rate, a modified intention-to-treat (ITT) analysis was performed. Dropouts were 
not treated as treatment failures and last observation carried forward methods of imputing 
missing data were not conducted. However, participants were not excluded based on adherence. 
ITT can be beneficial for increasing statistical power, improving generalizability and minimizing 
the risk of a type 1 error (Gupta 2011). However, when there is considerable variability in the 
endpoint data, it becomes difficult to predict outcomes (Gupta 2011). Furthermore, ITT can 
increase the susceptibility to type 2 errors, especially with higher dropout rates (Gupta 2011). In 
addition, the research question should be carefully considered prior to conducting an ITT 
analysis (Feinman 2009). In the NOW trial, we aimed to determine if individuals enrolled in a 
genetically tailored weight management program reduced their weight and body fat percentage 
and improved their dietary intake to a greater extent than those enrolled in population-based 
weight management program. Therefore, a modified ITT approach was more appropriate given 
that dropouts were no longer enrolled in the weight management programs.   
 
Previous research has been conducted within the GLB program at the EEFHT and five 
other Ontario primary care locations. In this previous study, the GLB program was offered 
during a 9-month period, and dropout rates throughout the study were 26.8% at 3-months, 46.8% 
at 6-months, and 63.0% at 9-months (Hillmer et al. 2017). This is the most comparable study to 
the NOW trial given the direct similarities in the intervention (GLB program) and setting 
(EEFHT in Aylmer, Ontario). With a longer intervention and study duration of 12 months, the 
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NOW trial still had an overall retention rate approximately 17% higher than previous research in 
the GLB program, which ran for only 9 months (Hillmer et al. 2017). We suspect that the 
provision of genetic information (at baseline for the GLB+NGx group and after 12-months for 
the standard GLB group) enhanced overall interest in the intervention/study, therefore helping to 
improve retention. This participant interest is further highlighted in Figure 7.1, whereby 140 
participants enrolled in the NOW trial out of the 141 patients who were invited to join the study. 
Nonetheless, although not statistically significant, there were notable clinically meaningful 
differences in percent weight change, whereby only the GLB+NGx group achieved >5% weight 
loss (at 6-months follow-up) and both the GLB and GLB+NGx group achieved 3-5% weight loss 
after 12-months (Jensen et al. 2014). Thus, both interventions were overall effective. 
 
The results of this study are primarily generalizable to populations of middle-aged, 
middle socio-economic status, Caucasian women with obesity (class II) enrolled in a lifestyle 
change weight management program. Given that participants who were enrolled in the GLB 
program were invited to participate in the study, this appears to be a representative sample of 
individuals interested in this weight management program. Furthermore, the NOW trial study 
population is similar to other reported GLB study populations (Alva 2019; Alva, Romaire, and 
Acquah 2019; Jeffers et al. 2019; McTigue et al. 2009). 
 
This study further demonstrated the feasibility of communicating genetic-based nutrition 
and PA information and advice in a group setting. The literature supports that group-based 
nutrition education can be more effective in motivating nutrition behaviour change and can be 
more meaningful for patients (Siero 2000; Abusabha, Peacock, and Achterberg 1999). However, 
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since this type of personalized nutrition advice is typically communicated in one-on-one patient 
settings, future research should seek to compare a nutrigenetic and/or lifestyle genomics 
intervention to standard of care, rather than gold-standard care as we have studied here. While 
the GLB program is the ‘gold-standard,’ it is only currently offered in nine primary care facilities 
in Canada (University of Pittsburgh, c2017). In the United States, this program is currently 
offered to the general public in over 50 facilities (University of Pittsburgh, c2017). As such, 
standard of care for weight management in dietetics typically consists of individual lifestyle 
counselling.  
 
7.1.6 Conclusion  
 
Nutrigenomics interventions can produce clinically meaningful health-related outcomes 
for patients over the short-term, moderate-term and long-term, with additional benefits observed 
above those achieved with gold-standard care over the short-term and moderate-term. Clinicians 
should consider implementing the GLB+NGx intervention for patients. As research continues to 
advance with the hopes of nutrigenetic tests becoming increasingly accurate, genetic-based 
lifestyle interventions hold considerable promise for improving health and wellbeing in a manner 
that is innovative and exciting for patients and healthcare professionals alike. It is certainly a 
science worth exploring further.  
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CHAPTER 8: DISCUSSION 
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This dissertation investigated the practical application of nutrigenomics in primary care 
for improving weight management, body composition, dietary intake, and adherence to specific 
dietary guidelines. The results indicated that the nutrigenetic-guided intervention was effective at 
improving body composition to a greater extent than standard advice after 3- and 6-month 
follow-up. Furthermore, the nutrigenetic-guided intervention motivated long-term changes in 
dietary fat intake and enhanced adherence to recommendations for total fat and saturated fat 
intake after 12-month follow-up. The results of this dissertation are generalizable primarily to 
college-educated, middle-aged women with overweight and obesity who are enrolled in a weight 
management program. Participants involved in the nutrigenomics, overweight/obesity and 
weight management (NOW) trial had positive attitudes towards improving their dietary intake 
and towards weight management, with neutral lifestyle-related subjective norms and perceived 
behavioural control, based on the TPB.  
 
8.1 Novel Research Contributions 
 
8.1.1 Overall  
 
This randomized controlled trial (RCT) provided a number of novel research 
contributions, building on previous work in the field (Arkadianos et al. 2007; Frankwich et al. 
2015; Celis-Morales et al. 2017). The NOW trial was the first adequately powered RCT to assess 
the pragmatic delivery of a nutrigenomics intervention with a weight-related primary outcome. 
Furthermore, the measurement of body fat percentage (BFP) provided a more informative health-
related outcome compared to the measurement of weight and body mass index (BMI). With the 
study taking place within the East Elgin Family Health Team’s (EEFHT’s) Group Lifestyle 
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Balance™ (GLB) program, the research proved to be highly pragmatic. This is further detailed in 
the PRECIS-2 scoring tool (Chapter 6, Table 6.6).  Overall, this trial provided a robust 
exploration of the impact of nutrigenomics testing on nutritional habits and weight-related 
(including body composition) outcomes.  
8.1.2 Methodological Contributions 
 
Cohort randomization was used in the NOW trial to allow all participants in each GLB 
group to receive the same intervention – either personalized based on genetics, or population-
based. Thus, the feasibility of cohort randomization in personalized nutrition research has been 
demonstrated.  
8.1.3 Theoretical Contributions   
 
This was the first genetic testing behaviour change study to intentionally incorporate the 
TPB into the study methods, including the statistical analyses. Interestingly, we found that 
income (a sub-component of behavioural control) was an important confounding factor to 
consider in the 3-month analysis of dietary adherence. Furthermore, the interventions (standard 
GLB and GLB+NGx) aimed to positively affect the key components of the TPB, in order to 
promote optimal health behaviour change. 
8.1.4 Clinical and Public Health Contributions  
 
With nutrigenomics typically offered through direct-to-consumer (DTC) genetic testing 
or through a one-on-one session with a healthcare professional, the NOW trial demonstrated the 
feasibility of incorporating personalized nutrition into a group-based public health program. This 
is a more efficient method of delivering nutrition information given that nutrition education can 
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be communicated to multiple patients at one time. Furthermore, the NOW trial provided novel 
insights into the clinical utility of the only nutrigenetic test currently offered to Canadian 
consumers exclusively through healthcare providers. Specifically, this was the first study to 
assess changes in calories, dietary fat and protein as well as weight-related (including body 
composition) outcomes resulting from the provision of this nutrigenetic test.  
8.2 Body Composition: An Overview  
 
8.2.1 Adiposity and Health  
 
Body fat percentage was selected as the primary outcome of this study given its 
association with health, and its importance to patients enrolled in weight management programs. 
Total adiposity is a more accurate measure of metabolic phenotypes when compared to measures 
of BMI (Goossens 2017). Body fat is positively correlated with insulin resistance and 
cardiometabolic disease (Goossens 2017). It has also been cross-sectionally associated with joint 
pain (Walsh et al. 2018), and linked to cancer and cognitive disfunction (Guo et al. 1999; Lutz et 
al. 2008). In addition to total adiposity, body fat distribution is further important given that 
adipose accumulation in the abdominal region is associated with comorbidities and all-cause 
mortality, whereas adipose accumulation in the gluteofemoral region has been shown to have a 
protective effect on cardiometabolic diseases (Snijder et al. 2004; Yusuf et al. 2005).   
8.2.2 Body Composition Tools and Techniques  
 
Various tools and techniques are available to assess body composition. Skinfold 
measurements provide the least expensive method of measuring body composition, but this 
method is also the least accurate (Lee and Nieman 2013). Calipers are used to measure a double 
fold of skin and subcutaneous adipose tissue, without muscle tissue. A tape measure is needed to 
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measure the appropriate skinfold locations, which can include chest, triceps, subscapular, 
midaxillary, suprailiac, abdomen, thigh and calf (Lee and Nieman 2013).  
Bioelectrical impedance analysis (BIA) is more accurate than skinfold measurements for 
assessing body composition. It involves the use of a low-frequency electrical current to measure 
impedance throughout the body. This is then used to estimate measures of body composition 
using regression equations (Nelms, Sucher and Lacey 2016).  
Hydrostatic (underwater) weighing is known to be a highly accurate method of body 
composition measurement, though it is also the least readily available tool. This method is based 
on the Archimedes Principle, which states that the buoyancy of an object submersed in water 
equals the weight of the displaced fluid of that object. This Principle can be used in hydrostatic 
weighing given that lean tissue (bone and muscle) are denser than water, and water is denser than 
fat tissue (Lee and Gallagher 2008). While highly accurate, this method is often not well 
tolerated by participants as it requires the participant to be completely submerged in water 
(Fosbol and Zerahn 2015). 
Dual energy X-ray absorptiometry (DXA) is another accurate method, and uses two 
different energy levels of X-rays, which pass through the body. The absorption of photons is 
measured and used to determine whole body bone mass and soft tissue composition (Shepherd et 
al. 2017). According to 2020 Clinical Practice Guidelines, DXA is considered a valid method of 
assessing fat mass in patients with various clinical conditions (Sheean et al. 2020). Notably, 
some newer DXA technologies can measure abdominal (visceral) fat mass in addition to total 
body fat.  
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Air displacement plethysmography is another body composition method that uses a 
measurement of the air displaced in a sealed chamber to estimate body composition. This method 
measures changes in pressure between two chambers: the test chamber and reference chamber. 
The equation used to measure body composition involves the measurement of volume and 
pressure prior to and while the subject enters the test chamber (Fields, Higgins and Hunter 2004). 
Air displacement plethysmography, DXA and hydrostatic weighing are generally considered to 
be comparably accurate for measuring body composition across the lifespan, including measures 
in infants, children and adults (Heds and Allison 2012; Bedogni et al. 2013; Edwards et al. 
2011).  
Lastly, computed tomography (CT) and magnetic resonance imaging (MRI) are generally 
considered the most accurate methods of measuring body composition, and can be used to 
measure total adipose tissue, visceral adipose tissue, subcutaneous adipose tissue, and interstitial 
adipose tissue (Ross and Janssen, 2005; Fosbol and Zerahn 2015). CT scans use an X-ray beam, 
which passes through tissues to construct images using mathematical techniques. One of the 
major downfalls of CT scans is the substantial radiation dosage needed to create the images.  
This is especially a concern in studies with multiple follow-ups (Fosbol and Zerahn 2015). MRIs 
do not expose participants to radiation, but rather determine body composition based on the 
interaction between hydrogen nuclei. Hydrogen nuclei align themselves with a magnetic field. In 
MRIs, a radio frequency signal is used to generate images based on energy released from the 
hydrogen nuclei (Edelman et al. 2006).  
These more accurate tools were not available or feasible in our research setting, therefore 
we used BIA given that it is more accurate that skinfold thickness, which was another option 
available for use in the NOW trial. Furthermore, BIA is safe (except in patients with electrical 
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devices such as pacemakers), inexpensive, low-maintenance, portable, rapid, and requires only 
minimal operator training (Buchholz, Bartok and Schoeller, 2004; Fosbol and Zerahn 2015). 
8.2.3 BIA Theory  
 
The link between bioimpedance and blood flow was first discovered in the 1950’s 
(Nyboer et al. 1959). Later, it was determined that bioimpedance could be used to predict body 
composition, based on the underlying theory that the impedance of a cylindrical conductor is 
related to its length, cross-sectional area, and the signal of the frequency that’s applied (Mulasi et 
al. 2015). Impedance, a measure of current obstruction, is calculated using resistance and 
reactance. Resistance refers to the resistive effect exhibited on the current (or current flow 
opposition). Thus, water and ionic substances provide a low-resistance pathway. Since water is 
contained in fat-free (lean) mass, lower fat-free (lean) mass results in more resistance; higher 
lean mass leads to lower resistance. Reactance refers to the conduction delay, which occurs when 
the current passes through cell membranes, tissues and non-ionic substances (Mulasi et al. 2015). 
The tetrapolar electrode approach that is commonly used today was first validated several 
decades ago by Hoffer et al. (1969). This approach involves the administration of electrical 
currents via leads attached to electrodes, typically placed on the hand and foot of the subject, 
which then differentiates the conductive and nonconductive tissues and fluids of the body 
(Mulasi et al. 2015). Tissues containing water and electrolytes (e.g. blood and muscle) conduct 
current well. Tissues that resist current include fat, bone and air-filled spaces. Predictions are 
then used, based on these measures, to predict body composition (Buchholz, Bartok and 
Schoeller, 2004; Mulasi et al. 2015).  
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Overall, BIA uses a low amperage current, which passes through the body, to estimate 
the amount of water contained in various biological tissues such as skeletal muscle, adipose 
tissue and bone. Distal (current injection) electrodes pass an alternating current through the body, 
and this current is returned to the proximal (voltage detection) electrodes.  The amount of 
electricity conducted is proportionate to the concentration of ions in the conductor; thus, when 
the concentration of ions decreases, resistance increases. Furthermore, when body fluid viscosity 
increases, height increases or the cross-sectional area of the body decreases, resistance 
subsequently increases. It is well-established that skeletal muscles are more highly conductive 
compared to adipose tissue, which contains less water (Scharfetter et al. 2001; Lukaski et al. 
1985). In fact, body fat is considered a non-conducting material, thus providing resistance to 
electrical current flowing through the body. Skeletal muscle is more conductive than bone 
(Buchholz, Bartok and Schoeller, 2004). 
8.2.4 BIA Device and Equation 
 
Body impedance refers to a bodily conductor opposing the flow of an alternating current. 
It is made up of resistance and reactance, which are measured using the unit, ohms. Higher 
frequency electrical currents can be used to determine total body water, while lower frequencies 
can be used to determine extracellular fluid. Extracellular fluid is then calculated based off these 
two measures. From there, fat-free mass is derived using proprietary equations that are based on 
the assumption that this mass is 73.2% hydrated. Then, fat mass can be determined by 
subtracting fat-free mass from total weight. There are also other methods of calculating body 
composition using various regression equations (Mulasi et al. 2015). Segmental BIA tends to be 
more accurate than whole body BIA given that segmental BIA equations are derived from the 
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segmentation of the body into five cylindrical compartments (2 arms, 1 trunk, 2 legs) as opposed 
to a single cylindrical compartment (Mulasi et al. 2015). 
The relationship between resistance and/or reactance and body fat is indirect. BIA 
devices use regression equations to estimate body composition, including BFP.  These equations 
take into consideration age, gender, weight, height, resistance and reactance (National Institutes 
of Health, 1994).  
The literature suggests that a midrange frequency current of 50 kHz, used to measure 
total body water, will incompletely penetrate intracellular water and therefore detects primarily 
extracellular fluid with some intracellular fluid. This can lead to inaccuracies in patients with 
altered body water compartmentalization for both intracellular water and extracellular water 
(Buchholz, Bartok and Schoeller, 2004; Mulasi et al. 2015). Thus, the addition of a low 
frequency, 5 kHz current, helps to more accurately predict extracellular water given that this low 
current negligibly penetrates the intracellular water (Gudivaka et al. 1999).  The BodyStat 
MDD1500 device used in the NOW trial measures resistance and reactance using dual frequency 
currents of 5 and 50 kHz. This whole body BIA device measures resistance and reactance, and 
based on this impedance measurement, body fat percentage is indirectly derived using a 
proprietary equation (BodyStat, 2017).  
8.2.5 Contraindications to BIA Use  
 
BIA is more accurate for the measurement of changes in body composition over time, as 
opposed to a single, cross-sectional measurement of body composition that may be taken in a 
clinical setting (Buchholz, Bartok and Schoeller, 2004). Importantly, BIA should not be used in 
individuals who have a pacemaker as the electrical signal from the BIA could alter the function 
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of the pacemaker device. Additionally, the safety of BIA has not been assessed in patients with 
other implanted electrical devices (e.g. spinal stimulators), and therefore it is recommended that 
the device not be used with these patients (BodyStat, 2017). 
8.2.6 BIA Limitations  
 
It is normal for fluid shifts to occur throughout the day, which can impact the BIA results. 
Asking participants to void prior to conducting the BIA can help to standardize total body fluid. 
In addition, repeating the BIA test at the same time of day throughout the duration of a study is 
additionally important (Most et al. 2018). However, due to logistical considerations, we were 
unable to standardize the time of day that the BIA assessments were conducted in the NOW trial; 
this was a limitation of the study.  
8.2.7 BIA Data Interpretation  
 
While body mass index (BMI) can be used to classify individuals into categories of 
underweight, normal weight, overweight and obese, established categories do not exist for body 
composition. This complicates the interpretation of body composition results, but some research 
groups have attempted to provide preliminary methods for data interpretation. Ozenoglu and 
colleagues (2009) compared body composition measured using BIA to established BMI 
categories in 327 adult females residing in Istanbul and found the following mean values for BFP 
within each BMI category, with significant differences (p=0.0001) in BFP between categories: 
• Normal Weight: 22.8±4.6% 
• Overweight: 29.7±3.3% 
• Obese: 35.0±3.3% 
• Morbid Obese: 40.2±3.6% 
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More recently, Sladjana et al. (2019) profiled BFP stratified by age in a sample of adult 
females from the Republic of Serbia. The results are as follows:  
• 18.0-19.9 years: 23.8±6.8% 
• 20.0-29.9 years: 24.8±7.4% 
• 30.0-39.9 years: 28.1±9.3% 
• 40.0-49.9 years: 32.4±8.3% 
• 50.0-59.9 years: 36.3±7.9%  
• 60.0-69.9 years: 39.9±7.9% 
 
To our knowledge, these are the only established interpretations of BIA for female adults. 
Reference standards, stratified using percentiles, for BIA-measured BFP in adults are not 
available. However, DXA-measured BFP reference standards for Caucasian adults have been 
recently published by Imboden and colleagues (2017), with decile cut-offs established for both 
male and female Caucasian adults in the United States. These are further detailed elsewhere 
(Imboden et al. 2017).  
The lack of available reference standards for BIA-measured BFP in samples of Canadian 
women poses challenges for the interpretation of the NOW trial results. In comparing the NOW 
trial results to the abovementioned studies (Sladjana et al. 2019; Ozenoglu et al. 2009; Imboden 
et al. 2017), the GLB group (mean age 56 years, 84% female, 99% Caucasian) exhibited a mean 
BFP higher than the mean reported BFP for this age group in Sladjana et al.’s (2019) study.  At 
baseline, they were between the 20th and 30th percentile for BFP and at 12-months, were 
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between the 40th and 50th percentiles (with BFP and percentile values being inversely related). 
The GLB+NGx group (mean age 54 years, 90% female, 97% Caucasian) also exhibited a mean 
BFP higher than the mean reported BFP for this age group in Sladjana et al.’s (2019) study. 
According to Imboden et al.’s (2017) reference standard charts, this group was between the 40th 
and 50th percentiles for BFP at baseline, and was between the 50th and 60th percentiles for BFP 
at 12 months. Both the GLB and GLB+NGx group fell within the ‘Morbid Obese’ category 
according to Ozenoglu et al’s (2009) study. However, these interpretations should be cautioned 
given the differences in study samples (Sladjana et al. 2019; Ozenoglu et al. 2009) and body 
composition devices (Imboden et al. 2017). Future research should seek to develop reference 
standard charts for BIA using a variety of devices and populations. In addition, future research 
should aim to explore associations between health outcomes such as blood pressure, cholesterol, 
blood glucose and other measures, and these reference standards of BFP. 
 
8.3 Challenges Associated with Long-Term Lifestyle Behaviour Change  
 
Altering lifestyle habits established over the course of an individual’s lifespan is a highly 
complex and challenging endeavour. This is referred to in the literature as “the adherence 
problem” and is a notable concern given that individuals who do not adhere to a lifestyle 
intervention experience fewer health benefits (Dimatteo et al. 2002). Adherence to weight 
management programs have demonstrated particularly low rates of long-term adherence 
(Middleton, Anton, and Perri 2013). Typically, lifestyle interventions (both weight-related and 
non-weight-related) experience short-term initial adherence, followed by reduced adherence over 
the long-term (Middleton, Anton, and Perri 2013). Consequently, it is of great interest to find 
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that a nutrigenetic-guided intervention was able to motivate long-term dietary adherence to a 
significantly greater extent than a population-based lifestyle intervention. The discussion below 
provides greater detail on the challenges of long-term behavioural adherence, while linking this 
previous knowledge to the results of the NOW trial.  
 A variety of factors contribute to challenges with long-term behavioural adherence. The 
obesogenic food environment makes high-calorie, high-fat foods easily accessible at a low cost 
(Brownell 2005). Technological innovation has led to highly sedentary lifestyles, with workers 
spending at least 6-8 hours daily sitting at a desk (Lakdawalla and Philipson 2009). In terms of 
fitting planned, moderate-intensity physical activity into one’s day, lack of time as well as 
feelings of stress and fatigue after work are commonly reported as perceived barriers to 
completing physical activity (Schutzer and Graves 2004; Heesch, Brown, and Blanton 2000). 
Furthermore, individuals tend to struggle with long-term adherence to lifestyle changes without 
ongoing support from a healthcare provider. Following initial treatment, which should include 
regular healthcare provider contact, long-term adherence to lifestyle changes can be optimized 
through meetings once or twice monthly (Perri et al. 2008; Wing et al. 2006; Svetkey et al. 
2008). The NOW trial was designed to provide ongoing support with a healthcare provider by 
including meetings approximately monthly between 3- and 12-month follow-up (with weekly 
meetings occurring in the first three months). Reported barriers to healthy eating include a lack 
of cooking skills, taste preferences, frequency of eating foods away from home, calorically-dense 
and large portion sizes served at family meals, perceived cost, the built environment, food 
availability, and behaviours of friends and family (social norms) (McMorrow et al. 2017; 
Scherme et al. 2014; Seguin et al. 2014). Therefore, individualized factors as well as the social 
and built environment can significantly impact dietary intake and adherence. While not 
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specifically assessed in the NOW trial, it is suspected that these challenges were similar between 
the GLB and the GLB+NGx groups, given that participant groups were randomized. 
 From a theoretical perspective, the TPB can be used to demonstrate the impact of 
attitudes, subjective norms and behavioural control on health behaviours. Given that the 
GLB+NGx group had greater behaviour change outcomes with respect to nutrition over the long-
term, it is possible that the more personalized lifestyle intervention had a greater impact on 
attitudes and/or subjective norms than the standard, population-based lifestyle intervention. This 
is an important future research endeavour, which can be completed using the NOW trial data. 
Other theories can further our comprehension of human behaviour in the context of lifestyle 
changes. The social cognitive theory, for example, suggests that personal factors (i.e. cognitions 
and emotions), as well as environmental factors (both social and physical environments) 
contribute to one’s behaviour, and that one’s behaviour can also impact personal and 
environmental factors (Bandura 1991). The social cognitive theory can be further broken down 
into four key constructs: health knowledge, self-efficacy beliefs and outcome expectations, self-
regulatory skills, and barriers to change (Bandura 1991). The standard GLB intervention 
promoted health knowledge through the 23 group-based and three one-on-one educational 
sessions about lifestyle guidelines and their importance for optimal health and weight 
management. This intervention encouraged positive self-efficacy beliefs and outcome 
expectations through weekly goal setting leading to successful experiences altering lifestyle 
habits. It promoted self-regulatory skills using goal setting, food and beverage tracking, and 
positive reinforcement from the facilitator and GLB group members alike. Lastly, the program 
educated participants on problem-solving and included participant-guided discussions related to 
problem-solving, thus positively impacting barriers to change. The GLB+NGx program also 
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affected the abovementioned components of the social cognitive theory, but may have further 
affected health knowledge and outcome expectations through the provision of personalized, 
genetic-based lifestyle information and advice. These theoretical perspectives demonstrate the 
complexities and multifactorial nature of behaviour change, while also helping to explain why 
the provision of genetic-based nutrition information resulted in greater nutrition-related 
behaviour change.     
 
8.4 Comparison to Outcomes of Previous Research on Nutrigenomics and 
Change in Nutrition-Related Behaviours  
 
With respect to behaviour change, the NOW trial adds promise to the body of literature by 
demonstrating that genetic-based nutrition information can better motivate individuals to change 
their nutritional habits. The NOW trial results also support literature demonstrating that the 
provision of actionable genetic-based recommendations is more likely to facilitate health 
behaviour change compared to the provision of non-actionable genetic-based information such as 
disease risk estimates (Horne et al. 2018). Examples of previous, related research are detailed 
below.  
A RCT conducted by Hieteranta-Luoma et al. (2014) found that when individuals were 
given genetic-based information related cardiovascular disease, they improved the quality of 
their diet to a greater extent than the control group. Similarly, in Nielsen and El-Sohemy’s RCT 
(2014), DNA-based nutrition advice motivated participants with high-risk genetic variants to 
reduce their sodium intake over the long-term (12-months), more so than the control group. 
These studies, and several others, were conducted in samples of participants who received the 
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genetic testing free of charge or at a reduced rate. Thus, it is interesting and important to also 
review the results of studies conducted in real-world genetic testing consumers. Kaufman et al. 
(2012) surveyed consumers of DTC genetic testing and found that one third of participants 
reported being more careful with their diet, 10% reported changing a nutritional supplement, and 
14% reported exercising more. Egglestone et al. (2013) surveyed consumers who had purchased 
DTC genetic tests and compared them to consumers considering purchasing a test or waiting for 
their results (control group). Of the consumers who had purchased DTC genetic tests and 
received their results, 27% reported changing health behaviours. The most commonly reported 
changes were “healthier diet,” “more exercise” and “taking vitamins or supplements” 
(Egglestone, Morris, and O’Brien 2013). With DTC genetic testing, consumers typically receive 
a substantial amount of health-related information. Therefore, there may be one or two specific 
components of the genetic report that stand out to an individual, and this is likely where the 
individual will focus their efforts in improving health behaviours. By assessing health behaviour 
change through asking more broad, open-ended questions, Egglestone et al. (2013) and Kaufman 
et al. (2012) provided an important assessment of overall behaviour change. With differing 
health priorities for different people, the focus of health behaviour change in genetic testing 
consumers can be highly variable.  
Many studies have, conversely, found a lack of health behaviour change resulting from 
genetic testing, as further detailed in Chapter 3. The first study to assess change in nutritional 
habits from genetic testing focused on changes in dietary fat intake as a result of receiving a 
routine clinical diagnosis of familial hypercholesterolemia, or receiving a routine clinical 
diagnosis in addition to genetic testing. This was a randomized trial and found no significant 
differences in nutritional intake over the 6-month follow-up (Marteau et al. 2004). Another of the 
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earlier studies randomized participants with obesity to receive a 1-session consult on how to 
manage obesity, which either included or excluded genetic information. They measured dietary 
restraint and found no significant differences between groups after 6-month follow-up (Rief et al. 
2007). Roke and colleagues’ (2017) RCT of young female adults found no significant differences 
in omega-3 intake after 12-week follow-up in a group receiving genetic-based information about 
FADS1 genotype and omega-3 compared to those receiving non-genetic-based information about 
omega-3. Another RCT of over 1200 young adults followed up after one month found no 
significant differences in nutrition and physical activity habits in a group receiving standard 
weight management advice, compared to a group receiving standard weight management advice 
in addition to information about FTO genotype (general information about the FTO gene, 
personal FTO genotype, mode of inheritance, and impact on weight) (Meisel et al. 2015). With 
respect to the weight-related interventional studies (Meisel et al. 2015; Rief et al. 2007), given 
the complexities of weight management discussed throughout the present dissertation, it is 
perhaps not surprising to find that the abovementioned weight management behaviour change 
research found no significant nutrition-related changes stemming from genetic-based 
interventions after 1-, 3-, or 6-month follow-up. It is also possible that participants were not 
followed up for long enough to exhibit substantial lifestyle behaviour changes, which can take 
time to develop and become habits. Following participants for at least 12-months appears to be a 
warranted endeavour. Notably, there are now four completed 12-month RCTs (including the 
NOW trial) assessing dietary change resulting from genetically-tailored advice, all of which 
demonstrated positive dietary changes after 12-month follow-up (Nielsen and El-Sohemy 2014; 
Chao et al. 2008; Hietaranta-Luoma et al. 2014). 
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Overall, research in the area of nutrigenomics interventions and lifestyle behaviour change is 
highly variable regarding the follow-up time points, methods, intervention strategies, 
participants, and therefore nutrition-related outcomes. Perhaps the truly important research 
question is not broadly “does genetic testing motivate improvements in health behaviours?” with 
a simple ‘yes’ or ‘no’ answer, but rather, “how can we use genetic testing to motivate 
improvements in health behaviours?” Indeed, the former has been the focus of more recent 
systematic reviews (Hollands et al. 2016; French et al. 2017). 
In terms of weight-related outcomes, further detailed in Chapter 4, previous research 
exploring the impact of nutrigenomics interventions on weight management have had mixed 
findings. Some research demonstrated effectiveness, while others reported no effect (Arkadianos 
et al. 2007; Celis-Morales et al. 2017; Frankwich et al. 2015). Study designs and nutrigenomics 
interventions have both been highly variable in the research that has been conducted to date. The 
NOW trial demonstrated that an actionable nutrigenomics-guided weight management 
intervention was effective at significantly reducing BFP after 3 and 6 months (Chapter 7). The 
first study assessing weight loss outcomes stemming from nutrigenomics interventions 
demonstrated an increased likelihood of maintaining some weight loss, with varying follow-up 
time points between 90 days and >365 days (Arkadianos et al. 2007). Later research in a sample 
of U.S. veterans, followed for 24 weeks, found that a nutrigenomics intervention had no impact 
on weight compared to general advice, but adherence to the nutrigenomics intervention was 
correlated with weight loss, whereas adherence to the standard diet was not (Frankwich et al. 
2015). More recently, Celis-Morales et al. (2017) found that, compared to the provision of other 
levels of personalization, there was no beneficial impact of communicating genotype-related 
information and advice on weight and waist circumference in a 6-month follow-up study. 
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Therefore, the NOW trial adds promise to the body of literature with respect to short-term and 
moderate-term reductions in BFP in a nutrigenomics-guided intervention, above and beyond BFP 
changes demonstrated in a highly regarded public health weight management program. However, 
over the long-term there were no significant differences in weight-related outcomes between 
groups (Chapter 7). This is curious, given the long-term significant differences in dietary change 
and adherence, whereby the nutrigenomics-guided intervention group made greater dietary 
changes and better adhered to the dietary guidelines compared to the standard intervention group.  
There are some plausible explanations for this, as discussed previously in Chapter 7. It is 
possible that participants noticed weight regain occurring from 6 until 12 months, and thus at 12 
months, became increasingly motivated to follow their genetic-based dietary guidelines. It is also 
possible that established biological adaptations occurring with weight loss could help to explain 
these diverging findings. This topic warrants further discussion, below.  
 
8.5 Biological Challenges of Long-Term Weight Loss and Maintenance 
 
 Over time, physiological mechanisms including adipose cellularity, endocrine function, 
energy metabolism and neural responsivity promote weight regain after a period of weight loss 
(Ochner et al. 2013). Decades of research have demonstrated that increased energy (calorie) 
intake can lead to increased fat cell size and fat cell number (Martinsson 1969; Hirsch and 
Batchelor 1976; Tchoukalova et al. 2010), and while weight loss may reduce the size of fat cells, 
it is unlikely to reduce the number of fat cells (Martinsson 1969; Björntorp et al. 1975; Hirsch 
and Han 1969; Arner and Spalding 2010; Gurr et al. 1982; Löfgren et al. 2005). Furthermore, 
while not well-established, preliminary research has demonstrated that this could encourage 
weight regain following periods of weight loss due to a reduction in the rate of fat oxidation and 
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increased retention of ingested energy (MacLean et al. 2006; Jackman et al. 2008; Knittle and 
Hirsch 1968; Kelley et al. 1999; Berggren et al. 2008). Changes in leptin (the satiety hormone) 
levels can also impact weight regain with research indicating that compared to a control, 
formerly obese individuals who had lost weight had reduced serum leptin levels despite having 
the same BFP (Löfgren et al. 2005). Several studies have shown a greater reduction in leptin 
levels following weight loss than one would expect (Arner and Spalding 2010; Löfgren et al. 
2005; Rosenbaum et al. 1997). Leptin depletion can lead to decreased metabolic rate (energy 
expenditure) and physical activity (Rosenbaum et al. 2010) as well as increased hunger and 
energy (calorie) intake (Kissileff et al. 2012). Peptide YY and cholecystokinin are other satiety-
promoting hormones, while ghrelin is a hunger-inducing hormone and changes in levels of these 
hormones have also been observed following periods of weight loss (Wren et al. 2001; 
Batterham et al. 2002; Sumithran et al. 2011; Lien et al. 2009). Therefore, weight loss could lead 
to both reduced satiety, and increased hunger, resulting in overeating and thus weight regain 
(Rosenbaum et al. 1997).  Additionally, research has demonstrated a decrease in thyroid function 
(and thus, a decrease in metabolic rate) after weight loss in individuals with obesity (Rosenbaum 
et al. 2000; Kozłowska and Rosołowska-Huszcz 2004; Moreno et al. 2008). Moreover, the 
activity of hypothalamic-pituitary-adrenal axis, which regulates cortisol levels, is heightened 
following weight loss and this can lead to increased appetite and fat accumulation (Björntorp 
2001).   
 In terms of changes in metabolic rate, a decrease in fat mass and lean mass will both lead 
to reductions in energy output/expenditure (Leibel, Rosenbaum, and Hirsch 1995; Gallagher et 
al. 1996). While a reduction in metabolic rate is normal and expected, studies have demonstrated 
that weight loss occurring from lifestyle interventions (behavioural weight loss) results in 
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‘metabolic adaptation’ (Leibel, Rosenbaum, and Hirsch 1995; Gallagher et al. 1996; Astrup et al. 
1999; Rosenbaum and Leibel 2010; Johannsen et al. 2012; Camps, Verhoef, and Westerterp 
2013; Tremblay and Chaput 2009). Metabolic adaptation refers to a greater reduction in 
metabolic rate than would be expected based on an individual’s body composition (Leibel, 
Rosenbaum, and Hirsch 1995; Gallagher et al. 1996; Astrup et al. 1999; Rosenbaum and Leibel 
2010; Johannsen et al. 2012; Camps, Verhoef, and Westerterp 2013; Tremblay and Chaput 
2009). This decrease in resting metabolic rate following weight loss leads to biological 
challenges with weight maintenance. The classic Minnesota semi-starvation experiment was one 
of the first studies to demonstrate a reduced resting metabolic rate during a period of weight 
regain following weight loss (Keys 1950). A number of studies have corroborated these findings 
following the publication of the Minnesota semi-starvation experiment (Leibel, Rosenbaum, and 
Hirsch 1995; Astrup et al. 1999; Rosenbaum and Leibel 2010; Johannsen et al. 2012; Camps, 
Verhoef, and Westerterp 2013; Tremblay and Chaput 2009). Weight cycling can also negatively 
affect resting metabolic rate, with research demonstrating that the fat-to-lean mass ratio of 
weight regained is greater than the fat-to-lean mass ratio of weight lost. Therefore, weight 
cycling can result in the body favouring fat mass over lean mass (Lahti-Koski et al. 2005). With 
lean mass having a greater contribution to energy expenditure compared to fat mass, over time 
multiple bouts of weight cycling can have a considerable impact on metabolic rate (Prentice et al. 
1992). 
 Long-term weight loss is further challenged by neural responsivity. Specifically, neural 
systems include: the homeostatic system, which functions to respond to caloric needs to maintain 
energy balance; the reward-related system, which functions to promote eating based on 
dopamine signalling, thus driving the perception of the reward-value of food; and the inhibitory 
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system, which functions to inhibit excessive food intake (Le et al. 2006). With caloric restriction, 
the homeostatic system upregulates the reward-related system, thus leading to greater 
consumption of high-calorie foods compared to low-calorie foods. This upregulation appears to 
persist during the period following weight loss (Kissileff et al. 2012; Murdaugh et al. 2012), 
which can result in weight regain (LaBar et al. 2001; Berthoud 2011). Indeed, research 
demonstrates that individuals crave “forbidden foods” during periods of dietary restriction 
(Soetens et al. 2008).  
 Ultimately, there are several biological mechanisms leading the body to resist weight 
loss, and drive weight regain.  This could explain why results from the NOW trial demonstrated 
weight regain trends occurring from 6-month to 12-month follow-up in both the GLB and 
GLB+NGx groups (Chapter 7). It is intriguing to notice the continued trend towards decreasing 
BFP (but not weight) in the GLB group only. It is hypothesized that the faster rate of BFP loss 
experienced in the GLB+NGx group led to an earlier onset of the biological responses promoting 
weight regain. Indeed, research supports this notion (MacLean et al. 2011). Additionally, 
considering the nutrition-related findings presented in Chapter 6, taken together with the weight-
related findings from Chapter 7, it is likely that the drivers of weight and fat mass regain in the 
GLB+NGx group were related more to metabolic adaptation, endocrine function, energy 
metabolism and adipose cellularity than to neural responsivity and hormonal changes associated 
with increased energy intake, such as changes in peptide YY, cholecystokinin and ghrelin. 
Overall, biological adaptations to weight loss will remain a challenge for researchers in the field 
of pragmatic nutrigenomics for weight loss.  
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8.6 Participant Retention in Weight Loss Research 
  
With these biological and behavioural challenges associated with sustaining weight loss 
long-term, it is not surprising to find higher dropout rates in weight loss studies compared to 
studies of other health-related outcomes. While the target dropout rate for an RCT is <20% 
(National Institutes of Health n.d.), studies demonstrate that this is typically challenging for long-
term weight loss studies (Hillmer et al. 2017; Truby et al. 2006; Jebb et al. 2011; Wadden et al. 
2004; Gill et al. 2012; Foster et al. 2003). Thus, the dropout rate of 46% in the NOW trial was 
not remarkable. Reasons for reduced participant retention could include scheduling conflicts, 
dissatisfaction with treatment, and lack of time to meet the study requirements (Wadden et al. 
2004). Having a lower education level, a higher level of obesity, and higher stress levels are also 
risk factors for dropping out of weight loss programs/studies (Michelini et al. 2014; Ortner 
Hadžiabdić et al. 2015). Many of these factors contributed to participant dropout in the NOW 
trial as further indicated in Chapter 7: Figure 7.1 and Table 7.1, and Chapter 6: Table 6.2. 
Notably, research has previously been conducted within the GLB program at the EEFHT and 
five other Ontario primary care locations. In this previous study, the program was offered during 
a 9-month period, and dropout rates throughout the study were 26.8% at 3-months, 46.8% at 6-
months, and 63.0% at 9-months (Hillmer et al. 2017). This is the most comparable study to the 
NOW trial, in terms of dropout rate, given the similarities in the intervention and setting. The 
addition of nutrigenetic information in the NOW trial may have helped achieve a higher retention 
rate (over a longer period of time) than this previous research.  
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8.7 Future Directions  
 
 Future research evaluating the impact of genetic testing on health behaviours should 
consider validated behaviour change theory, such as the TPB. Not only would this help to ensure 
important possible confounders of behaviour change are considered, but it would also help to 
inform high-quality, detailed results from future systematic reviews on this topic. Perhaps 
genetic testing for personalized nutrition helps to motivate health behaviour change only when 
attitudes and/or subjective norms and/or behavioural control and/or behavioural intentions are 
high? For example, participants in the NOW trial had highly positive attitudes towards changing 
their nutritional habits, with neutral subjective norms and behavioural control, and strong 
intentions to make changes to their nutritional intake. These participants successfully made long-
term changes to their total fat and saturated fat intake. If this study was repeated in a sample of 
participants with negative attitudes and weak intentions towards changing their nutritional habits, 
results may demonstrate no changes in nutritional intake even if behavioural control and/or 
subjective norms are positive in terms of encouraging behaviour change. Future studies should 
seek to test this concept. Additional TPB research should determine if, over time, genetic testing 
for personalized nutrition and physical activity positively affects one or more of the 
intermediates of behaviour change: attitudes, subjective norms, and/or perceived behavioural 
control. Overall, our understanding of the impact of genetic testing on health behaviour change is 
complex and knowledge is only in its infancy.  
 Future research should further seek to evaluate the impact of pragmatic nutrigenomics 
interventions on other indicators of health such as blood pressure, cholesterol, blood glucose, 
insulin, and others. In terms of weight management, assessing the impact of nutrigenomics 
interventions in samples of patients who may benefit from short-term and moderate-term 
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reductions in BFP would be beneficial. These specific patient populations are further outlined in 
Chapter 7. Ideally, an RCT methodology should be employed, with the consideration of 
validated behaviour change theory to guide both the genetic-based and the standard interventions 
as well as the statistical analyses. Given the established difficulties associated with long-term 
weight loss including biological adaptations to adipose cellularity, endocrine function, energy 
metabolism, and neural responsivity (Ochner et al. 2013), it appears to be of great importance for 
researchers to focus on obesity-prevention. Nonetheless, the present work did not seek to 
specifically  explore if biological mechanisms were responsible for long-term challenges with 
maintaining weight loss and fat mass loss from a genetic-based intervention, and thus future 
research should aim to replicate the NOW trial while exploring this phenomenon.  
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CHAPTER 9: CONCLUSION 
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 In the areas of nutrigenomics, health behaviour change, overweight/obesity and their 
interrelations, there is much that remains to be understood. The NOW trial provided an intriguing 
and insightful analysis of these topics, contributing to our overall understanding of the interplay 
between nutrition, genetics, health behaviours and health-related outcomes. The findings from 
the present dissertation generated strong insights for the focus of future research. As we continue 
to gain knowledge in the fields of nutrigenomics, health behaviour change, overweight/obesity 
and their interrelations, we are not only contributing greatly to the scientific community, but 
more importantly, to the health and wellbeing of individuals through the development of more 
precise and personalized health strategies.  
193 
 
REFERENCES 
 
23andMe. c2019. “23andMe.” Accessed August 12, 2019. https://www.23andme.ca. 
Abusabha R, Peacock J, and Achterberg C. 1999. “How to Make Nutrition Education More 
Meaningful through Facilitated Group Discussions.” Journal of the American Dietetic 
Association 99 (1): 72-76. 
Adan RAH, Tiesjema B, Hillebrand JJG, Fleur SE, Kas MJH, and De Krom M. 2006. “The MC4 
Receptor and Control of Appetite.” British Journal of Pharmacology 149: 815–27. 
https://doi.org/10.1038/sj.bjp.0706929. 
Ahmad T, Chasman DI, Mora S, Paré G, Cook NR, Buring JE, Ridker PM, and Lee IM. 2010. 
“The Fat-Mass and Obesity-Associated (FTO) Gene, Physical Activity, and Risk of Incident 
Cardiovascular Events in White Women.” American Heart Journal 160 (6): 1163–69. 
https://doi.org/10.1016/j.ahj.2010.08.002. 
Ahmetov II, Kulemin NA, Popov DV, Naumov VA, Akimov EB, Bravy YR, Egorova ES, et al. 
2015. “Genome-Wide Association Study Identifies Three Novel Genetic Markers 
Associated with Elite Endurance Performance.” Biology of Sport 32 (1): 3–9. 
https://doi.org/10.5604/20831862.1124568. 
Ahmetov II, Druzhevskaya AM, Lyubaeva EV, Popov DV, Vinogradova OL, and Williams AG. 
2011. “The Dependence of Preferred Competitive Racing Distance on Muscle Fibre Type 
Composition AndACTN3genotype in Speed Skaters.” Experimental Physiology 96 (12): 
1302–10. https://doi.org/10.1113/expphysiol.2011.060293. 
Ajzen I. c2019. “Constructing a Theory of Planned Behavior Questionnaire.” 
https://people.umass.edu/aizen/pdf/tpb.measurement.pdf. 
Ajzen I. 1991. “The Theory of Planned Behavior.” Organizational Behavior and Human 
Decision Making Processes 51: 179–211. 
Ajzen I. 2006. “Icek Ajzen: Theory of Planned Behavior.” 2006. 
http://people.umass.edu/aizen/tpb.html. 
Ajzen I. 2011. “The Theory of Planned Behaviour: Reactions and Reflections.” Psychology & 
Health 26 (9): 1113–27. https://doi.org/10.1080/08870446.2011.613995. 
Aller E, Larsen TM, Claus H, Lindroos AK, Kafatos A, Pfeiffer A, Martinez JA, et al. 2014. 
“Weight Loss Maintenance in Overweight Subjects on Ad Libitum Diets with High or Low 
Protein Content and Glycemic Index: The DIOGENES Trial 12-Month Results.” 
International Journal of Obesity 38 (12): 1511–17. https://doi.org/10.1038/ijo.2014.52. 
Alva ML. 2019. “How Much Does Attendance Impact Weight Loss and Health Care Spending in 
a Diabetes Prevention Program Serving Older Adults?” American Journal of Health 
Promotion 33 (7): 1067–72. https://doi.org/10.1177/0890117119848985. 
Alva ML, Romaire M, and Acquah J. 2019. “Impact of Financial Incentives on Diabetes 
Prevention Class Attendance and Program Completion: Evidence From Minnesota, 
Montana, and New York.” American Journal of Health Promotion 33 (4): 601–5. 
194 
 
https://doi.org/10.1177/0890117118794087. 
Anderson TJ, Grégoire J, Pearson GJ, Barry AR, Couture P, Dawes M, et al. 2016. "Canadian 
Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention 
of Cardiovascular Disease in the Adult." Can J Cardiol 32(11): 1263-82. 
Andreasen CH, Stender-Peterson KL, Mogensen MS, Torekov SS, Wegner L, Andersen G, 
Nielsen AL, et al. 2008. “Low Physical Activity Accentuates the Effect of the FTO 
Rs9939609 Polymorphism on Body Fat Accumulation.” Diabetes 57: 95–101. 
Andrew BJ, Mullan BA, De Wit JBF, Monds LA, Todd J, Kothe EJ. 2016. “Does the Theory of 
Planned Behaviour Explain Condom Use Behaviour Among Men Who Have Sex with 
Men ? A Meta-Analytic Review of the Literature.” AIDS and Behavior 20 (12): 2834–44. 
https://doi.org/10.1007/s10461-016-1314-0. 
Annan J, Clement N, Macpherson GJ, Brenkel IJ, Ballantyne JA, and Dunstan E. 2018. “Body 
Mass Index, Hip Function and Surgeon Volume Are Independent Predictors of Dislocation: 
An Analysis of 4334 Total Hip Replacements.” European Journal of Orthopaedic Surgery 
and Traumatology 28 (5): 899–905. https://doi.org/10.1007/s00590-017-2078-6. 
Appleton KM. 2016. "Barriers to and Facilitators of the Consumption of Animal-Based Protein-
Rich Foods in Older Adults." Nutrients 8(4).  
Arena R, McNeil A, Sagner M, and Hills AP. 2017. “The Current Global State of Key Lifestyle 
Characteristics: Health and Economic Implications.” Progress in Cardiovascular Diseases 
Arena Ross Progress in Cardiovascular Diseases 9. 
https://doi.org/10.1016/j.pcad.2017.02.002. 
Arkadianos I, Valdes AM, Marinos E, Florou A, Gill RD, and Grimaldi KA. 2007. “Improved 
Weight Management Using Genetic Information to Personalize a Calorie Controlled Diet.” 
Nutrition Journal 6: 29. https://doi.org/10.1186/1475-2891-6-29. 
Arksey H, and O’Malley L. 2005. “Scoping Studies: Towards a Methodological Framework.” 
International Journal of Social Research Methodology 8 (1): 19–32. 
Armitage CJ and Conner M. 2001. “Efficacy of the Theory of Planned Behaviour: A Meta-
Analytic Review.” British Journal of Social Psychology 40: 471–99. 
https://doi.org/10.1348/014466601164939. 
Arner P and Spalding KL. 2010. “Fat Cell Turnover in Humans.” Biochemical and Biophysical 
Research Communications 396 (1): 101–4. https://doi.org/10.1016/j.bbrc.2010.02.165. 
Astrup A, Gøtzsche PC, Van De Werken K, Ranneries C, Toubro S, Raben A, and Buemann B. 
1999. “Meta-Analysis of Resting Metabolic Rate in Formerly Obese Subjects.” American 
Journal of Clinical Nutrition 69 (6): 1117–22. https://doi.org/10.1093/ajcn/69.6.1117. 
Athletigen. 2018. “Nutrition Report.” 2018. https://athletigen.com/products/nutrition-report/. 
Audrain J, Boyd NR, Roth J, Main D, Caporaso NE, and Lerman C. 1997. “Genetic 
Susceptibility Testing in Smoking-Cessation Treatment: One-Year Outcomes of a 
Randomized Trial.” Addictive Behaviors 22 (6): 741–51. https://doi.org/10.1016/S0306-
4603(97)00060-9. 
195 
 
Azuma K, Rádiková Z, Mancino J, Toledo FGS, Thomas E, Kangani C, Man CD, et al. 2008. 
“Measurements of Islet Function and Glucose Metabolism with the Dipeptidyl Peptidase 4 
Inhibitor Vildagliptin in Patients with Type 2 Diabetes.” Journal of Clinical Endocrinology 
and Metabolism 93 (2): 459–64. https://doi.org/10.1210/jc.2007-1369. 
Bandura A. 1991. “Social Cognitive Theory of Self-Regulation.” Organ Behav Hum Dec 50 (2): 
248–87. 
Banks NF, Tomko PM, Colquhoun RJ, Muddle TWD, Emerson SR, and Jenkins NDM. 2019. 
“Genetic Polymorphisms in ADORA2A and CYP1A2 Influence Caffeine’s Effect on 
Postprandial Glycaemia.” Scientific Reports 9 (1): 1–9. https://doi.org/10.1038/s41598-019-
46931-0. 
Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wrem AM, et al. 2002. 
“Gut Hormone PYY 3-36 Physiologically Inhibits Food Intake.” Nature 418 (August): 728–
30. 
Berezowska AF, Ronteltap ARH, Kuznesof A, Macready S, Fallaize A, van Trijp R. 2014. 
“Understanding Consumer Evaluations of Personalised Nutrition Services in Terms of the 
Privacy Calculus: A Qualitative Study.” Public Health Genomics 17 (3): 127–40. 
Bedogni G, Agosti F, De Col A, et al. 2013. “Comparison of dual energy X-ray absorptiometry, 
air displacement plethysmography and bioelectrical impedance analysis for the assessment 
of body composition in morbidly obese women.” European Journal of Clinical Nutrition 
67(11):1129-32.  
Berggren JR, Boyle KE, Chapman WH, and Houmard JA. 2008. “Skeletal Muscle Lipid 
Oxidation and Obesity: Influence of Weight Loss and Exercise.” American Journal of 
Physiology - Endocrinology and Metabolism 294 (4): 726–32. 
https://doi.org/10.1152/ajpendo.00354.2007. 
Berthoud HR. 2011. “Metabolic and Hedonic Drives in the Neural Control of Appetite: Who’s 
the Boss?” Current Opinions in Neurobiology 21 (6): 889–96. 
https://doi.org/10.1038/jid.2014.371. 
Best D, Avenell A, and Bhattacharya S. 2017. “How Effective Are Weight-Loss Interventions 
for Improving Fertility in Women and Men Who Are Overweight or Obese? A Systematic 
Review and Meta-Analysis of the Evidence.” Human Reproduction Update 23 (6): 681–
705. https://doi.org/10.1093/humupd/dmx027. 
Best RL and Appleton KM. 2013. "The Consumption of Protein-Rich Foods in Older Adults: An 
Exploratory Focus Group Study." Journal of Nutrition Education and Behavior 45(6):751-
5. 
Björntorp P. 2001. “Do Stress Reactions Cause Abdominal Obesity and Comorbidities?” Obesity 
Reviews 2 (2): 73–86. https://doi.org/10.1046/j.1467-789x.2001.00027.x. 
Björntorp P, Carlgren G, Isaksson B, Krokiewski M, Larsson B, and Sjöström L. 1975. “Effect 
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APPENDIX A:  
Selected TPB Survey Questions Included in Attrition Analysis  
 
Attitudes/Behavioural Beliefs/Outcome Evaluations 
 
Meeting the recommendation for physical activity outlined in my 1-page report will help me to better 
manage my weight.  
 
Unlikely    1      2      3      4      5      6       7      Likely 
 
Meeting the recommendation for calories outlined in my 1-page report will help me to better manage my 
weight. 
 
Unlikely    1      2      3      4      5      6       7      Likely 
 
Meeting the recommendation(s) for fat (either total fat and/or different types of fat) outlined in my 1-
page report will help me to better manage my weight. 
 
Unlikely    1      2      3      4      5      6       7      Likely 
 
Meeting the recommendation for protein outlined in my 1-page report will help me to better manage my 
weight. 
 
Unlikely    1      2      3      4      5      6       7      Likely 
 
Subjective (Perceived) Norms/Injunctive Normative Beliefs/Motivation to Comply 
 
My friends eat a generally healthy diet. 
 
Disagree    1      2      3      4      5      6       7      Agree 
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My family eats a generally healthy diet. 
 
Disagree    1      2      3      4      5      6       7      Agree 
 
Perceived Behavioural Control/Control Beliefs/Power of Control Factors 
 
For me, making beneficial changes to my calorie intake over the next three months will be: 
 
Extremely Difficult    1      2      3      4      5      6       7      Extremely Easy 
 
For me, making beneficial changes to my fat intake (either total fat and/or different types of fat) over 
the next three months will be:  
 
Extremely Difficult    1      2      3      4      5      6       7      Extremely Easy 
 
For me, making beneficial changes to my protein intake over the next three months will be:  
 
Extremely Difficult    1      2      3      4      5      6       7      Extremely Easy 
 
When it comes to making changes to your lifestyle (diet or physical activity), which sentence best 
describes your attitude: 
 
a. I do not believe that I need to make any changes to my lifestyle 
b. I might need to make some changes to my lifestyle 
c. I am determined to make changes to my lifestyle but haven’t started to make any changes yet 
d. I have started making positive changes to my lifestyle over the past three months 
e. I have started making positive changes to my lifestyle, which I have sustained over the past 3-6 
months 
f. I have started making positive changes to my lifestyle, which I have sustained for over 6 
months 
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Actual Behavioural Control  
 
What is your highest level of education? 
 
1. Elementary School 
2. Middle School (Grade 7/8) 
3. High School 
4. College 
5. University  
 
[Annual household income (CDN$) taken from participant demographic questionnaire] 
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APPENDIX B:  
 
BIA Data Collection Methods  
 
The data collection methods detailed below were adapted with guidance from the 
National Institute for Health Research Biomedical Research Centre (National Institute for Health 
Research, 2014) and the BodyStat 1500MDD instruction manual (BodyStat, 2017). One 
researcher (JH) completed all BIA assessments with participants and therefore inter-rater 
reliability assessments were not needed. Before each BIA assessment, safety screening was 
conducted. Participants were asked if they had a pacemaker or any other implanted electrical 
device and if so, the BIA was not conducted (n=2). Participants were asked to remove all right-
sided jewellery and were given the opportunity to void prior to the BIA assessment. They were 
then asked to remove their right shoe and sock and lay in a supine position while the researcher 
set up the BIA machine and input patient-specific data. The data that was input into the BIA 
device included: measured height and weight, age, gender, and physical activity level. Physical 
activity level was determined based on the participant’s self-reported 7-day physical activity 
recall, which they completed immediately prior to completing the BIA assessment. Alcohol 
wipes were used to thoroughly clean the area of the skin where the electrodes would be attached. 
Two electrode pads were placed on the right foot, and two on the right hand and wrist as 
indicated in Image 1 and Image 2, below. Specifically, the current injection (red) electrodes were 
placed proximally to the phalangeal joints and the voltage detection (black) electrodes were 
placed at the pisiform prominence of the wrist and on the ankle, in between the medial and 
lateral malleoli. The process of setting up the BIA device took approximately 5 minutes, and this 
was completed while the patient was laying in the supine position.  
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Image 1     Image 2 
 
 
 
 
 
 
Images taken from: National Institute for Health Research, 2014 
 
 It should be noted that some test violations occurred since dietary intake and physical 
activity data collection occurred at the same time period as body composition data collection. 
Participants were not asked: to avoid eating 4-5 hours before the test, to avoid caffeine and 
alcohol 24 hours before the test or to avoid exercise for 12 hours before the test.  
There was one unexpected deviation from the protocol above, in the case of a participant 
who experienced extreme pain in the supine position and therefore the participant’s BIA 
assessment was conducted in a seated position. This participant, however, only completed the 
baseline assessment and therefore their data was not included in the final analysis.  
 
  
227 
 
Curriculum Vitae 
 
Justine Horne, MScFN, RD, PhD  
                     
 
Profile             
• Registered dietitian experienced in clinical, community, industry and research settings 
with a passion for knowledge translation, research and teaching  
• Proficient in both English (first language) and French (second language)  
 
Education  
• Doctor of Philosophy (PhD) in Health and Aging: September 2016 – March 2020, Western 
University, Health and Rehabilitation Sciences  
o Supervisors: Jason Gilliland, PhD; Janet Madill, PhD, RD 
o Major Project: The Nutrigenomics, Overweight/Obesity and Weight 
Management Trial (The NOW Trial): A pragmatic randomized controlled trial of 
personalized, genetic-based lifestyle advice  
o CIHR Frederick Banting and Charles Best Canada Graduate Scholarship Doctoral 
Research Award recipient ($105,000) 
• Master of Science in Food and Nutrition (MScFN) with Distinction: June 2015, Western 
University (Brescia University College) 
o Supervisor: Colleen O’Connor, PhD, RD 
o Major Project: Exploring knowledge and attitudes of personal nutrigenomics 
testing among dietetic students and its value as a component of dietetic 
education & practice. 
o MScFN Leadership Award recipient 
• Bachelor of Science (BSc) in Food and Nutrition – Honours Specialization in Nutrition 
and Dietetics with Distinction: June 2013, Western University 
o Western Gold Medal recipient 
• Certificate in Practical French: June 2013, Western University 
o Sir Wilfrid Laurier Memorial Prize recipient   
 
Student Mentorship  
 
• Preceptor: Diploma in Dietetic Education and Practical Training, Brescia University 
College (BUC), 2017 – present  
o Supervised 5 dietetic interns for their research placements 
o Supervised 3 dietetic interns for their community nutrition/public health 
placement 
o Supervised 1 dietetic intern for their clinical nutrition placement 
228 
 
• Lead Coordinator: The NOW Trial Experiential Learning Group, BUC, 2016 – January 
2020  
o Oversee 50+ student volunteers involved in data collection for The NOW Trial  
• Undergraduate Independent Study Co-Advisor: BUC Honours BScFN Program, 2019 – 
present   
o  Co-advising undergraduate student with Janet Madill, PhD, RD 
• Preceptor: MScFN Program, Brescia University College, 2015 – 2017  
o Supervised 4 dietetic interns for their clinical nutrition placements 
 
Awards and Recognitions 
 
• Top Scoring Abstract, ASPEN Nutrition Science and Practice Conference: March 2020 
(complimentary conference registration) 
• CNS Graduate Student and Trainee Award – Poster Competition Finalist: May 2019 
• Campus Collaboration Award (the NOW Experiential Learning Group): April 2019 
• Canadian Institutes of Health Research (CIHR) – Frederick Banting and Charles Best 
Canada Graduate Scholarship Doctoral Research Award: 2018 – present, CIHR 
($105,000) 
• Ontario Graduate Scholarship: 2017-2018 (2018-2019: offered & declined), Government 
of Ontario ($15,000) 
• Ontario Respiratory Care Society (ORCS) Fellowship Award: 2017-2018, ORCS ($9200) 
• Dean’s Honour List with Distinction: 2009 – 2020, Western University 
• Dean’s Honour Roll of Teaching: 2015 – 2018, Western University (Brescia University 
College) 
• TalentEdge Internship Grant: 2015, Ontario Centres for Excellence ($20,000) 
• MScFN Leadership Award: 2015, Brescia University College 
• CIS Academic All-Canadian: 2010-2014, Western University 
• Sir Wilfrid Laurier Memorial Prize: 2013, Western University ($375) 
• A.K. Knill Award: 2013, Western University (Residence Staff) 
• Western Gold Medal: 2013, Western University 
• Excellence in Leadership Award: 2010-2011, Western University   
 
Certifications 
 
• Registered Dietitian: May 2015 – present, College of Dietitians of Ontario 
• Certified Lifestyle Coach: May 2017 – present, Group Lifestyle Balance™/Diabetes 
Prevention Program  
• DELF Level B2 and DALF Level C1 French Bilingual Certification: May 2013, French 
Ministry of Education  
 
 
 
229 
 
Professional Dietetics Experience 
 
East Elgin Family Health Team: Registered Dietitian, and Health Programs & Research Co-
ordinator, January 2017 – March 2020  
 
Justine the RD & Associates - Personalized Nutrition Consulting: Owner, January 2016 – 
October 2018 
 
Nutrigenomix Inc: Manager of Research & Education, May 2015 – Dec 2017  
 
Nutrition Professionals of Canada: Consulting Dietitian, April 2016 – November 2016   
 
Kitchener Downtown Community Health Centre: Registered Dietitian and Diabetes Educator, 
May 2015 – September 2015  
 
Brescia University College: Dietetic Intern, May 2014 – April 2015 
 
Teaching Experience 
 
Brescia University College: Adjunct Faculty, January – April 2018  
• Nutrition Through the Human Life Cycle, FN2241B 
• Dean’s Honour Roll of Teaching 
 
Brescia University College: Adjunct Faculty, September 2015 – December 2016    
• Clinical Nutrition 1, FN3351A 
• Dean’s Honour Roll of Teaching 
 
Western University: Guest Lecturer, January 2014 – April 2018 
• Health Policy, Law & Equity: MPH9009, Lecture Topic: Nutrigenomics: Genetic Testing 
for Personalized Nutrition (Graduate Level), April 2018  
• Musculoskeletal Disorders in Rehabilitation Science: RS3360, Lecture Topic: 
Rehabilitation from the Nutrition Perspective (Undergraduate Level), March 2018 
• Guidelines for Physical Activity and Exercise in Older Adults: KIN4474, Lecture Topic: 
Nutrition for Healthy Aging and Participation in Physical Activity (Undergraduate Level), 
February 2018 
• Advances in Clinical Nutrition: FN9444B, Lecture Topics: 1. Long-Term Care; 2. 
Nutrigenomics: Genetic Testing for Personalized Nutrition (Graduate Level), January 
2015 
• Clinical Nutrition 1: FN3351A, Lecture Topic: Disordered Eating (Undergraduate Level), 
January 2014 
• Nutrition Through the Human Life Cycle: FN2242, Lecture Topics: 1. Nutrition During 
Pregnancy; 2. Early Childhood Nutrition; 3. Adult Nutrition (Undergraduate Level), 
March - April 2014 
• Clinical Nutrition III: FN4453A, Lecture Topic: Nutrigenomics: Genetic Testing for 
Personalized Nutrition (Undergraduate Level), January 2014/2015/2016/2017/2018 
230 
 
 
Western University:  Teaching Assistant, September – December 2016 
• Foundations of Mental Health, HS4620F: Supervisor – Louis Charland, PhD 
• Population Health Interventions, HS4250A: Supervisor – Jean Samuel, PhD 
 
Self-Employed: Private Tutor, April – June 2014                                                                                             
 
Brescia University College: Course Assistant, October 2013 – April 2014  
• Clinical Nutrition 1, FN3351A and Nutrition Through the Human Life Cycle, FN2242: 
Supervisors – Colleen O’Connor, PhD, RD and Janet Madill, PhD, RD  
 
Peer-Reviewed Publications  
 
1. Horne J, Gilliland J, Madill J, Shelley J. A critical examination of legal and ethical 
considerations of nutrigenetic testing with recommendations for improving regulation in 
Canada: From science to consumer. Journal of Law and the Biosciences. 2020 [in press]. 
2. Horne J. Are we losing sight of the true meaning of “evidence-based nutrition?” International 
Journal of Public Health. 2020 [in press]. 
3. Guest NS, Horne J, Vanderhout S, El-Sohemy A. Sport nutrigenomics: Personalized nutrition 
for athletic performance. Frontiers in Nutrition. 2019;6:8.  
 
4. Toth J, O'Connor C, Hartman B, Dworatzek P, Horne J. "Detoxify or Die": Qualitative 
assessments of Ontario nutritionists' and dietitians' blog posts related to detoxification diets. 
Canadian Journal of Dietetic Practice and Research. 2019;1-6. 
 
5. Horne J, Gilliland J, O’Connor C, Seabrook J, Hannaberg P, Madill J. Study Protocol of a 
pragmatic randomized controlled trial incorporated into the Group Lifestyle Balance™ Program: 
The Nutrigenomics, Overweight/Obesity and Weight Management Trial (The NOW Trial). BMC 
Public Health. 2019;19(1):310.  
 
6. Horne J, Madill J, O ’Connor C, Shelley J, Gilliland J. A Systematic Review of Genetic Testing 
and Lifestyle Behaviour Change: Are We Using High-Quality Genetic Interventions and 
Considering Behaviour Change Theory? Lifestyle Genomics. 2018;11(1):49-63.  
 
7. Horne J, Madill J, Gilliland J. Incorporating the ‘Theory of Planned Behaviour’ into 
personalized healthcare behavior change research: a call to action. Personalized Medicine. 
2017;14(6):521–9.  
 
8. Rinaldi S, Horne J, Madill J. An evolving understanding of modifiable risk factors for post-
transplant mortality. [Letter to the Editor] Transplant International. 2017;30(5): 533-534. 
 
  
231 
 
9. Horne J, O’Connor C, Madill J, Rinaldi S, Gilliland J. Re: Polymorphisms of three genes (ACE, 
AGT andCYP11B2) in the renin-angiotensin-aldosterone system are not associated with blood 
pressure salt sensitivity: A systematic meta-analysis. [Letter to the Editor] Blood Pressure. 
2016;26(4): 255-256. 
  
10. Horne J, Madill J, O’Connor C. Exploring knowledge and attitudes of personal nutrigenomics 
testing among dietetic students and its value as a component of dietetic education and 
practice. Canadian Journal of Clinical Nutrition. 2016;4(1): 50-62.  
 
Abstracts and Poster Presentations  
 
1. Horne J, Gilliland J, Seabrook J, O’Connor C, Madill J. Change in weight, BMI, and body 
composition after 3, 6, and 12 months in a population-based intervention vs. genetic-based 
intervention: Results from the NOW randomized controlled trial. ASPEN Nutrition Science and 
Practice Conference. Tampa, United States. March 29, 2019 (Top Scoring Abstract). 
[International] 
 
2. Horne J, Gilliland J, Seabrook J, O’Connor C, Madill J. Exploring the Canadian general public’s 
attitudes towards genetic-based lifestyle advice for weight management: Results from the 
NOW randomized controlled trial. ASPEN Nutrition Science and Practice Conference. Tampa, 
United States. March 30, 2019. [International] 
 
3. Horne J, Gilliland J, Seabrook J, O’Connor C, Madill J. Genetic-based lifestyle information and 
recommendations are superior to population-based guidelines for improving body composition 
after 3-month follow-up: Results from the NOW trial. European Conference on Personalized 
Nutrition and Health. Wageningen, Netherlands. October 8, 2019. [International] 
  
4. Horne J, Gilliland J, Seabrook J, O’Connor C, Madill J. Exploring the Canadian general public’s 
attitudes towards genetic-based lifestyle advice for weight management: Results from the 
NOW randomized controlled trial. European Conference on Personalized Nutrition and 
Health. Wageningen, Netherlands. October 8, 2019. [International] 
 
5. Horne J, Gilliland J, Seabrook J, O’Connor C, Madill J. Genetic-based lifestyle information and 
recommendations are superior to population-based guidelines for improving body composition 
after 3-month follow-up: Results from the NOW trial. Canadian Nutrition Society Annual 
Conference. May 3-4, 2019 (Poster Competition Finalist). [National] 
 
6. Veloce D, Fisher M, O’Connor C, Hartman B, Horne J. Does the Ontario public understand the 
difference between registered dietitians and nutritionists? A cross-sectional mixed methods 
study assessing public awareness and experiences with different nutrition providers. Canadian 
Nutrition Society Annual Conference. May 3-4, 2019. [National] 
 
232 
 
7. Hannaberg P, Horne J, Rinaldi S, Gilliland J, Madill J. Phase angle and malnutrition in Canadian 
community-dwelling adults: Preliminary results. Dietitians of Canada National Conference. 
Vancouver, BC. June 8, 2018. [National] 
 
8. Rinaldi S, Kurowski C, Horne J, Hannaberg P, Brown C, Mura M, Mehta S, Madill J. Vitamin D 
intake and status in three patient populations: Interstitial lung disease, pulmonary hypertension 
and patients participating in the Group Lifestyle Balance™ weight management program. ASPEN 
2018: Nutrition Science & Practice Conference. 2018:53-4. [International] 
 
9. Horne J, Madill J, O’Connor C. Nutrigenomics: An evident need for education in the field of 
dietetics. Canadian Journal of Dietetic Practice and Research. 2015;76(3):9. [Oral Presentation 
by O’Connor C; National]  
 
10. Horne J, Madill J, O’Connor C. Exploring knowledge and attitudes of personal nutrigenomics 
testing among dietetic students and its value as a component of dietetic education and 
practice. Journal of Parenteral and Enteral Nutrition. 2015:95. ASPEN’s Clinical Nutrition Week, 
Long Beach, United States. [International] 
 
Conference Presentations       
 
Horne J. Change in weight, BMI, and body composition after 3, 6, and 12 months in a 
population-based intervention vs. genetic-based intervention: Results from the NOW 
randomized controlled trial. ASPEN Nutrition Science and Practice Conference. Tampa, United 
States. March 29, 2019. [Oral Presentation] 
 
Horne J. Nutritional genomics: Where are we now and where do we go from here? Hamilton 
Health Sciences Annual Dietetics Meeting. Hamilton, Canada. June 11, 2019 [Invited Keynote] 
 
Horne J and El-Sohemy A. Are we ready for nutritional genomics in clinical practice? Canadian 
Nutrition Society Annual Conference. Niagara Falls, Canada. May 4, 2019 [Invited Talk] 
 
Horne J and Buccino J. Finding your advocacy passion and taking the first step. Dietitians of 
Canada: Ontario RD Networking Meeting. London, Canada. October 10, 2019 [Invited Keynote] 
 
Caulfield T, El-Sohemy A, Horne J, MacKay D. Debate forum - Are we ready for personalized 
nutrition? International Society of Nutrigenetics and Nutrigenomics Annual Meeting, Winnipeg, 
Canada. October 3, 2018 [Invited Talk] 
 
Horne J. Lifestyle genomics testing for obesity management in Canada: A critical review with 
implications for policy and legislation. Canadian Obesity Network: Student Meeting, London, 
Canada. June 22, 2018 [Oral Presentation] 
 
Horne J. Nutrigenomics, behaviour change and The NOW Trial. Dietitians of Canada FHT 
Registered Dietitians and Primary Care Conference, Barrie, Canada. September 28, 2017 
[Invited Talk] 
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Community Outreach (Oral Presentations)  
 
Horne J. The NOW Trial Results. East Elgin Family Health Team Physician and Healthcare 
Professionals Meeting. Aylmer, Canada. February 13, 2020 
 
Horne J. The NOW Trial Results. East Elgin Family Health Team Patients Meeting. Aylmer, 
Canada. February 13, 2020 
 
Horne J. Nutrigenomics and the NOW Trial. SW Regional Diabetes Educators’ Meeting. London, 
ON. June 7, 2019. [Keynote] 
 
Veloce D, Buccino J, Sauvé A, Horne J. Protect “Nutritionist.” Protect “Registered.” Protect the 
Public. College of Dietitians of Ontario. Toronto, Canada. October 26, 2018. 
Horne J. Nutrigenomics, Behaviour Change and The Nutrigenomics, Overweight/Obesity and 
Weight Management Trial. London Primary Care Dietitians' Meeting. London, Canada. 
December 7, 2017. 
 
Horne J. The Group Lifestyle Balance Program and The Nutrigenomics, Overweight/Obesity and 
Weight Management Trial. Thames Valley FHT Quarterly Meeting. Canada. November 24, 2017.  
Horne J and Madill J. The Nutrigenomics, Overweight/Obesity and Weight Management Trial. 
Canadian Society of Transplantation: Patient Meeting. Toronto, Canada. April 8, 2017. 
Horne J. Nutrigenomics and Personalized Nutrition. Southwestern Ontario Regional Dietitians’ 
Meeting. Woolwich, Canada. May 6, 2016. 
Horne J. The Science of Nutrigenomics. RD Appreciation Day. Stratford, Canada. April 13, 2016. 
 
Other Publications  
 
Horne J. Nutrigenomics and weight management. Dietitians in Integrative and Functional 
Medicine Newsletter (Academy of Nutrition and Dietetics). Invited.  
Horne J and O’Connor C. The truth about detox diets [guest blog post]. Weighty Matters Blog 
(Yoni Freedhoff). [2019]. Invited. 
Horne J. Nutritional genomics: Genetic testing for personalized nutrition. Nutrition Nibbles 
(Hamilton Family Health Team). [2019]. Invited. 
Horne J. What RDs Do. Something Nutrishus Blog. [2017]. Available from: 
http://nutrishus.blogspot.com/2017/04/what-rds-do-justine-horne-msc-rd-phd.html  
Horne J and Cianfrini L. Integrating nutrigenomics into undergraduate dietetic education. 
Dietetic Educators’ Network Newsletter (Dietitians of Canada). 2013. Invited. 
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Affiliations/Memberships 
 
• Canadian Nutrition Society: 2018 – present  
• Dietitians of Canada:  2013-2016, 2018 - present 
• Ontario Respiratory Care Society: 2017 – present   
• College of Dietitians of Ontario: 2015 – present  
• Collegiate and Professional Sports Dietitians’ Association: 2016 – 2017 
 
 
Academic Conference Attendance  
 
• ASPEN Nutrition Science and Practice Conference, Tampa, United States: March 2020 
• European Conference on Personalized Nutrition and Health, Wageningen, Netherlands:  
October 2019 
• Canadian Society of Nutrition Annual Conference, Niagara, Canada: May 2019 
• International Society for Nutrigenetics and Nutrigenomics, Winnipeg, Canada: 
September 2018 
• Canadian Obesity Network: Student Meeting, London, Canada: May 2018 
• Association of Family Health Teams of Ontario Conference, Toronto, Canada: October 
2017 
• Dietitians of Canada Family Health Team and Primary Care RD Conference, Barrie, 
Canada: September 2017  
• Low German Mennonite Networking Conference, Aylmer, Canada: May 2017  
• Canadian Nutrition Society: Advances in Nutrition, Gut Health and the Microbiome, 
Toronto, Canada: January 2017 
• Food and Nutrition Conference and Expo (Exhibitor), Nashville, United States: 
September 2015 
• Canadian Association of Nephrology Dietitians National Meeting, Toronto, Canada: 
September 2015 
• APSEN’s Clinical Nutrition Week, Long Beach, United States: February 2015 
 
Other Professional Development Activities 
 
• Speaker, Dietitians of Canada Webinar, Nutrigenomics: Impact on Weight and Body 
Composition, 2020 
• Intuitive Eating PRO Skills Training Course, 2019 
• Speaker, Dietitians of Canada Learning on Demand course: The NOW Trial: 
Nutrigenomics, Overweight/Obesity and Weight Management, 2017 
• Diabetes Prevention Program training, March 2017 
• ASPEN pre-conference course: ‘Taste Signaling – Impact on Food Selection, Intake, and 
Health,’ February 2015 
• Dietitians of Canada online courses completed: 
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o Critical Care Nutrition, 2015 
o Population and Public Health Needs Assessment, 2014 
o Herbal Supplements, 2013 
o World Health Organization Growth Charts, 2012 
• Crisis Prevention Institute’s non-violent crisis intervention training, 2014 
• Bridges Out of Poverty training, 2014 
• Hope’s Garden Eating Disorders Awareness Breakfast attendee, 2014 
 
Journal Article Reviews 
 
• BMJ Open, 2020: Number of works reviewed/refereed: 1 
• Medicine, 2019: Number of works reviewed/refereed: 1  
• Lifestyle Genomics, 2018, 2019: Number of works reviewed/refereed: 3 
• PLoS One, 2018: Number of works reviewed/refereed: 1 
• Nutrition and Health, 2017, 2019: Number of works reviewed/refereed: 2 
• Annals of Behavioural Medicine, 2017: Number of works reviewed/refereed: 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
